

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

22ND EDITION

Cumulative Supplement 11

November 2002

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes	iv
1.3 Waived Exclusivity	vi
1.4 Tramadol Hydrochloride Tablets	vi
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Change Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

Library Use Only

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

22ND EDITION

CUMULATIVE SUPPLEMENT 10
November 2002

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 22nd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 22nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 23rd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
DANBURY PHARMACEUTICALS INC (DANBURY PHARMA)	WATSON LABORATORIES INC (WATSON LABS)
DURAMED PHARMACEUTICALS INC (DURAMED)	DURAMED PHARMACEUTICALS INC SUB OF BARR LABORATORIES INC (DURAMED PHARM BARR)
DERMIK LABORATORIES INC (DERMIK LABS)	DERMIK LABORATORIES DIVISION OF AVENTIS PHARMACEUTICALS INC (DERMIK LABS)
DERMIK LABORATORIES INC SUB RORER (DERMIK LABS)	DERMIK LABORATORIES DIVISION OF AVENTIS PHARMACEUTICALS INC (DERMIK LABS)
JANSSEN RESEARCH FDN (JANSSEN)	JANSSEN PHARMACEUTICA PRODUCTS LP (JANSSEN PHARMA)
JANSSEN RESEARCH FDN DIV JOHNSON AND JOHNSON (JANSSEN)	JANSSEN PHARMACEUTICA PRODUCTS LP (JANSSEN PHARMA)
JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT LLC (JOHNSON AND JOHNSON)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
MCNEIL CONSUMER HEALTHCARE DIVISION (MCNEIL CONS)	MCNEIL CONSUMER AND SPECIALTY PHARMACEUTICALS DIVISION MCNEIL PPC (MCNEIL CONS SPECLT)
MOVA PHARMACEUTICALS CORPORATION (MOVA)	CLONMEL HEALTHCARE LTD (CLONMEL HLTH)
NMC LABORATORIES INC	ALPHARMA US PHARMACEUTICAL DIV (ALPHARMA US PAHRM)
PARKE DAVIS PHARMACEUTICALS LTD (PARKE DAVIS PHARMS)	PFIZER PHARMACEUTICALS LTD (PFIZER PHARM LTD)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE (JOHNSON RW)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV ORTHO PHARMACEUTICAL CORP (JOHNSON RW)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
THAMES PHARMACAL COMPANY INC (THAMES)	TARO PHARMACEUTICALS NORTH AMERICA INC (TARO PHARMS US)
WHITEHALL LABORATORIES INC DIV AMERICAN HOME PRODUCTS CORP (WHITEHALL LABS)	WYETH CONSUMER HEALTHCARE (WYETH CONS)
WHITEHALL ROBINS HEALTHCARE (WHITEHALL LABS)	WYETH CONSUMER HEALTHCARE (WYETH CONS)

1.3 WAIVED EXCLUSIVITY

Waived exclusivity - If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book.

However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

1.4 TRAMADOL HYDROCHLORIDE TABLETS. Tramadol Hydrochloride 50 mg tablet products approved under section 505(j) are marked with a (*) because there are special considerations governing the substitution of these products. The tramadol hydrochloride 50 mg tablets marked with a (*) are therapeutically equivalent (AB) to RW Johnson's Ultram (Tramadol Hydrochloride) 50 mg tablets. However, because of RW Johnson's exclusivity and patent protection for the 25 mg titration dosing regimen, tramadol hydrochloride drug products approved under section 505(j) may not carry the labeling for the 25 mg titration dosing regimen. Ultram 50 mg tablets are scored for use in the 25 mg titration schedule; tramadol hydrochloride 50 mg tablets approved under 505(j) are not scored. Prescribers and dispensers should be aware of this scoring difference between Ultram and other tramadol hydrochloride tablets and take it into account when writing a prescription or practicing drug product selection.

1.5 AVAILABILITY OF THE EDITION

The 22nd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is \$105.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
<http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the hard copy monthly supplement is at
<http://www.fda.gov/cder/orange/supplement/cspreface.htm>. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
<http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 22nd annual edition of the 2001 Orange Book Patent and Exclusivity List is at
<http://www.fda.gov/cder/orange/22bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
<http://www.fda.gov/cder/orange/docket.pdf>. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
<http://www.fda.gov/cder/orange/patdecl.pdf>
<http://www.fda.gov/cder/orange/patdecl.html>

The current listing of the Orphan Product Designations and Approvals is available at
<http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2001) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product

activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2001</u>	<u>MAR 2002</u>	<u>JUN 2002</u>	<u>SEP 2002</u>
DRUG PRODUCTS LISTED	10166	10357	10193	10329
SINGLE SOURCE	2665 (26.2%)	2645 (25.5%)	2400 (23.5%)	2399 (23.2%)
MULTISOURCE	7391 (72.7%)	7602 (73.4%)	7687 (75.4%)	7824 (75.7%)
THERAPEUTICALLY EQUIVALENT	7105 (69.9%)	7309 (70.6%)	7402 (72.6%)	7549 (73.1%)
NOT THERAPEUTICALLY EQUIVALENT	286 (2.8%)	293 (2.8%)	285 (2.8%)	275 (2.7%)
EXCEPTIONS ¹	110 (1.1%)	110 (1.1%)	106 (1.0%)	106 (1.0%)
NEW MOLECULAR ENTITIES APPROVED	10	1	5	5
NUMBER OF APPLICANTS	574	574	574	582

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL
SECTRAL
AB ESP PHARMA EQ 200MG BASE N18917 001 DEC 28, 1984 JUL CAHN
AB + EQ 400MG BASE N18917 003 DEC 28, 1984 JUL CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE
AB VINTAGE PHARMS 325MG;50MG;40MG;30MG N75929 001 APR 22, 2002 APR NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL
PHENAPHEN W/ CODEINE NO. 2
a ROBINS AH 325MG;15MG N84444 001 MAY DISC
SOLUTION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
AA + ALPHARMA 120MG/5ML;12MG/5ML N85861 001 MAY CRLD
TYLENOL W/ CODEINE
a JOHNSON RW 120MG/5ML;12MG/5ML N85057 001 MAY DISC
TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
AA ABLE 300MG;30MG N40452 001 AUG 01, 2002 AUG NEWA
AA 300MG;60MG N40459 001 AUG 01, 2002 AUG NEWA
a PUREPAC PHARM 300MG;60MG N86683 001 MAY DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
AA KV PHARM 500MG/15ML;7.5MG/15ML N40366 001 JAN 23, 2002 JAN NEWA
TABLET; ORAL
AA ABLE 325MG;7.5MG N40464 001 OCT 23, 2002 OCT NEWA
AA 325MG;10MG N40464 002 OCT 23, 2002 OCT NEWA
>A> AA 325MG;5MG N40478 001 NOV 08, 2002 NOV NEWA
>A> AA 500MG;10MG N40473 001 NOV 06, 2002 NOV NEWA
>A> AA 500MG;5MG N40477 001 NOV 06, 2002 NOV NEWA
AA 650MG;10MG N40476 001 OCT 23, 2002 OCT NEWA
AA 750MG;7.5MG N40469 001 OCT 25, 2002 OCT NEWA
AA + MALLINCKRODT 660MG;10MG N40084 003 JUL 29, 1996 JUL CTNA
AA 750MG;10MG N40468 001 OCT 31, 2002 OCT NEWA
AA UCB 500MG;10MG N40210 001 AUG 13, 1997 JUN CAHN
AA + WATSON LABS 750MG;10MG N40094 004 MAR 22, 1999 OCT CFTG
NORCO
AA + WATSON LABS 325MG;5MG N40099 001 JUN 25, 1997 MAY CTNA

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
ACETAMINOPHEN AND PENTAZOCINE HCL
AB AMIDE PHARM 650MG;EQ 25MG BASE N76202 001 AUG 02, 2002 AUG NEWA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
DARVOCET
© AAIPHARMA LLC

325MG;32.5MG

N16844 001

JUN CAHN

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
DARVOCET-N 100
AB + AAIPHARMA LLC 650MG;100MG
DARVOCET-N 50
AB AAIPHARMA LLC 325MG;50MG

N17122 002

JUN CAHN

N17122 001

JUN CAHN

ACYCLOVIR

TABLET; ORAL
ACYCLOVIR
AB NEOSAN PHARMS 400MG
AB 800MG

N74946 001 NOV 19, 1997 JUL CAHN

N74946 002 NOV 19, 1997 JUL CAHN

ADEFOVIR DIPIVOXIL

TABLET; ORAL
HEPSERA
+ GILEAD 10MG

N21449 001 SEP 20, 2002 SEP NEWA

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION
CHROMALBIN
© ISO TEX 100uCi/VIAL

N17835 001

JUN DISC

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I-125
© MALLINCKRODT 6.67uCi/ML
© 100uCi/ML

N17844 003

JUN DISC

N17844 002

JUN DISC

ALBUTEROL

AEROSOL, METERED; INHALATION
PROVENTIL
BN + SCHERING 0.09MG/INH

N17559 001

JUN CRLD

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
PROVENTIL-HFA
BX + 3M EQ 0.09MG BASE/INH
VENTOLIN HFA
BX + GLAXOSMITHKLINE EQ 0.09MG BASE/INH
TABLET, EXTENDED RELEASE; ORAL
ALBUTEROL SULFATE
AB SIDMAK LABS EQ 4MG BASE
AB EQ 8MG BASE
VOLMAX
AB + MURO EQ 4MG BASE
AB + EQ 8MG BASE

N20503 001 AUG 15, 1996 MAR CTEC

N20983 001 APR 19, 2001 MAR CTEC

N76130 002 SEP 26, 2002 SEP NEWA

N76130 003 SEP 26, 2002 SEP NEWA

N19604 002 DEC 23, 1992 SEP CFTG

N19604 001 DEC 23, 1992 SEP CFTG

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

CAHN AP + GD SEARLE LLC

EQ 0.5MG BASE/ML

N19353 001 DEC 29, 1986 JUL CAHN

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

CAHN @ GENZYME

10 UNITS/ML

N20057 004 MAY 08, 1992 JUN DISC

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM

+ DSM PHARMS

EQ 500MG BASE/VIAL

N20298 001 MAY 17, 1996 JUN CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN;DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATESODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

INJECTABLE; INJECTION

INFUVITE ADULT

+ SABEX 2002

2 IU/ML;20MG/ML;12UGM/ML;40

IU/ML;1UGM/ML;3MG/ML;80UGM/ML;8MG/M
L;0.8MG/ML;0.72MG/ML;0.6MG/ML;600

IU/ML

N21163 001 MAY 18, 2000 AUG CTNA

MULTI-12

+ SABEX 2002

2 IU/ML;20MG/ML;12UGM/ML;40

IU/ML;1UGM/ML;3MG/ML;80UGM/ML;8MG/M
L;0.8MG/ML;0.72MG/ML;0.6MG/ML;600

IU/ML

N21163 001 MAY 18, 2000 APR CAHN

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

DISC PHARMACIA AND UPJOHN

0.01MG/VIAL

N21212 001 JUN 11, 2002 JUN NEWA

0.02MG/VIAL

N21212 002 JUN 11, 2002 JUN NEWA

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HCL

CRLD AA CAROLINA MEDCL

50MG/5ML

N75819 001 SEP 11, 2002 SEP NEWA

AMCINONIDE

LOTION; TOPICAL

>A> AMCINONIDE

CTEC >A> AB ALTANA

0.1%

N76329 001 NOV 06, 2002 NOV NEWA

CYCLOCORT

CTEC >D> + FUJISAWA HLTHCARE

0.1%

N19729 001 JUN 13, 1988 NOV CFTG

NEWA >A> AB +

0.1%

N19729 001 JUN 13, 1988 NOV CFTG

NEWA OINTMENT; TOPICAL

CTEC >A> AMCINONIDE

CFTG >A> AB ALTANA

0.1%

N76096 001 NOV 19, 2002 NOV NEWA

AMCINONIDE

OINTMENT; TOPICAL

CYCLOCORT

>D>	+	FUJISAWA HLTHCARE	0.1%	N18498 001	NOV	CFTG
>A>	AB	+	0.1%	N18498 001	NOV	CFTG

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

@ MEDIMMUNE ONCOLOGY

375MG/VIAL

N20221 002 SEP 10, 1999 JUN DISC

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 7%

@ ABBOTT

7% (7GM/100ML)

N17673 002 JUN DISC

AMINOSYN 8.5%

@ ABBOTT

8.5% (8.5GM/100ML)

N17673 004 JUN DISC

AMINOSYN II 3.5%

@ ABBOTT

3.5% (3.5GM/100ML)

N19438 001 APR 03, 1986 JUN DISC

BRANCHAMIN 4%

@ BAXTER HLTHCARE

4% (4GM/100ML)

N18678 001 SEP 28, 1984 JUN DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP	ABBOTT	50MG/ML	N75955 001	OCT 18, 2002	OCT	NEWA
AP	AM PHARM PARTNERS	50MG/ML	N75761 001	OCT 15, 2002	OCT	NEWA
AP	BEDFORD	50MG/ML	N76018 001	OCT 15, 2002	OCT	NEWA
AP	BEDFORD LABS	50MG/ML	N76299 001	OCT 24, 2002	OCT	NEWA
AP	BEN VENUE	50MG/ML	N76088 001	OCT 15, 2002	OCT	NEWA
AP	FAULDING	50MG/ML	N76108 001	OCT 15, 2002	OCT	NEWA
AP	PHARMAFORCE	50MG/ML	N76217 001	OCT 15, 2002	OCT	NEWA

CORDARONE

AP	+	WYETH AYERST	50MG/ML	N20377 001	AUG 03, 1995	OCT	CFTG
----	---	--------------	---------	------------	--------------	-----	------

TABLET; ORAL

>A>	AMIODARONE HCL						
>D>	+	EON	400MG	N75315 002	JUN 30, 2000	NOV	CFTG
>A>	AB	+	400MG	N75315 002	JUN 30, 2000	NOV	CFTG
		+	400MG	N75315 002	JUN 30, 2000	OCT	CRLD
>A>	AB	TARO	400MG	N76362 001	NOV 29, 2002	NOV	NEWA

CORDARONE

AB	WYETH AYERST	200MG	N18972 001	DEC 24, 1985	OCT	CRLD
----	--------------	-------	------------	--------------	-----	------

AMLEXANOX

PASTE; DENTAL

APHTHASOL

+ GLAXOSMITHKLINE CONS 5%

N20511 001 DEC 17, 1996 JUL CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

NOVARTIS

+

EQ 5MG BASE;20MG
EQ 10MG BASE;20MGN20364 004 MAR 03, 1995 AUG CRLD
N20364 005 JUN 20, 2002 AUG NEWAAMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	CLAY PARK	EQ 12% BASE	N75774 001	MAY 01, 2002	MAY	NEWA
	LAC-HYDRIN					
AB	+ WESTWOOD SQUIBB	EQ 12% BASE	N20508 001	AUG 29, 1996	MAY	CFTG
	LOTION; TOPICAL					
	AMMONIUM LACTATE					
AB	PADDICK	EQ 12% BASE	N75575 001	JUN 11, 2002	JUN	NEWA
	LAC-HYDRIN					
AB	+ WESTWOOD SQUIBB	EQ 12% BASE	N19155 001	APR 24, 1985	JUN	CFTG

AMOXICILLIN

FOR SUSPENSION; ORAL

>A>	AMOXICILLIN					
>A>	AB RANBAXY	200MG/5ML	N65113 001	NOV 29, 2002	NOV	NEWA
>A>	AB	400MG/5ML	N65113 002	NOV 29, 2002	NOV	NEWA
	AMOXIL					
>D>	GLAXOSMITHKLINE	200MG/5ML	N50760 001	APR 15, 1999	NOV	CFTG
>A>	AB	200MG/5ML	N50760 001	APR 15, 1999	NOV	CFTG
>D>	+	400MG/5ML	N50760 002	APR 15, 1999	NOV	CFTG
>A>	AB +	400MG/5ML	N50760 002	APR 15, 1999	NOV	CFTG
	TABLET, CHEWABLE; ORAL					
	AMOXICILLIN					
@	APOTHECON	125MG	N64131 001	MAY 06, 1996	JUL	DISC
@		250MG	N64131 002	MAY 06, 1996	JUL	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	GENEVA PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	N65066 001	JUN 05, 2002	JUN	NEWA
AB		400MG/5ML;EQ 57MG BASE/5ML	N65066 002	JUN 05, 2002	JUN	NEWA
	AUGMENTIN '200'					
AB	GLAXOSMITHKLINE	200MG/5ML;EQ 28.5MG BASE/5ML	N50725 001	MAY 31, 1996	JUN	CFTG
	AUGMENTIN '400'					
AB	GLAXOSMITHKLINE	400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	JUN	CFTG
		400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	FEB	CRLD
	TABLET; ORAL					
	AMOXICILLIN AND CLAVULANATE POTASSIUM					
AB	GENEVA PHARMS	500MG;EQ 125MG BASE	N65064 001	MAR 15, 2002	MAR	NEWA
AB		875MG;EQ 125MG BASE	N65063 001	MAR 14, 2002	MAR	NEWA
>A>	AB LEK SVCS	875MG;EQ 125MG BASE	N65093 001	NOV 21, 2002	NOV	NEWA
>A>	AB RANBAXY	500MG;EQ 125MG BASE	N65109 001	NOV 04, 2002	NOV	NEWA
AB		875MG;EQ 125MG BASE	N65102 001	SEP 17, 2002	SEP	NEWA
AB	TEVA	500MG;EQ 125MG BASE	N65101 001	OCT 30, 2002	OCT	NEWA
AB		875MG;EQ 125MG BASE	N65096 001	OCT 29, 2002	OCT	NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>	AB	LEK SVCS	500MG;EQ 125MG BASE	N65117 001	NOV 27, 2002	NOV	NEWA
		AUGMENTIN '500'					
AB		GLAXOSMITHKLINE	500MG;EQ 125MG BASE	N50564 002	AUG 06, 1984	MAR	CFTG
		AUGMENTIN '875'					
AB	+	GLAXOSMITHKLINE	875MG;EQ 125MG BASE	N50720 001	FEB 13, 1996	MAR	CFTG
		TABLET, CHEWABLE; ORAL					
		AMOXICILLIN AND CLAVULANATE POTASSIUM					
AB		GENEVA PHARMS	200MG;EQ 28.5MG BASE	N65065 001	APR 18, 2002	APR	NEWA
AB			400MG;EQ 57MG BASE	N65065 002	APR 18, 2002	APR	NEWA
		AUGMENTIN '200'					
AB		GLAXOSMITHKLINE	200MG;EQ 28.5MG BASE	N50726 001	MAY 31, 1996	APR	CFTG
		AUGMENTIN '400'					
AB	+	GLAXOSMITHKLINE	400MG;EQ 57MG BASE	N50726 002	MAY 31, 1996	APR	CFTG
		TABLET, EXTENDED RELEASE; ORAL					
		AUGMENTIN XR					
	+	GLAXOSMITHKLINE	1GM;62.5MG	N50785 001	SEP 25, 2002	SEP	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

SHIRE PHARM 2.5MG;2.5MG;2.5MG;2.5MG N21303 001 OCT 11, 2001 AUG CAHN

ADDERALL XR 15

SHIRE LABS 3.75MG;3.75MG;3.75MG;3.75MG N21303 006 MAY 22, 2002 JUN NEWA

SHIRE PHARM 3.75MG;3.75MG;3.75MG;3.75MG

ADDERALL XR 20

SHIRE PHARM 5MG;5MG;5MG;5MG N21303 002 OCT 11, 2001 AUG CAHN

ADDERALL XR 25

SHIRE LABS 6.25MG;6.25MG;6.25MG;6.25MG N21303 004 MAY 22, 2002 JUN NEWA

SHIRE PHARM 6.25MG;6.25MG;6.25MG;6.25MG

ADDERALL XR 30

SHIRE PHARM 7.5MG;7.5MG;7.5MG;7.5MG N21303 003 OCT 11, 2001 AUG CAHN

ADDERALL XR 5

SHIRE LABS 1.25MG;1.25MG;1.25MG;1.25MG N21303 005 MAY 22, 2002 JUN NEWA

SHIRE PHARM 1.25MG;1.25MG;1.25MG;1.25MG

TABLET; ORAL

ADDERALL 10

AB SHIRE LABS 2.5MG;2.5MG;2.5MG;2.5MG N11522 007 FEB 13, 1996 FEB CFTG

ADDERALL 20

AB SHIRE LABS 5MG;5MG;5MG;5MG N11522 008 FEB 13, 1996 FEB CFTG

ADDERALL 30

AB + SHIRE LABS 7.5MG;7.5MG;7.5MG;7.5MG N11522 010 MAY 12, 1997 FEB CFTG

ADDERALL 5

AB SHIRE LABS 1.25MG;1.25MG;1.25MG;1.25MG N11522 009 MAY 12, 1997 FEB CFTG

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB BARR 1.25MG;1.25MG;1.25MG;1.25MG N40422 001 FEB 11, 2002 FEB NEWA

AB 2.5MG;2.5MG;2.5MG;2.5MG N40422 002 FEB 11, 2002 FEB NEWA

AB 5MG;5MG;5MG;5MG N40422 003 FEB 11, 2002 FEB NEWA

		AB		7.5MG;7.5MG;7.5MG	N40422 004	FEB 11, 2002	FEB	NEWA
		AB	COREPHARMA	1.25MG;1.25MG;1.25MG;1.25MG	N40444 001	JUN 19, 2002	JUN	NEWA
		AB		2.5MG;2.5MG;2.5MG;2.5MG	N40444 002	JUN 19, 2002	JUN	NEWA
		AB		5MG;5MG;5MG;5MG	N40444 003	JUN 19, 2002	JUN	NEWA
		AB		7.5MG;7.5MG;7.5MG;7.5MG	N40444 004	JUN 19, 2002	JUN	NEWA
NOV	NEWA	AB	EON	1.25MG;1.25MG;1.25MG;1.25MG	N40470 001	SEP 27, 2002	SEP	NEWA
MAR	CFTG	AB		2.5MG;2.5MG;2.5MG;2.5MG	N40439 001	JUN 14, 2002	JUN	NEWA
MAR	CFTG	AB		5MG;5MG;5MG;5MG	N40439 002	JUN 14, 2002	JUN	NEWA
		AB		7.5MG;7.5MG;7.5MG;7.5MG	N40439 003	JUN 14, 2002	JUN	NEWA
		<u>AMPHOTERICIN B</u>						
		INJECTABLE, LIPID COMPLEX; INJECTION						
		ABELCET						
APR	NEWA	>D>	+ ELAN PHARMS	5MG/ML	N50724 001	NOV 20, 1995	NOV	CAHN
			+	5MG/ML	N50724 001	NOV 20, 1995	JAN	CAHN
APR	CFTG	>A>	+ ENZON	5MG/ML	N50724 001	NOV 20, 1995	NOV	CAHN
		SUSPENSION; ORAL						
APR	CFTG	FUNGIZONE						
		@ BRISTOL MYERS SQUIBB		100MG/ML	N50341 003		JUN	DISC
SEP	NEWA	<u>AMPICILLIN SODIUM; SULBACTAM SODIUM</u>						
		INJECTABLE; INJECTION						
		AMPICILLIN AND SULBACTAM						
		AP	ESI LEDERLE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65074 001	MAR 19, 2002	MAR	NEWA
		AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65074 002	MAR 19, 2002	MAR	NEWA
		AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65076 001	MAR 19, 2002	MAR	NEWA
AUG	CAHN	UNASYN						
JUN	NEWA	AP	+ PFIZER	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N50608 002	DEC 31, 1986	MAR	CFTG
AUG	CAHN	AP	+	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N50608 001	DEC 31, 1986	MAR	CFTG
		AP	+	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N50608 005	DEC 10, 1993	MAR	CFTG
AUG	CAHN	<u>AMPRENAVIR</u>						
		CAPSULE; ORAL						
JUN	NEWA	AGENERASE						
AUG	CAHN	@ GLAXOSMITHKLINE		50MG	N21007 001	APR 15, 1999	MAY	DISC
		@		150MG	N21007 002	APR 15, 1999	MAY	DISC
AUG	CAHN	SOLUTION; ORAL						
		@ GLAXOSMITHKLINE		15MG/ML	N21039 001	APR 15, 1999	MAY	DISC
JUN	NEWA							
AUG	CAHN	>A>	<u>ARIPIPRAZOLE</u>					
		>A>	TABLET; ORAL					
		>A>	ABILITY					
FEB	CFTG	>A>	OTSUKA	2MG	N21436 006	NOV 15, 2002	NOV	NEWA
		>A>		5MG	N21436 005	NOV 15, 2002	NOV	NEWA
FEB	CFTG	>A>		10MG	N21436 001	NOV 15, 2002	NOV	NEWA
		>A>		15MG	N21436 002	NOV 15, 2002	NOV	NEWA
FEB	CFTG	>A>		20MG	N21436 003	NOV 15, 2002	NOV	NEWA
		>A>	+	30MG	N21436 004	NOV 15, 2002	NOV	NEWA
FEB	CFTG							
FEB	NEWA							
FEB	NEWA							
FEB	NEWA							

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SABEX 2002 80MG/VIAL;0.02MG/VIAL;400
IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14M
G/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIA
L;1.2MG/VIAL;7 IU/VIAL;2,300
IU/VIAL;0.2MG/VIAL

N21265 001 FEB 21, 2001 APR CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ AAIPHARMA 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;
5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17
MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/V
IAL;EQ 1.2MG
BASE/VIAL;0.7MG/VIAL;7MG/VIAL

N18920 001 SEP 21, 2000 JUL CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

AP + AAIPHARMA 10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/
ML;20
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.3
6MG/ML;0.3MG/ML;330 UNITS/ML;1
IU/ML

N08809 004 AUG 08, 1985 JUL CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

+ AAIPHARMA LLC 389MG;32.4MG;32MG

N10996 006 MAR 08, 1983 JUN CAHN

DARVON COMPOUND-65

AA + AAIPHARMA LLC 389MG;32.4MG;65MG

N10996 007 MAR 08, 1983 JUN CAHN

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

@ SANOFI SYNTHELABO

325MG;EQ 12.5MG BASE

N16891 001

JUN DISC

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

+ AAIPHARMA LLC

325MG;65MG

N10996 005

JUN CAHN

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL				
DARVON-N W/ ASA				
@ AAIPHARMA LLC	325MG;100MG	N16829	001	JUN CAHN
TABLET; ORAL				
@ AAIPHARMA LLC	325MG;100MG	N16863	001	JUN CAHN

>A > ATOMOXETINE HYDROCHLORIDE

>A >	CAPSULE; ORAL			
>A >	STRATTERA			
>A >	LILLY	5MG	N21411	001 NOV 26, 2002 NOV NEWA
>A >		10MG	N21411	002 NOV 26, 2002 NOV NEWA
>A >		18MG	N21411	003 NOV 26, 2002 NOV NEWA
>A >		25MG	N21411	004 NOV 26, 2002 NOV NEWA
>A >		40MG	N21411	005 NOV 26, 2002 NOV NEWA
>A >	+	60MG	N21411	006 NOV 26, 2002 NOV NEWA

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR				
ATNAA				
+ @ US ARMY	2.1MG/0.7ML;600MG/2ML	N21175	001 JAN 17, 2002 JAN NEWA	
@	2.1MG/0.7ML;600MG/2ML	N21175	001 JAN 17, 2002 FEB NEWA	

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC				
OPTIVAR				
+ MURO	0.05%	N21127	001 MAY 22, 2000 MAY CAHN	

AZITHROMYCIN DIHYDRATE

TABLET; ORAL				
ZITHROMAX				
+ PFIZER	EQ 500MG BASE	N50784	001 MAY 24, 2002 MAY NEWA	

AZTREONAM

INJECTABLE; INJECTION				
AZACTAM				
@ BRISTOL MYERS SQUIBB	500MG/VIAL	N50580	001 DEC 31, 1986 JUN DISC	
@	1GM/VIAL	N50580	002 DEC 31, 1986 JUN DISC	
@	2GM/VIAL	N50580	003 DEC 31, 1986 JUN DISC	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
BACITRACIN ZINC AND POLYMYXIN B SULFATE				
AT ALTANA	500 UNITS/GM;10,000 UNITS/GM	N65022	001 FEB 27, 2002 FEB NEWA	

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL				
VANCENASE AQ				
@ SCHERING	EQ 0.084MG DIPROP/SPRAY	N20469	001 JUN 26, 1996 OCT DISC	

APR CAHN

JUL CAHN

JUL CAHN

JUN CAHN

JUN CAHN

JUN DISC

JUN CAHN

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

@ APOTHECON	10MG	N12164 003	JUN DISC
NATURETIN-5			
+ APOTHECON	5MG	N12164 002	JUN CRLD

BENZONATATE

CAPSULE; ORAL

TESSALON

+ FOREST LABS	200MG	N11210 003	JUN 25, 1999	MAR NEWA
---------------	-------	------------	--------------	----------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

DUAC

+ STIEFEL	5%;EQ 1% BASE	N50741 001	AUG 26, 2002	AUG NEWA
-----------	---------------	------------	--------------	----------

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA COREPHARMA	0.5MG	N72264 001	FEB 27, 1989	MAY CAHN
AA	1MG	N72265 001	FEB 27, 1989	MAY CAHN
AA	2MG	N72266 001	FEB 27, 1989	MAY CAHN
AA + PAR PHARM	0.5MG	N88877 001	APR 11, 1985	AUG CRLD
AA +	1MG	N88894 001	APR 11, 1985	AUG CRLD
AA +	2MG	N88895 001	APR 11, 1985	AUG CRLD
COGENTIN				
@ MERCK	0.5MG	N09193 004		AUG DISC
@	1MG	N09193 003		AUG DISC
@	2MG	N09193 002		AUG DISC

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+ SCHWARZ PHARMA	60UMOLAR	N50114 001		JUL CAHN
------------------	----------	------------	--	----------

BETAMETHASONE DIPROPIONATE

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

AB + FOUGERA	EQ 0.05% BASE	N19141 001	SEP 04, 1984	AUG CRLD
DIPROSONE				
@ SCHERING	EQ 0.05% BASE	N17691 001		AUG DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB ALPHARMA US PHARM	EQ 0.05% BASE;1%	N76002 001	AUG 02, 2002	AUG NEWA
----------------------	------------------	------------	--------------	----------

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

@ LOREX	5MG;12.5MG	N19807 001	OCT 30, 1992	JUN DISC
---------	------------	------------	--------------	----------

⑧ 10MG;12.5MG N19807 002 OCT 30, 1992 JUN DISC

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

⑧ ALCON

EQ 0.25% BASE;1.75%

N20619 001 APR 17, 1997 JUN DISC

JUN DISC

JUN CRLD

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

⑧ ABBOTT

5MG/ML

N12418 002

JUN DISC

MAR NEWA

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB MUTUAL PHARM

5MG

N75474 001 OCT 25, 2002 OCT NEWA

AB 10MG

N75474 002 OCT 25, 2002 OCT NEWA

AUG NEWA

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

⑧ SANOFI SYNTHELABO

0.37MG/INH

N18770 001 DEC 28, 1984 JUN DISC

MAY CAHN

MAY CAHN

MAY CAHN

AUG CRLD

AUG CRLD

AUG CRLD

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

⑧ ALLERGAN

0.2%

N20613 001 SEP 06, 1996 AUG DISC

AUG DISC

AUG DISC

AUG DISC

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

AB LEK SVCS

EQ 2.5MG BASE

N74631 001 JAN 13, 1998 JAN CMFD

PARLODEL

AB + NOVARTIS

EQ 2.5MG BASE

N17962 001 JAN CFTG

JUL CAHN

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

BROMANYL

⑧ ALPHARMA

12.5MG/5ML;10MG/5ML

N88343 001 AUG 15, 1984 MAY DISC

AUG CRLD

AUG DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

⑧ ALPHARMA

2MG/5ML;10MG/5ML;30MG/5ML

N88722 001 MAR 07, 1985 OCT DISC

BROMFED-DM

AUG NEWA >D> AA MURO	2MG/5ML;10MG/5ML;30MG/5ML	N89681 001 DEC 22, 1988 NOV CAHN
>A> AA VERUM PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	N89681 001 DEC 22, 1988 NOV CAHN

JUN DISC

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HCL KIT

© ABBOTT	0.075%	N19978 001	SEP 03, 1992	JUN	DISC	
©	0.114%	N19978 002	SEP 03, 1992	JUN	DISC	
©	0.23%	N19978 003	SEP 03, 1992	JUN	DISC	
	BUPIVACINE HCL PRESERVATIVE FREE					
AP	INTL MEDICATED	0.25%	N76012 001	JAN 09, 2002	JAN	NEWA
AP		0.5%	N76012 002	JAN 09, 2002	JAN	NEWA
AP		0.75%	N76012 003	JAN 09, 2002	JAN	NEWA

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBUTEX

RECKITT BENCKISER	EQ 2MG BASE	N20732 002	OCT 08, 2002	OCT	NEWA
+	EQ 8MG BASE	N20732 003	OCT 08, 2002	OCT	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER	2MG;0.5MG	N20733 001	OCT 08, 2002	OCT	NEWA
+	8MG;2MG	N20733 002	OCT 08, 2002	OCT	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

WELLBUTRIN SR

GLAXOSMITHKLINE	150MG	N20358 003	OCT 04, 1996	JUL	CRLD
+	200MG	N20358 004	JUN 14, 2002	JUL	NEWA

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR

© BRISTOL MYERS SQUIBB	5MG	N21190 001	DEC 20, 2000	JUN	DISC
©	7.5MG	N21190 002	DEC 20, 2000	JUN	DISC
©	10MG	N21190 003	DEC 20, 2000	JUN	DISC
©	15MG	N21190 004	DEC 20, 2000	JUN	DISC

TABLET; ORAL

BUSPIRONE HCL

AB	EGIS	5MG	N75119 001	MAR 14, 2002	MAR	NEWA
AB		10MG	N75119 002	MAR 14, 2002	MAR	NEWA
AB	GENEVA PHARMS	5MG	N75413 001	MAR 19, 2002	MAR	NEWA
AB		10MG	N75413 002	MAR 19, 2002	MAR	NEWA
AB		15MG	N75413 003	MAR 19, 2002	MAR	NEWA
AB	KV PHARM	5MG	N75572 001	FEB 27, 2002	FEB	NEWA
AB		10MG	N75572 002	FEB 27, 2002	FEB	NEWA
AB		15MG	N75572 003	FEB 27, 2002	FEB	NEWA
AB	MYLAN	5MG	N75272 001	MAR 01, 2002	MAR	NEWA
AB		10MG	N75272 002	MAR 01, 2002	MAR	NEWA
AB		30MG	N76008 001	JUN 28, 2001	MAY	CAHN
AB	PAR PHARM	5MG	N75467 001	FEB 28, 2002	FEB	NEWA
AB		10MG	N75467 003	FEB 28, 2002	FEB	NEWA
AB		15MG	N75467 004	FEB 28, 2002	FEB	NEWA

AB	PHARMEX PRODS	5MG	N75388 001	MAY 09, 2002	MAY	NEWA
AB		10MG	N75388 002	MAY 09, 2002	MAY	NEWA
AB		15MG	N75388 003	MAY 09, 2002	MAY	NEWA
AB	TEVA	5MG	N75022 001	FEB 28, 2002	FEB	NEWA
AB		10MG	N75022 002	FEB 28, 2002	FEB	NEWA
AB		15MG	N75022 003	FEB 28, 2002	FEB	NEWA
AB	TORPHARM	5MG	N75521 001	APR 05, 2002	APR	NEWA
AB		10MG	N75521 002	APR 05, 2002	APR	NEWA
AB		15MG	N75521 003	APR 05, 2002	APR	NEWA
AB	ZENITH GOLDLINE	5MG	N75385 001	MAR 01, 2002	MAR	NEWA
AB		10MG	N75385 002	MAR 01, 2002	MAR	NEWA
AB		15MG	N75385 003	MAR 01, 2002	MAR	NEWA

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

@ WALLACE LABS

15MG

N00793 002

OCT DISC

@

100MG

N00793 005

OCT DISC

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX-TC

+ BERTEK

1%

N21408 001 OCT 17, 2002 OCT NEWA

BUTORPHANOL TARTRATE

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

AB ROXANE

1MG/SPRAY

N75824 001 MAR 12, 2002 MAR NEWA

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERCATAB

+ GENEVA PHARMS

100MG;1MG

N84294 001

JUN CTEC

WIGRAINE

@ ORGANON

100MG;1MG

N86562 001

JUN DISC

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

@ ORGANON

0.02MG

N18312 001

JUN DISC

@

0.05MG

N18312 002

JUN DISC

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

+ BRISTOL MYERS SQUIBB

0.005%

N20273 001 DEC 29, 1993 FEB CAHN

SOLUTION; TOPICAL

+ BRISTOL MYERS SQUIBB

0.005%

N20611 001 MAR 03, 1997 FEB CAHN

CAPTOPRIL

TABLET; ORAL

CAPOTEN

AB PAR PHARM

12.5MG

N18343 005 JAN 17, 1985 MAY CAHN

AB		25MG	N18343 002	MAY	CAHN	
	@	37.5MG	N18343 006	SEP 17, 1986	MAY	CAHN
AB		50MG	N18343 001		MAY	CAHN
	@	75MG	N18343 007	JUN 13, 1995	MAY	CAHN
AB +		100MG	N18343 003		MAY	CAHN
	@	150MG	N18343 004	JUN 13, 1995	MAY	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL						
@ SHIRE LABS		100MG	N20712 003	DEC 22, 1999	JUL	DISC
@		200MG	N20712 001	SEP 30, 1997	JUL	DISC
@		300MG	N20712 002	SEP 30, 1997	JUL	DISC
+ SHIRE PHARM		100MG	N20712 003	SEP 30, 1997	SEP	CMFD
+		200MG	N20712 001	SEP 30, 1997	SEP	CMFD
+		300MG	N20712 002	SEP 30, 1997	SEP	CMFD

SUSPENSION; ORAL

CARBAMAZEPINE						
AB MORTON GROVE		100MG/5ML	N75714 001	JUN 05, 2002	JUN	NEWA
TABLET; ORAL						
AB APOTEX		200MG	N75948 001	FEB 27, 2002	FEB	NEWA
TABLET, CHEWABLE; ORAL						
+ TARO PHARM IND		200MG	N75687 002	JUL 29, 2002	JUL	NEWA

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HCL						
AT NOVEX		1%	N76097 001	FEB 06, 2002	FEB	NEWA

CEFACLOR

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD						
@ LILLY		EQ 375MG BASE	N50673 001	JUN 28, 1996	JUN	DISC
CEFACLOR						
TEVA		EQ 375MG BASE	N65058 001	SEP 04, 2002	SEP	NEWA
AB		EQ 500MG BASE	N65058 002	SEP 04, 2002	SEP	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

DURICEF						
@ GALEN CHEM		EQ 250MG BASE	N50512 002		MAY	CAHN
@ WARNER CHILCOTT		EQ 250MG BASE	N50512 002		JUL	CAHN
AB +		EQ 500MG BASE	N50512 001		JUL	CAHN
FOR SUSPENSION; ORAL						
GALEN CHEM		EQ 125MG BASE/5ML	N50527 002		MAY	CAHN
		EQ 250MG BASE/5ML	N50527 003		MAY	CAHN
+		EQ 500MG BASE/5ML	N50527 001		MAY	CAHN
WARNER CHILCOTT		EQ 125MG BASE/5ML	N50527 002		JUL	CAHN
		EQ 250MG BASE/5ML	N50527 003		JUL	CAHN
+		EQ 500MG BASE/5ML	N50527 001		JUL	CAHN
TABLET; ORAL						
AB + GALEN CHEM		EQ 1GM BASE	N50528 001		MAY	CAHN
AB + WARNER CHILCOTT		EQ 1GM BASE	N50528 001		JUL	CAHN

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

@ LILLY

EQ 10GM BASE/VIAL

N50504 004

JUN DISC

CEFORANIDE

INJECTABLE; INJECTION

PRECEF

@ BRISTOL

500MG/VIAL

N50554 001 MAY 24, 1984 JUN DISC

@

1GM/VIAL

N50554 002 MAY 24, 1984 JUN DISC

@

2GM/VIAL

N50554 003 MAY 24, 1984 JUN DISC

@

10GM/VIAL

N50554 004 MAY 24, 1984 JUN DISC

@

20GM/VIAL

N50554 005 MAY 24, 1984 JUN DISC

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

>A>	AP	HIKMA	EQ 500MG BASE/VIAL	N65072 001 NOV 20, 2002 NOV NEWA
>A>	AP		EQ 1GM BASE/VIAL	N65072 002 NOV 20, 2002 NOV NEWA
>A>	AP		EQ 2GM BASE/VIAL	N65072 003 NOV 20, 2002 NOV NEWA
>A>	AP		EQ 10GM BASE/VIAL	N65071 001 NOV 20, 2002 NOV NEWA

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AB	RANBAXY	EQ 50MG BASE/5ML	N65082 001 MAY 31, 2002 MAY NEWA
AB		EQ 100MG BASE/5ML	N65082 002 MAY 31, 2002 MAY NEWA
VANTIN			
AB	PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N50675 001 AUG 07, 1992 MAY CFTG
AB	+	EQ 100MG BASE/5ML	N50675 002 AUG 07, 1992 MAY CFTG

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

@ FUJISAWA HLTHCARE EQ 500MG BASE/VIAL

N50560 001 SEP 15, 1983 JUL DISC

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

@ HLR	EQ 500MG BASE/VIAL;1%	N50585 007 MAY 08, 1996 JUN DISC
@	EQ 1GM BASE/VIAL;1%	N50585 006 MAY 08, 1996 JUN DISC

CEFUROXIME AXETIL

TABLET; ORAL

CEFTIN

AB	GLAXOSMITHKLINE	EQ 125MG BASE	N50605 001 DEC 28, 1987 FEB CFTG
AB		EQ 250MG BASE	N50605 002 DEC 28, 1987 FEB CFTG
AB	+	EQ 500MG BASE	N50605 003 DEC 28, 1987 FEB CFTG
CEFUROXIME AXETIL			
AB	APOTEX	EQ 250MG BASE	N65069 001 OCT 02, 2002 OCT NEWA
AB		EQ 500MG BASE	N65069 002 OCT 02, 2002 OCT NEWA
AB	RANBAXY	EQ 125MG BASE	N65043 003 FEB 15, 2002 FEB NEWA

AB	EQ 250MG BASE	N65043 002	FEB 15, 2002	FEB	NEWA
AB	EQ 500MG BASE	N65043 001	FEB 15, 2002	FEB	NEWA

CELECOXIB

CAPSULE; ORAL					
CELEBREX					
GD SEARLE LLC	200MG	N20998 002	DEC 31, 1998	AUG	CRLD
+	400MG	N20998 003	AUG 29, 2002	AUG	NEWA

CEPHALEXIN

FOR SUSPENSION; ORAL					
CEPHALEXIN					
@ TEVA	EQ 125MG BASE/5ML	N62873 001	MAY 23, 1988	APR	DISC
@	EQ 250MG BASE/5ML	N62867 001	APR 15, 1988	APR	DISC
TABLET; ORAL					
TEVA	EQ 500MG BASE	N63024 001	JAN 12, 1989	JUN	CTEC
KEFLET					
@ LILLY	EQ 500MG BASE	N50440 001		JUN	DISC
@	EQ 1GM BASE	N50440 002		JUL	DISC

CEPHALOGLYGIN

CAPSULE; ORAL					
KAFOCIN					
@ LILLY	250MG	N50219 001		MAY	DISC

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION					
KEFLIN					
@ LILLY	EQ 20GM BASE/VIAL	N50482 007		JUN	DISC

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION					
CEFADYL					
APOTHECON	EQ 500MG BASE/VIAL	N62961 001	SEP 20, 1988	JUN	DISC
@	EQ 1GM BASE/VIAL	N62961 002	SEP 20, 1988	JUN	DISC
@	EQ 2GM BASE/VIAL	N62961 003	SEP 20, 1988	JUN	DISC
@	EQ 4GM BASE/VIAL	N62961 004	SEP 20, 1988	JUN	DISC

CERIVASTATIN SODIUM

TABLET; ORAL					
BAYCOL					
@ BAYER	0.2MG	N20740 003	JUN 26, 1997	JAN	DISC
@	0.3MG	N20740 004	JUN 26, 1997	JAN	DISC
@	0.4MG	N20740 005	MAY 24, 1999	JAN	DISC
@	0.8MG	N20740 006	JUL 24, 2000	JAN	DISC

CHLORAMPHENICOL

FOR SOLUTION; OPHTHALMIC					
CHLOROMYCETIN					
@ PARKEDALE	25MG/VIAL	N50143 001		JUL	DISC

FEB NEWA
FEB NEWA

CHLORAMPHENICOL PALMITATE
SUSPENSION; ORAL
CHLOROMYCETIN PALMITATE
© PARKE DAVIS EQ 150MG BASE/5ML N50152 001 JUN DISC

AUG CRLD
AUG NEWA

CHLORAMPHENICOL; HYDROCORTISONE ACETATE
FOR SUSPENSION; OPHTHALMIC
CHLOROMYCETIN HYDROCORTISONE
© PARKADEL 12.5MG/VIAL;25MG/VIAL N50202 001 JUL DISC

APR DISC
APR DISC
JUN CTEC

CHLORMEZANONE
TABLET; ORAL
TRANCOPAL
© SANOFI SYNTHELABO 100MG N11467 003 JUN DISC
© 200MG N11467 005 JUN DISC

JUN DISC
JUL DISC

CHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
CHLOROTHIAZIDE AND RESERPINE
© WEST WARD 250MG;0.125MG N88557 001 DEC 22, 1983 AUG DISC
© 500MG;0.125MG N88365 001 DEC 22, 1983 AUG DISC
CHLOROTHIAZIDE-RESERPINE
© MYLAN 250MG;0.125MG N87744 001 MAY 06, 1982 AUG DISC
© 500MG;0.125MG N87745 001 MAY 06, 1982 AUG DISC

JUN DISC

CHLORPHENESIN CARBAMATE
TABLET; ORAL
MAOLATE
© PHARMACIA AND UPJOHN 400MG N14217 002 JUN DISC

JUN DISC
JUN DISC
JUN DISC
JUN DISC

CHLORPROMAZINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
THORAZINE
© GLAXOSMITHKLINE 30MG N11120 016 JUN DISC
© 75MG N11120 017 JUN DISC
© 150MG N11120 018 JUN DISC

JAN DISC
JAN DISC
JAN DISC
JAN DISC

CHLORPROPAMIDE
TABLET; ORAL
CHLORPROPAMIDE
© LEDERLE 100MG N89561 001 SEP 04, 1987 MAY DISC
© 250MG N89562 001 SEP 04, 1987 MAY DISC

JUL DISC

CHLORTETRACYCLINE HYDROCHLORIDE
OINTMENT; OPHTHALMIC
AUREOMYCIN
© LEDERLE 1% N50404 001 JUN DISC

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE
TABLET; ORAL
CLONIDINE HCL AND CHLORTHALIDONE
© PAR PHARM 15MG;0.3MG N71142 001 DEC 16, 1987 OCT DISC

@	15MG;0.2MG	N71178 001	DEC 16, 1987	OCT	DISC
@	15MG;0.1MG	N71179 001	DEC 16, 1987	OCT	DISC
CLORPRES					
+ MYLAN	15MG;0.3MG	N71325 001	FEB 09, 1987	OCT	CRLD
COMBIPRES					
@ BOEHRINGER INGELHEIM	15MG;0.1MG	N17503 001		OCT	DISC
@	15MG;0.2MG	N17503 002		OCT	DISC
@	15MG;0.3MG	N17503 003	APR 10, 1984	OCT	DISC

CHLORTHALIDONE; RESERPINE

TABLET; ORAL					
DEMI-REGROTON					
@ AVENTIS PHARMS	25MG;0.125MG	N15103 002		JUL	DISC
REGROTON					
@ AVENTIS PHARMS	50MG;0.25MG	N15103 001		JUL	DISC

CHOLESTYRAMINE

TABLET; ORAL					
QUESTRAN					
@ APOTHECON	EQ 800MG RESIN	N73403 002	DEC 27, 1999	JUN	DISC

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION					
OVIDREL					
+ SERONO INC	0.25MG/VIAL	N21149 001	SEP 20, 2000	FEB	CAHN

CHYMOPAPAIN

INJECTABLE; INJECTION					
CHYMODIACTIN					
@ ABBOTT	4,000 UNITS/VIAL	N18663 002	AUG 21, 1984	JUN	DISC

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC					
ZOLYSE					
@ ALCON	750 UNITS/VIAL	N11903 001		JUN	DISC

CICLOPIROX

SOLUTION; TOPICAL					
PENLAC					
+ DERMICK LABS	8%	N21022 001	DEC 17, 1999	JUN	CAHN

CIMETIDINE

TABLET; ORAL					
CIMETIDINE					
AB LEK LJUBLJANA	300MG	N74250 002	JUN 29, 1995	FEB	CMFD
AB	400MG	N74250 003	JUN 29, 1995	FEB	CMFD
AB	800MG	N74250 004	JUN 29, 1995	FEB	CMFD

CINOXACIN

CAPSULE; ORAL					
CINOBAC					
@ LILLY	250MG	N18067 001		JUN	DISC
@	500MG	N18067 002		JUN	DISC

CLADRIBINE

INJECTABLE; INJECTION
 LEUSTATIN
 + ORTHO BIOTECH 1MG/ML N20229 001 FEB 26, 1993 MAR CAHN

CLARITHROMYCIN

FOR SUSPENSION; ORAL
 BIAXIN
 @ ABBOTT 187MG/5ML N50698 003 SEP 30, 1998 JUN DISC

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
 CLINDAGEL
 BT GALDERMA LABS LP EQ 1% BASE N50782 001 NOV 27, 2000 OCT CTNA
 LOTION; TOPICAL
 CLEOCIN T
 AB + PHARMACIA AND UPJOHN EQ 1% BASE N50600 001 MAY 31, 1989 JAN CFTG
 CLINDAMYCIN PHOSPHATE
 AB ALTANA EQ 1% BASE N65067 001 JAN 31, 2002 JAN NEWA
 SWAB; TOPICAL
 AT CLAY PARK EQ 1% BASE N65049 001 MAY 25, 2000 FEB CDFR

CLOBETASOL PROPIONATE

GEL; TOPICAL
 EMBELINE
 AB HEALTHPOINT 0.05% N76141 001 APR 12, 2002 APR NEWA

CLOFAZIMINE

CAPSULE; ORAL
 LAMPRENE
 @ NOVARTIS 100MG N19500 001 DEC 15, 1986 JUN DISC

CLONAZEPAM

TABLET; ORAL
 KLONOPIPIN
 @ ROCHE 0.125MG N17533 005 APR 09, 1997 JUN DISC
 @ 0.25MG N17533 006 APR 09, 1997 JUN DISC
 TABLET, ORALLY DISINTEGRATING; ORAL
 KLONOPIPIN RAPIDLY DISINTEGRATING
 @ ROCHE 0.125MG N20813 001 DEC 23, 1997 JUN DISC
 @ 0.25MG N20813 002 DEC 23, 1997 JUN DISC
 @ 0.5MG N20813 003 DEC 23, 1997 JUN DISC
 @ 1MG N20813 004 DEC 23, 1997 JUN DISC
 @ 2MG N20813 005 DEC 23, 1997 JUN DISC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
 TRANXENE
 @ OVATION PHARMS 3.75MG N17105 001 SEP CAHN
 @ 7.5MG N17105 002 SEP CAHN
 @ 15MG N17105 003 SEP CAHN

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

TRANXENE

AB	OVATION PHARMS	3.75MG	N17105 006	SEP	CAHN
AB		7.5MG	N17105 007	SEP	CAHN
AB +		15MG	N17105 008	SEP	CAHN
	TRANXENE SD				
	OVATION PHARMS	11.25MG	N17105 005	SEP	CAHN
+ +		22.5MG	N17105 004	SEP	CAHN

CLOZAPINE

TABLET; ORAL

CLOZAPINE

>A>	AB	CARACO	25MG	N75713 001	NOV 15, 2002	NOV	NEWA
>A>	AB		100MG	N75713 002	NOV 15, 2002	NOV	NEWA
		CLOZARIL					
	AB	NOVARTIS	25MG	N19758 001	SEP 26, 1989	MAY	CRLD
	AB +		100MG	N19758 002	SEP 26, 1989	MAY	CRLD

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID

BP	+	WATSON LABS	0.5MG;500MG	N84279 001	JUN	CRLD
		COLBENEMID				
	@	MERCK	0.5MG;500MG	N12383 001	JUN	DISC

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL

WELCHOL

@ SANKYO

375MG

N21141 001 MAY 26, 2000 JUN DISC

CORTICOTROPIN

INJECTABLE; INJECTION

CORTICOTROPIN

+ ORGANICS LAGRANGE

40 UNITS/ML

N10831 001

AUG CRLD

H.P. ACTHAR GEL

@ QUESTCOR PHARMS

40 UNITS/ML

N08372 006

JUL DISC

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTONE

@ MERCK

25MG/ML

N07110 002

JUN DISC

@

50MG/ML

N07110 003

JUN DISC

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

AN	NOVEX	10MG/ML	N75333 001	APR 30, 2002	APR	NEWA
----	-------	---------	------------	--------------	-----	------

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A
DICOPAC KIT

@ AMERSHAM HLTH

N/A;N/A;N/A

N17406 001

FEB DISC

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

@ MALLINCKRODT

0.1MG;0.5uci;60MG

N16635 001

JUN DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

FLEXERIL

@ MCNEIL CONS SPECLT 5MG
AB + 10MG

N17821 001

JUN CAHN

N17821 002

JUN CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP	BAXTER HLTHCARE	100MG/VIAL	N88371 001	JUL 03, 1986	JUN	CAHN
AP		200MG/VIAL	N88372 001	JUL 03, 1986	JUN	CAHN
AP		500MG/VIAL	N88373 001	JUL 03, 1986	JUN	CAHN
AP		1GM/VIAL	N88374 001	SEP 24, 1986	JUN	CAHN

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1	ABBOTT	25MG	N65003 001	MAY 12, 2000	MAY	CTEC
BX		50MG	N65003 002	MAY 12, 2000	MAY	CTEC
AB1		100MG	N65003 003	MAY 12, 2000	MAY	CTEC
AB1	EON	25MG	N65017 002	JAN 13, 2000	MAY	CTEC
AB1		100MG	N65017 001	JAN 13, 2000	MAY	CTEC
AB1	SIDMAK LABS	25MG	N65044 002	DEC 20, 2000	MAY	CTEC
AB1		100MG	N65044 001	DEC 20, 2000	MAY	CTEC
AB2	TORPHARM	25MG	N65040 001	MAY 09, 2002	MAY	CTEC
AB2		100MG	N65040 002	MAY 09, 2002	MAY	NEWA

NEORAL

AB1	NOVARTIS	25MG	N50715 001	JUL 14, 1995	MAY	CTEC
AB1 +		100MG	N50715 002	JUL 14, 1995	MAY	CTEC

SANDIMMUNE

AB2	NOVARTIS	25MG	N50625 001	MAR 02, 1990	MAY	CTEC
AB2 +		100MG	N50625 002	MAR 02, 1990	MAY	CTEC

SOLUTION; ORAL

CYCLOSPORINE

AB	ABBOTT	100MG/ML	N65025 001	MAR 03, 2000	JAN	CMFD
----	--------	----------	------------	--------------	-----	------

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL

>D>	AA	IVAX PHARMS	4MG	N87056 001	NOV	CRLD
>A>	AA +		4MG	N87056 001	NOV	CRLD

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL				
>D>	PERIACTIN			
>D>	AA + MERCK	4MG	N12649 001	NOV DISC
>A>	@	4MG	N12649 001	NOV DISC

CYTARABINE

INJECTABLE; INJECTION				
CYTARABINE				
+ FAULDING	100MG/ML		N75383 001	NOV 22, 1999 AUG CPOT

DACARBAZINE

INJECTABLE; INJECTION				
DACARBAZINE				
>A> AP BEDFORD	500MG/VIAL		N75812 002	OCT 31, 2002 NOV NEWA
AP + GENSIA SICOR PHARMS	500MG/VIAL		N75259 001	SEP 22, 2000 OCT CRLD

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)				
SYNERCID				
+ AVENTIS	350MG/VIAL;150MG/VIAL		N50748 001	SEP 21, 1999 JUN CRLD
@	420MG/VIAL;180MG/VIAL		N50748 002	AUG 24, 2000 JUN DISC

DANAPAROID SODIUM

INJECTABLE; INJECTION				
ORGARAN				
@ ORGANON	750 UNITS/0.6ML		N20430 001	DEC 24, 1996 JUN DISC

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION				
DESFERAL				
+ NOVARTIS	2GM/VIAL		N16267 002	MAY 25, 2000 FEB CPOT

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC				
HUMORSOL				
@ MERCK	0.125%		N11860 002	JUN DISC
@	0.25%		N11860 001	JUN DISC

DEMECTOCYCLINE HYDROCHLORIDE

TABLET; ORAL				
DECLOMYCIN				
@ LEDERLE	75MG		N50261 001	JUN DISC

DESLORATADINE

TABLET, ORALLY DISINTEGRATING; ORAL				
CLARINEX				
+ SCHERING	5MG		N21312 001	JUN 26, 2002 JUN NEWA

DESMOPRESSIN ACETATE

SOLUTION; NASAL						
CONCENTRAID						
@ FERRING	0.01%		N19776	001	DEC 26, 1990	JUN DISC
DDAVP						
+ AVENTIS	0.01%		N17922	001		SEP CTEC
SPRAY; NASAL						
DESMOPRESSIN ACETATE						
+ FERRING	0.1MG/SPRAY		N21333	001	SEP 16, 2002	SEP NEWA
SPRAY, METERED; NASAL						
DDAVP						
@ AVENTIS	0.01MG/SPRAY		N17922	002	FEB 06, 1989	MAY DISC
DESMOPRESSIN ACETATE						
AB + BAUSCH AND LOMB	0.01MG/SPRAY		N74830	001	JAN 25, 1999	MAY CRLD

DESOGESTREL; ETHINYLL ESTRADIOL

TABLET; ORAL-28						
KARIVA						
AB BARR	0.15MG;0.02MG;0.01MG		N75863	001	APR 05, 2002	APR NEWA
MIRCETTE						
AB + ORGANON	0.15MG;0.02MG;0.01MG		N20713	001	APR 22, 1998	APR CFTG

DESONIDE

LOTION; TOPICAL						
DESONIDE						
AB ALTANA	0.05%		N75860	001	MAR 19, 2002	MAR NEWA
DESOWEN						
AB + GALDERMA LABS LP	0.05%		N72354	001	JAN 24, 1992	MAR CFTG

DESOXIMETASONE

OINTMENT; TOPICAL						
DESOXIMETASONE						
@ ALTANA	0.25%		N73440	001	APR 01, 1998	MAY DISC

DEXAMETHASONE

AEROSOL; TOPICAL						
DECASPRAY						
@ MERCK	0.04%		N12731	002		JUN DISC
TABLET; ORAL						
DEXAMETHASONE						
@ WATSON LABS	0.25MG		N85455	001		AUG DISC
@	0.5MG		N85458	001		AUG DISC
@	1.5MG		N85456	001		AUG DISC

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION						
DECADRON-LA						
@ MERCK	EQ 8MG BASE/ML		N16675	001		APR DISC
DEXAMETHASONE ACETATE						
@ STERIS	EQ 8MG BASE/ML		N84315	001		APR DISC
@	EQ 16MG BASE/ML		N87711	001	MAY 24, 1982	APR DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION				
DECADRON				
@ MERCK	EQ 4MG PHOSPHATE/ML	N12071 002	OCT	DISC
@	EQ 24MG PHOSPHATE/ML	N12071 004	OCT	DISC
DEXAMETHASONE				
@ AM PHARM PARTNERS	EQ 10MG PHOSPHATE/ML	N88469 001	JAN 25, 1984	OCT DISC
DEXAMETHASONE SODIUM PHOSPHATE				
AP + GENSIA SICOR PHARMS	EQ 10MG PHOSPHATE/ML	N81126 001	AUG 31, 1990	OCT CRLD
AP + LUITPOLD	EQ 4MG PHOSPHATE/ML	N87440 001	JUL 21, 1982	OCT CRLD
@ STERIS	EQ 4MG PHOSPHATE/ML	N89169 001	APR 09, 1986	OCT DISC
@	EQ 10MG PHOSPHATE/ML	N87668 001	JUL 01, 1982	OCT DISC
HEXDROL				
@ ORGANON	EQ 4MG PHOSPHATE/ML	N14694 002	OCT DISC	
@	EQ 10MG PHOSPHATE/ML	N14694 003	OCT DISC	
OINTMENT; OPHTHALMIC				
MAXIDEX				
@ ALCON	EQ 0.05% PHOSPHATE	N83342 001	JUN	DISC

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
DECADRON W/ XYLOCAINE				
@ MERCK	EQ 4MG PHOSPHATE/ML; 10MG/ML	N13334 002	JUN	DISC

DEXTRAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL					
DEXEDRINE					
AB + GLAXOSMITHKLINE	5MG	N17078 001	JAN	CFTG	
AB +	10MG	N17078 002	JAN	CFTG	
AB +	15MG	N17078 003	JAN	CFTG	
DEXTROAMPHETAMINE SULFATE					
AB BARR	5MG	N76137 001	JAN 18, 2002	JAN	NEWA
AB	10MG	N76137 002	JAN 18, 2002	JAN	NEWA
AB	15MG	N76137 003	JAN 18, 2002	JAN	NEWA
TABLET; ORAL					
AA KV PHARM	5MG	N40365 001	OCT 31, 2002	OCT	NEWA
AA	10MG	N40367 001	OCT 31, 2002	OCT	NEWA
AA MALLINCKRODT	5MG	N40436 001	JAN 29, 2002	JAN	NEWA
AA	10MG	N40436 002	JAN 29, 2002	JAN	NEWA

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION				
DIATRIZOATE MEGLUMINE				
@ BRACCO	76%	N10040 017	JUN	DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION				
RENOVIST				
@ BRACCO	34.3%;35%	N10040 020	JUN	DISC
RENOVIST II				
@ BRACCO	28.5%;29.1%	N10040 019	JUN	DISC

DIATRIZOATE SODIUM

INJECTABLE; INJECTION				
HYPaque				
@ AMERSHAM HLTH	25%	N09561 003	JUN	DISC
SOLUTION; ORAL, RECTAL				
@ AMERSHAM HLTH	40%	N11386 003	JUL	DISC
SOLUTION; URETERAL				
HYPaque Sodium 20%				
@ AMERSHAM HLTH	20%	N09561 002	JUN	DISC

DIAZEPAM

INJECTABLE; INJECTION				
DIAZEPAM				
AP + ABBOTT	5MG/ML	N71583 001	OCT 13, 1987	OCT CRLD
VALIUM				
@ ROCHE	5MG/ML	N16087 001	OCT	DISC

DIAZOXIDE

CAPSULE; ORAL				
PROGLYCEM				
@ BAKER NORTON	50MG	N17425 001	JUN	DISC

DICLOFENAC POTASSIUM

TABLET; ORAL				
DICLOFENAC POTASSIUM				
AB MUTUAL PHARM	50MG	N75470 001	FEB 21, 2002	FEB NEWA

DICLOFENAC SODIUM

GEL; TOPICAL				
SOLARAZE				
+ BIOGLAN PHARMA	3%	N21005 001	OCT 16, 2000	JUL CAHN
TABLET, DELAYED RELEASE; ORAL				
DICLOFENAC SODIUM				
AB ALPHAPHARM	50MG	N75281 002	FEB 12, 2002	FEB NEWA
AB	75MG	N75281 003	FEB 12, 2002	FEB NEWA
TABLET, EXTENDED RELEASE; ORAL				
>A> AB DEXCEL LTD	100MG	N76201 001	NOV 06, 2002	NOV NEWA
AB PUREPAC PHARM	100MG	N75910 001	JAN 07, 2002	JAN NEWA

DICUMAROL

TABLET; ORAL				
DICUMAROL				
@ ABBOTT	25MG	N05545 003	JUN	DISC

DIENESTROL

CREAM; VAGINAL				
DIENESTROL				
+ ORTHO MCNEIL	0.01%	N06110 005	JUN	CAHN

DIGOXIN

TABLET; ORAL
DIGOXIN

AB STEVENS J	0.125MG	N76268 001	JUL 26, 2002	JUL	NEWA
AB	0.25MG	N76268 002	JUL 26, 2002	JUL	NEWA

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

XCEL PHARMS	1MG/ML	N05929 001	JUN	CAHN	
SPRAY, METERED; NASAL					
MIGRANAL					
+ XCEL PHARM	0.5MG/INH	N20148 001	DEC 08, 1997	JUL	CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

CARDIZEM

AP + BIOVAIL	5MG/ML	N20027 001	OCT 24, 1991	JUN	CAHN
+	25MG/VIAL	N20027 003	AUG 18, 1995	JUN	CAHN
DILTIAZEM HCL					
+ GENSIA SICOR PHARMS	10MG/ML	N74894 002	APR 19, 2002	APR	NEWA

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

+ BIOVAIL	EQ 180MG HCL;5MG	N20507 001	OCT 04, 1996	JUN	CAHN
-----------	------------------	------------	--------------	-----	------

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

>A>	DIMETHYL SULFOXIDE					
>A> AT	BIONICHE (CANADA)	50%	N76185 001	NOV 29, 2002	NOV	NEWA
	RIMSO-50					
>D>	+ RES INDS	50%	N17788 001		NOV	CFTG
>A> AT +		50%	N17788 001		NOV	CFTG

DIMYRISTOYL LECITHIN; PERFLUXANE

INJECTABLE; INTRAVENOUS

IMAGENT

+ ALLIANCE PHARM	0.92MG/VIAL;0.092MG/VIAL	N21191 001	MAY 31, 2002	MAY	NEWA
------------------	--------------------------	------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

AP AM PHARM PARTNERS	50MG/ML	N40466 001	MAY 28, 2002	MAY	NEWA
----------------------	---------	------------	--------------	-----	------

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

VONTROL

@ GLAXOSMITHKLINE EQ 25MG BASE

N16033 001

JUN DISC

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

>A> AP APOTEX 5MG/ML N75769 001 NOV 27, 2002 NOV NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

ABBOTT

EQ 250MG VALPROIC ACID

N21168 002 MAY 31, 2002 JUL NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

EISAI MEDCL RES

5MG

N20690 002 NOV 25, 1996 MAY CAHN

+

10MG

N20690 001 NOV 25, 1996 MAY CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

@ LEDERLE

EQ 10MG BASE

N71685 001 JAN 05, 1988 MAY DISC

@

EQ 25MG BASE

N71686 001 JAN 05, 1988 MAY DISC

@

EQ 50MG BASE

N71673 001 JAN 05, 1988 MAY DISC

@

EQ 75MG BASE

N71674 001 JAN 05, 1988 MAY DISC

@

EQ 100MG BASE

N71675 001 JAN 05, 1988 MAY DISC

@

EQ 150MG BASE

N71676 001 JAN 05, 1988 MAY DISC

CREAM; TOPICAL

ZONALON

+ BIOGLAN PHARMS

5%

N20126 001 APR 01, 1994 JUN CAHN

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

PERIOSTAT

@ COLLAGENEX

EQ 20MG BASE

N50744 001 SEP 30, 1998 JUN DISC

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

+ ABBOTT

2.5MG/ML;EQ 0.05MG BASE/ML

N71982 001 MAY 04, 1988 JUN CTEC

@ ASTRazeneca

2.5MG/ML;EQ 0.05MG BASE/ML

N72026 001 APR 13, 1989 JUN DISC

DUTASTERIDE

CAPSULE; ORAL

AVODART

+ GLAXOSMITHKLINE

0.5MG

N21319 001 NOV 20, 2001 OCT CTNA

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

@ AYERST

0.03%

N11963 002 JUN DISC

@

0.06%

N11963 004 JUN DISC

@

0.25%

N11963 003 JUN DISC

ECONAZOLE NITRATE

CREAM; TOPICAL

>A>	ECONAZOLE NITRATE						
>A>	AB	ALTANA	1%	N76075	001	NOV 26, 2002	NOV NEWA
>A>	AB	TARO	1%	N76005	001	NOV 26, 2002	NOV NEWA
	SPECTAZOLE						
>D>	+ JOHNSON AND JOHNSON		1%	N18751	001	DEC 23, 1982	NOV CFTG
>A>	AB	+	1%	N18751	001	DEC 23, 1982	NOV CFTG

EDETA TE DISODIUM

INJECTABLE; INJECTION

EDETA TE DISODIUM

>A>	AP	APOTEX	150MG/ML	N40376	001	NOV 04, 2002	NOV NEWA
	AP	PHARMAFORCE	150MG/ML	N40437	001	JUL 09, 2002	JUL NEWA

EFAVIRENZ

TABLET; ORAL

SUSTIVA

	BRISTOL MYERS SQUIBB	300MG	N21360	001	FEB 01, 2002	FEB NEWA
	+	600MG	N21360	002	FEB 01, 2002	FEB NEWA

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

	+ WOMEN FIRST HLTHCARE	13.9%	N21145	001	JUL 27, 2000	JUL CAHN
--	------------------------	-------	--------	-----	--------------	----------

ENALAPRIL MALEATE

TABLET; ORAL

VASOTEC

AB	BIOVAIL	2.5MG	N18998	005	JUL 26, 1988	MAY CAHN
AB		5MG	N18998	001	DEC 24, 1985	MAY CAHN
AB		10MG	N18998	002	DEC 24, 1985	MAY CAHN
AB	+	20MG	N18998	003	DEC 24, 1985	MAY CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

AB	BIOVAIL	5MG;12.5MG	N19221	003	JUL 12, 1995	MAY CAHN
AB	+	10MG;25MG	N19221	001	OCT 31, 1986	MAY CAHN

ENALAPRILAT

INJECTABLE; INJECTION

VASOTEC

AP	+	BIOVAIL	1.25MG/ML	N19309	001	FEB 09, 1988	MAY CAHN
----	---	---------	-----------	--------	-----	--------------	----------

ENOXACIN

TABLET; ORAL

PENETREX

@ AVENTIS		200MG	N19616	004	DEC 31, 1991	JUN DISC
@		400MG	N19616	005	DEC 31, 1991	JUN DISC

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

@ AVENTIS

90MG/0.6ML

N20164 006 JUN 02, 2000 JUN DISC

EPINEPHRINE

INJECTABLE; INJECTION

SUS-PHRINE SULFITE-FREE

@ FORREST LABS

1.5MG/AMP

@

5MG/ML

N07942 003 FEB 05, 1999 JUN DISC

N07942 001 JUN DISC

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

@ MERIDIAN MEDCL TECHN

0.15MG/DELIVERY

N19430 004 AUG 03, 1995 JUN DISC

EPIPEN E Z PEN

@ MERIDIAN MEDCL TECHN

0.3MG/DELIVERY

N19430 003 AUG 03, 1995 JUN DISC

EPLERENONE

TABLET; ORAL

INSPRA

GD SEARLE LLC

25MG

N21437 001 SEP 27, 2002 SEP NEWA

50MG

N21437 002 SEP 27, 2002 SEP NEWA

+

100MG

N21437 003 SEP 27, 2002 SEP NEWA

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

BIOVAIL PHARMS

EQ 300MG BASE

N20738 004 DEC 22, 1997 JUN CAHN

EQ 400MG BASE

N20738 005 DEC 22, 1997 JUN CAHN

+

EQ 600MG BASE

N20738 006 MAY 27, 1999 JUN CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

BIOVAIL PHARMS

600MG;12.5MG

N21268 001 NOV 01, 2001 JUN CAHN

+

600MG;25MG

N21268 002 NOV 01, 2001 JUN CAHN

EPTIFIBATIDE

INJECTABLE; INJECTION

INTEGRILIN

+ MILLENNIUM PHARMS

2MG/ML

N20718 001 MAY 18, 1998 FEB CAHN

+

75MG/100ML

N20718 002 MAY 18, 1998 FEB CAHN

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

@ NOVARTIS

1MG

N18706 001 JAN 18, 1983 JUN DISC

SOLUTION; ORAL

HYDERGINE

@ NOVARTIS

1MG/ML

N18418 001 JUN DISC

ERYTHROMYCIN

GEL; TOPICAL

E-GLADES

AT GLADES PHARMS 2% N65009 001 MAR 18, 2002 MAR NEWA

ESCITALOPRAM OXALATE

>A>	SOLUTION; ORAL						
>A>	LEXAPRO						
>A>	+ FOREST LABS	EQ 5MG BASE/5ML		N21365 001	NOV 27, 2002	NOV	NEWA
	TABLET; ORAL						
	FOREST LABS	5MG		N21323 001	AUG 14, 2002	AUG	NEWA
		10MG		N21323 002	AUG 14, 2002	AUG	NEWA
	+	20MG		N21323 003	AUG 14, 2002	AUG	NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ALORA

BX	WATSON LABS	0.025MG/24HR		N20655 004	APR 05, 2002	MAY	CMS1
BX		0.025MG/24HR		N20655 004	APR 16, 2002	APR	NEWA
>D>	FEMPATCH						
>D>	BX + PARKE DAVIS	0.025MG/24HR		N20417 001	DEC 03, 1996	NOV	WDAG
>A>	@	0.025MG/24HR		N20417 001	DEC 03, 1996	NOV	WDAG
	TABLET; ORAL						
	ESTRADOL						
AB	USL PHARMA	0.5MG		N40297 001	APR 17, 2002	APR	NEWA
AB		1MG		N40297 002	APR 17, 2002	APR	NEWA
AB		2MG		N40297 003	APR 17, 2002	APR	NEWA

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

+ NOVO NORDISK 1MG;0.5MG N20907 001 NOV 18, 1998 JUN CTNA

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ORTHO-PREFEST

+ KING PHARMS 1MG;1MG;0.09MG N21040 001 OCT 22, 1999 MAY CAHN

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

DURAMED	0.3MG		N20992 001	JUN 21, 2002	AUG	CAHN
DURAMED PHARM BARR	0.3MG		N20992 001	JUN 21, 2002	JUL	NEWA

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)

@ WYETH AYERST 0.625MG;0.625MG;5MG N20303 002 DEC 30, 1994 JUN DISC

PREMPRO (PREMARIN;CYCRIN)

@ WYETH AYERST 0.625MG;0.625MG;2.5MG;2.5MG N20303 001 DEC 30, 1994 JUN DISC

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

PMB 200				
@ WYETH AYERST	0.45MG;200MG	N10971	005	JUN DISC
PMB 400				
@ WYETH AYERST	0.45MG;400MG	N10971	003	JUN DISC

ETHCHLORVYNOL

CAPSULE; ORAL

PLACIDYL				
@ ABBOTT	200MG	N10021	007	JUN DISC
@	500MG	N10021	002	JUN DISC
@	750MG	N10021	010	JUN DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

AB + WYETH AYERST	0.02MG;0.1MG	N20683	001	MAR 27, 1997	MAR	CTEC
AB1 +	0.02MG;0.1MG	N20683	001	MAR 27, 1997	MAY	CTEC

AVIANE-21

AB1 DURAMED PHARM BARR	0.02MG;0.1MG	N75796	002	APR 30, 2001	MAR	CTEC
------------------------	--------------	--------	-----	--------------	-----	------

LESSINA-21

AB2 BARR	0.02MG;0.1MG	N75803	001	MAR 20, 2002	MAR	NEWA
----------	--------------	--------	-----	--------------	-----	------

LEVLITE

AB2 + BERLEX LABS	0.02MG;0.1MG	N20860	001	JUL 13, 1998	MAR	CTEC
-------------------	--------------	--------	-----	--------------	-----	------

PORTIA-21

AB BARR	0.03MG;0.15MG	N75866	001	MAY 23, 2002	MAY	NEWA
---------	---------------	--------	-----	--------------	-----	------

TABLET; ORAL-28

ALESSE

AB1 WYETH AYERST	0.02MG;0.1MG	N20683	002	MAR 27, 1997	MAR	CTEC
------------------	--------------	--------	-----	--------------	-----	------

AVIANE-28

AB1 DURAMED PHARM BARR	0.02MG;0.1MG	N75796	001	APR 30, 2001	MAR	CTEC
------------------------	--------------	--------	-----	--------------	-----	------

LESSINA-28

AB BARR	0.02MG;0.1MG	N75803	002	MAR 20, 2002	MAR	NEWA
---------	--------------	--------	-----	--------------	-----	------

LEVLITE

AB BERLEX LABS	0.02MG;0.1MG	N20860	002	JUL 13, 1998	MAR	CTEC
----------------	--------------	--------	-----	--------------	-----	------

PORTIA-28

AB BARR	0.03MG;0.15MG	N75866	002	MAY 23, 2002	MAY	NEWA
---------	---------------	--------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORTREL 0.5/35-21

AB BARR	0.035MG;0.5MG	N72692	001	FEB 28, 1992	AUG	CTNA
---------	---------------	--------	-----	--------------	-----	------

NORTREL 1/35-21

AB BARR	0.035MG;1MG	N72693	001	FEB 28, 1992	AUG	CTNA
---------	-------------	--------	-----	--------------	-----	------

NORTREL 7/7/7

AB BARR	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .75MG	N75478	001	AUG 30, 2002	AUG	NEWA
---------	--	--------	-----	--------------	-----	------

ORTHO-NOVUM 7/7/7-21

AB + ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .75MG	N18985	001	APR 04, 1984	AUG	CFTG
-------------------------	--	--------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28
NORTREL 0.5/35-28

AB	BARR	0.035MG;0.5MG	N72695 001	FEB 28, 1992	AUG	CTNA
	NORTREL 1/35-28					
AB	BARR	0.035MG;1MG	N72696 001	FEB 28, 1992	AUG	CTNA
	NORTREL 7/7/7					
AB	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75M G,1MG	N75478 002	AUG 30, 2002	AUG	NEWA
	ORTHO-NOVUM 7/7/7-28					
AB	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .75MG	N18985 002	APR 04, 1984	AUG	CFTG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21
ESTROSTEP 21
@ PARKE DAVIS

	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 001	OCT 09, 1996	JUN	DISC
--	-----------------------------------	------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28
ORTHO CYCLEN-28

AB	+ ORTHO MCNEIL PHARM	0.035MG;0.25MG	N19653 002	DEC 29, 1989	SEP	CFTG
	ORTHO TRI-CYCLEN					
+ ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.18MG,0.21 5MG,0.25MG	N19697 001	JUL 03, 1992	SEP	CRLD	
	ORTHO TRI-CYCLEN LO					
+ JOHNSON AND JOHNSON	0.025MG,0.025MG,0.025MG;0.18MG,0.25 MG,0.215MG	N21241 001	AUG 22, 2002	AUG	NEWA	
	SPRINTEC					
AB	BARR	0.035MG;0.25MG	N75804 001	SEP 25, 2002	SEP	NEWA

ETHOSUXIMIDE

CAPSULE; ORAL
ETHOSUXIMIDE

AB	BANNER PHARMACAPS	250MG	N40430 001	OCT 28, 2002	OCT	NEWA
	ZARONTIN					
AB	+ PARKE DAVIS	250MG	N12380 001		OCT	CFTG

ETHOTOIN

TABLET; ORAL
PEGANONE

+ ABBOTT	250MG	N10841 001	JUN	CRLD
@	500MG	N10841 003	JUN	DISC

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURANEST

@ ASTRazeneca	1%	N17751 005	SEP	DISC
---------------	----	------------	-----	------

ETODOLAC

CAPSULE; ORAL
ETODOLAC

AB	NEOSAN PHARMS	300MG	N74929 001	JAN 30, 1998	JUL	CAHN
AB	NEOSAN PHARMS	400MG	N74927 001	OCT 30, 1997	JUL	CAHN
TABLET, EXTENDED RELEASE; ORAL						
AB	EON	400MG	N75943 001	JUL 26, 2002	JUL	NEWA
AB		500MG	N75943 002	JUL 26, 2002	JUL	NEWA
AB		600MG	N75943 003	JUL 26, 2002	JUL	NEWA

EZETIMIBE

TABLET; ORAL
ZETIA

+ MSP SINGAPORE	10MG	N21445 001	OCT 25, 2002	OCT	NEWA
-----------------	------	------------	--------------	-----	------

FAMOTIDINE

INJECTABLE; INJECTION
FAMOTIDINE

AP	APOTEX	10MG/ML	N75942 001	AUG 02, 2002	AUG	NEWA
AP	BAXTER HLTHCARE	10MG/ML	N75799 001	APR 30, 2002	APR	NEWA
FAMOTIDINE PRESERVATIVE FREE						
>A>	APOTEX	10MG/ML	N76324 001	NOV 27, 2002	NOV	NEWA
	@ APOTHECON	10MG/ML	N75708 001	APR 16, 2001	MAR	WDAG
AP	BAXTER HLTHCARE	10MG/ML	N75789 001	APR 30, 2002	APR	NEWA
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)						
>A>	APOTEX	10MG/ML	N76322 001	NOV 27, 2002	NOV	NEWA

FENOFIBRATE

CAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

AB	TEVA	67MG	N75753 001	SEP 03, 2002	SEP	NEWA
AB		134MG	N75753 002	APR 09, 2002	APR	NEWA
AB		200MG	N75753 003	APR 09, 2002	APR	NEWA
TRICOR (MICRONIZED)						
AB	ABBOTT	67MG	N19304 002	FEB 09, 1998	SEP	CFTG
AB		134MG	N19304 003	JUN 30, 1999	APR	CFTG
AB +		200MG	N19304 004	JUN 30, 1999	APR	CFTG

FENOPROFEN CALCIUM

CAPSULE; ORAL
NALFON

AB +	RANBAXY	EQ 300MG BASE	N17604 002		JUN	CAHN
NALFON 200						
AB	RANBAXY	EQ 200MG BASE	N17604 003		JUN	CAHN
TABLET; ORAL						
FENOPROFEN CALCIUM						
>D>	AB MYLAN	EQ 600MG BASE	N72267 001	AUG 17, 1988	NOV	CRLD
>A>	AB +	EQ 600MG BASE	N72267 001	AUG 17, 1988	NOV	CRLD
>D>	NALFON					
>D>	AB + DISTA	EQ 600MG BASE	N17710 001		NOV	DISC
>A>	@	EQ 600MG BASE	N17710 001		NOV	DISC

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL

FENTANYL

@ ANESTA	EQ 0.1MG BASE	N20195 007	OCT 30, 1995	JUN	DISC
@	EQ 0.2MG BASE	N20195 001	OCT 04, 1993	JUN	DISC
@	EQ 0.3MG BASE	N20195 002	OCT 04, 1993	JUN	DISC
@	EQ 0.4MG BASE	N20195 003	OCT 04, 1993	JUN	DISC

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

@ AMERSHAM HLTH	600MG/PACKET	N20292 001	OCT 14, 1997	JUL	DISC
-----------------	--------------	------------	--------------	-----	------

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB BARR	50MG	N75882 001	OCT 28, 2002	OCT	NEWA
AB	100MG	N75882 002	OCT 28, 2002	OCT	NEWA
AB	150MG	N75882 003	OCT 28, 2002	OCT	NEWA
AB GENEVA PHARMS TECH	50MG	N76030 001	OCT 28, 2002	OCT	NEWA
AB	100MG	N76030 002	OCT 28, 2002	OCT	NEWA
AB	150MG	N76030 003	OCT 28, 2002	OCT	NEWA

FLOXURIDINE

INJECTABLE; INJECTION

FUDR

AP + FAULDING	500MG/VIAL	N16929 001		APR	CAHN
---------------	------------	------------	--	-----	------

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F 18

@ DOWNSTATE CLINCL	4-40mCi/ML	N20306 001	AUG 19, 1994	JUL	DISC
--------------------	------------	------------	--------------	-----	------

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

AB + KING PHARMS	0.1MG	N10060 001		MAR	CFTG
	FLUDROCORTISONE ACETATE				

AB IMPAX LABS	0.1MG	N40431 001	MAR 18, 2002	MAR	NEWA
---------------	-------	------------	--------------	-----	------

FLUNISOLIDE

SPRAY, METERED; NASAL

FLUNISOLIDE

AB BAUSCH AND LOMB	0.025MG/SPRAY	N74805 001	FEB 20, 2002	FEB	NEWA
	NASALIDE				

AB + IVAX RES	0.025MG/SPRAY	N18148 001		FEB	CTEC
---------------	---------------	------------	--	-----	------

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALAR-HP

@ MEDICIS	0.2%	N16161 002		JUN	DISC
-----------	------	------------	--	-----	------

FLUOCINOLONE ACETONIDE

SOLUTION; TOPICAL

FLUONID

@ ALLERGAN HERBERT

0.01%

N87158 001 MAR 17, 1983 MAY DISC

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA

+ HILL DERMAC

0.01%;4%;0.05%

N21112 001 JAN 18, 2002 JAN NEWA

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

AB TEVA

0.05%

N72490 001 FEB 07, 1989 AUG CTNA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

AB ALPHAPHARM

EQ 10MG BASE

N75577 001 JAN 29, 2002 JAN NEWA

AB

EQ 20MG BASE

N75577 002 JAN 29, 2002 JAN NEWA

AB BARR

EQ 10MG BASE

N74803 002 JAN 30, 2002 JAN NEWA

AB CARLSBAD

EQ 10MG BASE

N76022 001 JAN 30, 2002 JAN NEWA

AB

EQ 20MG BASE

N76022 002 JAN 30, 2002 JAN NEWA

AB DR REDDYS LABS INC

EQ 10MG BASE

N75465 001 JAN 29, 2002 JAN NEWA

AB

EQ 20MG BASE

N75465 002 JAN 29, 2002 JAN NEWA

AB EON

EQ 10MG BASE

N75807 001 JAN 29, 2002 JAN NEWA

AB

EQ 20MG BASE

N75807 002 JAN 29, 2002 JAN NEWA

AB IVAX PHARMS

EQ 10MG BASE

N75245 002 JAN 31, 2002 JAN NEWA

AB

EQ 20MG BASE

N75245 001 JAN 31, 2002 JAN NEWA

AB MALLINCKRODT

EQ 10MG BASE

N75658 001 JAN 29, 2002 JAN NEWA

AB

EQ 20MG BASE

N75658 002 JAN 29, 2002 JAN NEWA

AB MUTUAL PHARMA

EQ 10MG BASE

N75787 001 JAN 29, 2002 JAN NEWA

AB

EQ 20MG BASE

N75787 002 JAN 29, 2002 JAN NEWA

AB MYLAN

EQ 10MG BASE

N75207 001 JAN 30, 2002 JAN NEWA

AB

EQ 20MG BASE

N75207 002 JAN 30, 2002 JAN NEWA

AB RANBAXY

EQ 10MG BASE

N76165 001 FEB 01, 2002 FEB NEWA

AB

EQ 20MG BASE

N76165 002 FEB 01, 2002 FEB NEWA

AB SIDMAK LABS

EQ 10MG BASE

N76001 001 JAN 29, 2002 JAN NEWA

AB

EQ 20MG BASE

N76001 002 JAN 29, 2002 JAN NEWA

AB SIEGFRIED

EQ 10MG BASE

N75464 001 JAN 30, 2002 JAN NEWA

AB

EQ 20MG BASE

N75464 002 JAN 30, 2002 JAN NEWA

AB TEVA

EQ 10MG BASE

N75452 001 JAN 29, 2002 JAN NEWA

AB

EQ 20MG BASE

N75452 002 JAN 29, 2002 JAN NEWA

AB

EQ 40MG BASE

N75452 003 JAN 29, 2002 JAN NEWA

AB WATSON LABS

EQ 10MG BASE

N75662 001 JAN 29, 2002 JAN NEWA

AB

EQ 20MG BASE

N75662 002 JAN 29, 2002 JAN NEWA

FLUOXETINE HCL

AB GENEVA PHARMS

EQ 20MG BASE

N75049 002 JAN 29, 2002 JAN NEWA

AB

EQ 40MG BASE

N75049 003 JAN 29, 2002 JAN NEWA

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL

FLUOXETINE

AA	ALPHARMA	EQ 20MG BASE/5ML	N75690 001	JAN 31, 2002	JAN	NEWA
AA	MALLINCKRODT	EQ 20MG BASE/5ML	N75920 001	JAN 29, 2002	JAN	NEWA
AA	NOVEX	EQ 20MG BASE/5ML	N75292 001	FEB 07, 2002	FEB	NEWA
AA	PHARM ASSOC	EQ 20MG BASE/5ML	N76015 001	JAN 30, 2002	JAN	NEWA
	FLUOXETINE HCL					
AA	HI TECH PHARMA	EQ 20MG BASE/5ML	N75525 001	JUN 27, 2002	JUN	NEWA
AA	MORTON GROVE	EQ 20MG BASE/5ML	N75514 001	AUG 29, 2002	AUG	NEWA
	TABLET; ORAL					
AB	BARR	EQ 10MG BASE	N75810 001	FEB 01, 2002	FEB	NEWA
AB	DR REDDYS LABS INC	EQ 10MG BASE	N76006 001	JAN 30, 2002	JAN	NEWA
AB	EON	EQ 10MG BASE	N76024 001	JAN 29, 2002	JAN	NEWA
AB	TEVA	EQ 10MG BASE	N75872 001	JAN 29, 2002	JAN	NEWA
AB	ZENITH GOLDLINE	EQ 10MG BASE	N75865 001	FEB 28, 2002	FEB	NEWA

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

PROLIXIN ENANTHATE

@ APOTHECON 25MG/ML

N16110 001

JUN DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

>D>	PERMITIL					
>D>	BP SCHERING	2.5MG	N12034 004		NOV	WDAG
>A>	@	2.5MG	N12034 004		NOV	WDAG
>D>	BP	5MG	N12034 005		NOV	WDAG
>A>	@	5MG	N12034 005		NOV	WDAG

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	+	EON	100MG	N75888 003	NOV 29, 2000	MAY	CRLD
AB		MUTUAL PHARM	25MG	N76125 001	APR 29, 2002	APR	NEWA
AB			50MG	N76125 002	APR 29, 2002	APR	NEWA
AB			100MG	N76125 003	APR 29, 2002	APR	NEWA
AB		TEVA	25MG	N75893 001	SEP 10, 2002	SEP	NEWA
AB			50MG	N75893 002	SEP 10, 2002	SEP	NEWA
AB			100MG	N75893 003	SEP 10, 2002	SEP	NEWA
	LUVOX						
	@ SOLVAY	25MG		N20243 001	DEC 05, 1994	MAY	DISC
	@	50MG		N20243 002	DEC 05, 1994	MAY	DISC
	@	100MG		N20243 003	DEC 05, 1994	MAY	DISC

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	+	WATSON LABS	1MG	N80680 001		FEB	CAHN
----	---	-------------	-----	------------	--	-----	------

FOLLITROPIN ALFA/BETA

INJECTABLE; INJECTION

GONAL-F

@ SERONO

37.5 IU/VIAL

N20378 003 MAY 25, 2000 JUN DISC

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

+ ASTRazeneca

50MG/ML

N21344 001 APR 25, 2002 APR NEWA

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

@ SHIRE LABS

50MG/15ML

N11323 002 JUL DISC

TABLET; ORAL

@ SHIRE LABS

100MG

N11270 002 JUL DISC

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION

NEOSCAN

@ AMERSHAM HLTH

2mCi/ML

N17655 001 JUN DISC

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

@ GENTA

25MG/ML

N19961 002 JAN 17, 1991 JUL CAHN

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

+ TEVA

20MG/VIAL

N20622 001 DEC 20, 1996 JUN CDFR

INJECTABLE; SUBCUTANEOUS

+ TEVA

20MG/ML

N20622 002 FEB 12, 2002 JUN NEWA

GLIPIZIDE

TABLET, EXTENDED RELEASE; ORAL

GLUCOTROL XL

PFIZER

2.5MG

N20329 003 AUG 10, 1999 FEB CRLD

5MG

N20329 001 APR 26, 1994 FEB CRLD

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

METAGLIP

BRISTOL MYERS SQUIBB

2.5MG;250MG

N21460 001 OCT 21, 2002 OCT NEWA

2.5MG;500MG

N21460 002 OCT 21, 2002 OCT NEWA

+

5MG;500MG

N21460 003 OCT 21, 2002 OCT NEWA

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

@ LILLY

EQ 1MG BASE/VIAL

N12122 001 JUN DISC

GLYBURIDE

TABLET; ORAL						
<u>GLYBURIDE</u>						
>A>	AB	AMIDE PHARM	1.5MG	N75947 001	NOV 14, 2002	NOV NEWA
>A>	AB		3MG	N75947 002	NOV 14, 2002	NOV NEWA
>A>	AB		6MG	N75947 003	NOV 14, 2002	NOV NEWA
	AB	COREPHARMA	1.25MG	N76257 001	JUN 27, 2002	JUN NEWA
	AB		2.5MG	N76257 002	JUN 27, 2002	JUN NEWA
	AB		5MG	N76257 003	JUN 27, 2002	JUN NEWA

GONADORELIN ACETATE

INJECTABLE; INJECTION						
<u>LUTREPULSE KIT</u>						
@ FERRING		0.8MG/VIAL	N19687 001	OCT 10, 1989	JUL DISC	
@		3.2MG/VIAL	N19687 002	OCT 10, 1989	JUN DISC	

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION						
<u>FACTREL</u>						
@ WYETH AYERST		EQ 0.5MG BASE/VIAL	N18123 003	SEP 30, 1982	JUN DISC	

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION						
<u>A.P.L.</u>						
@ WYETH AYERST		20,000 UNITS/VIAL	N17055 003		JUN DISC	
<u>CHORIONIC GONADOTROPIN</u>						
@ STERIS		2,000 UNITS/VIAL	N17016 011	FEB 16, 1990	JUN DISC	

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL						
<u>KYTRIL</u>						
@ ROCHE		EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUN DISC	

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL						
<u>GRISACTIN</u>						
@ WYETH AYERST		500MG	N60212 001		MAY DISC	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL						
<u>GRISACTIN ULTRA</u>						
@ WYETH AYERST		165MG	N62438 001	NOV 17, 1983	MAY DISC	
@		330MG	N62438 002	NOV 17, 1983	MAY DISC	

GUANADREL SULFATE

TABLET; ORAL						
<u>HYLOREL</u>						
@ PHARMACIA AND UPJOHN		10MG	N18104 001	DEC 29, 1982	JUN DISC	
@		25MG	N18104 002	DEC 29, 1982	JUN DISC	

GUANETHIDINE MONOSULFATE

TABLET; ORAL

ISMELIN

@ NOVARTIS

@

EQ 10MG SULFATE

N12329 001

JUN DISC

EQ 25MG SULFATE

N12329 002

JUN DISC

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

TENEX

AB ESP PHARMA

AB +

@

EQ 1MG BASE

N19032 001 OCT 27, 1986 APR CAHN

EQ 2MG BASE

N19032 002 NOV 07, 1988 APR CAHN

EQ 3MG BASE

N19032 003 NOV 07, 1988 APR CAHN

HALOPERIDOL

TABLET; ORAL

HALDOL

@ ORTHO MCNEIL

0.5MG

N15921 001 AUG DISC

@

1MG

N15921 002 AUG DISC

@

2MG

N15921 003 AUG DISC

@

5MG

N15921 004 AUG DISC

@

10MG

N15921 005 AUG DISC

@

20MG

N15921 006 FEB 02, 1982 AUG DISC

HALOPERIDOL

+ GENEVA PHARMS

20MG

N71211 001 MAR 11, 1988 AUG CRLD

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

@ ORTHO MCNEIL

EQ 2MG BASE/ML

N15922 001 AUG DISC

HALOPERIDOL

@ ALPHARMA

EQ 2MG BASE/ML

N70318 001 APR 11, 1986 MAY DISC

AA + TEVA

EQ 2MG BASE/ML

N71015 001 AUG 25, 1987 AUG CRLD

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

@ WYETH AYERST

99.99%

N11338 001 APR DISC

HALOTHANE

AN + ABBOTT

99.99%

N83254 001 APR CTEC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP-LOCK

AP + ELKINS SINK

10 UNITS/ML

N17037 007 JUN CRLD

AP +

100 UNITS/ML

N17037 006 JUN CRLD

HEPARIN LOCK FLUSH

@ WYETH AYERST

10 UNITS/ML

N17007 008 JUN DISC

@

100 UNITS/ML

N17007 009 JUN DISC

HEPARIN SODIUM

AP + ABBOTT

2,500 UNITS/ML

N88099 001 APR 28, 1983 JUN CRLD

AP + AM PHARM PARTNERS

20,000 UNITS/ML

N17029 004 JUN CRLD

@ WYETH AYERST

1,000 UNITS/ML

N17007 001 JUN DISC

@	2,500 UNITS/ML	N17007 007	JUN DISC
@	5,000 UNITS/ML	N17007 002	JUN DISC
@	5,000 UNITS/0.5ML	N17007 010	JUN DISC
@	7,500 UNITS/ML	N17007 003	JUN DISC
@	10,000 UNITS/ML	N17007 004	JUN DISC
@	20,000 UNITS/ML	N17007 006	JUN DISC

HEXACHLOROPHENONE

SOAP; TOPICAL			
GAMOPHEN			
@ ARBROOK	2%	N06270 003	JUN DISC
SPONGE; TOPICAL			
E-Z SCRUB			
@ BECTON DICKINSON	450MG	N17452 001	JUN DISC

HISTRELIN ACETATE

INJECTABLE; INJECTION			
SUPPRELIN			
@ SHIRE LABS	EQ 0.2MG BASE/ML	N19836 001 DEC 24, 1991	JUL DISC
@	EQ 0.5MG BASE/ML	N19836 002 DEC 24, 1991	JUL DISC
@	EQ 1MG BASE/ML	N19836 003 DEC 24, 1991	JUL DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL			
HYDROCHLOROTHIAZIDE			
AB VINTAGE PHARMS	12.5MG	N75907 001 SEP 17, 2002	SEP NEWA
TABLET; ORAL			
ESIDRIX			
AB + NOVARTIS	100MG	N11793 009	MAR CRLD
@	100MG	N11793 009	SEP DISC
HYDROCHLOROTHIAZIDE			
AB + IVAX PHARMS	100MG	N85022 001	SEP CRLD
@ LEDERLE	100MG	N87060 001	SEP DISC
AB VINTAGE PHARMS	25MG	N40412 001 MAR 29, 2002	MAR NEWA
AB	50MG	N40412 002 MAR 29, 2002	MAR NEWA
@ WATSON LABS	100MG	N81190 001 JAN 24, 1992	SEP DISC
HYDRODIURIL			
@ MERCK	25MG	N11835 003	MAR DISC
@	50MG	N11835 006	MAR DISC
@	100MG	N11835 007	MAR DISC
ORETIC			
@ ABBOTT	25MG	N11971 001	SEP DISC

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL			
LISINOPRIL AND HYDROCHLOROTHIAZIDE			
AB EON	12.5MG;10MG	N76262 001 JUL 01, 2002	JUL NEWA
	12.5MG;20MG	N76262 002 JUL 01, 2002	JUL NEWA
AB	25MG;20MG	N76262 003 JUL 01, 2002	JUL NEWA
AB GENEVA PHARMS TECH	12.5MG;10MG	N75926 001 JUL 01, 2002	JUL NEWA
AB	12.5MG;20MG	N75926 002 JUL 01, 2002	JUL NEWA
AB	25MG;20MG	N75926 003 JUL 01, 2002	JUL NEWA
AB IVAX PHARMS	12.5MG;10MG	N75776 001 JUL 01, 2002	JUL NEWA

AB		12.5MG;20MG	N75776 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N75776 003	JUL 01, 2002	JUL	NEWA
AB	MYLAN	12.5MG;10MG	N76113 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76113 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76113 003	JUL 01, 2002	JUL	NEWA
AB	PUREPAC PHARM	12.5MG;10MG	N76230 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76230 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76230 003	JUL 01, 2002	JUL	NEWA
AB	RANBAXY	12.5MG;10MG	N76007 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76007 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76007 003	JUL 01, 2002	JUL	NEWA
AB	TEVA	12.5MG;10MG	N75869 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N75869 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N75869 003	JUL 01, 2002	JUL	NEWA
AB	WATSON LABS	12.5MG;20MG	N76194 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;10MG	N76194 003	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76194 002	JUL 01, 2002	JUL	NEWA
AB	WEST WARD	12.5MG;10MG	N76265 001	JUL 08, 2002	JUL	NEWA
AB		12.5MG;20MG	N76265 002	JUL 08, 2002	JUL	NEWA
AB		25MG;20MG	N76265 003	JUL 08, 2002	JUL	NEWA

HYDROCHLOROTHIAZIDE; MOXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIRETIC

SCHWARZ PHARMA	12.5MG;15MG	N20729 003	FEB 14, 2002	JUN	NEWA
----------------	-------------	------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

@ WYETH AYERST	50MG;120MG	N19059 002	JUL 03, 1985	JUN	DISC
----------------	------------	------------	--------------	-----	------

INDERIDE LA 160/50

@ WYETH AYERST	50MG;160MG	N19059 003	JUL 03, 1985	JUN	DISC
----------------	------------	------------	--------------	-----	------

INDERIDE LA 80/50

@ WYETH AYERST	50MG;80MG	N19059 001	JUL 03, 1985	JUN	DISC
----------------	-----------	------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDRORES 25

@ MERCK	25MG;0.125MG	N11958 002		JUN	DISC
---------	--------------	------------	--	-----	------

HYDRORES 50

@ MERCK	50MG;0.125MG	N11958 003		JUN	DISC
---------	--------------	------------	--	-----	------

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

@ ALPHARMA	5MG/5ML;25MG/5ML	N75103 001	SEP 29, 2000	SEP	DISC
------------	------------------	------------	--------------	-----	------

HYCOMINE

@ ENDO PHARMS	5MG/5ML;25MG/5ML	N19410 001	AUG 17, 1990	SEP	DISC
---------------	------------------	------------	--------------	-----	------

HYCOMINE PEDIATRIC

@ ENDO PHARMS	2.5MG/5ML;12.5MG/5ML	N19411 001	AUG 17, 1990	SEP	DISC
---------------	----------------------	------------	--------------	-----	------

HYDROCORTISONE

TABLET; ORAL					
CORTEF					
+ PHARMACIA AND UPJOHN	5MG	N08697 003	MAY	CRLD	
	5MG	N08697 003	OCT	CRLD	
BP +	10MG	N08697 001	MAY	CRLD	
BP	10MG	N08697 001	OCT	CRLD	
BP +	20MG	N08697 002	MAY	CRLD	

HYDROCORTISONE ACETATE

CREAM; TOPICAL					
MICORT-HC					
+ FERNDALE LABS	2%	N40398 001	MAR 29, 2002	MAR	NEWA
INJECTABLE; INJECTION					
HYDROCORTISONE ACETATE					
+ STERIS	25MG/ML	N83128 001	JUN	CRLD	
@	25MG/ML	N83128 001	OCT	DISC	
HYDROCORTONE					
@ MERCK	25MG/ML	N08228 001	JUN	DISC	
@	50MG/ML	N08228 004	JUN	DISC	

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL					
LOCOID					
+ FERNDALE LABS	0.1%	N18514 001	MAR 31, 1982	MAR	CAHN
LOCOID LIPOCREAM					
+ FERNDALE LABS	0.1%	N20769 001	SEP 08, 1997	MAR	CAHN
OINTMENT; TOPICAL					
LOCOID					
+ FERNDALE LABS	0.1%	N18652 001	OCT 29, 1982	MAR	CAHN

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC					
ACHROMYCIN					
@ LEDERLE	1.5%;1%	N50272 001		JUN	DISC

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL					
RESERPINE AND HYDROFLUMETHIAZIDE					
@ PAR PHARM	50MG;0.125MG	N88907 001	SEP 20, 1985	AUG	DISC
SALUTENSIN-DEMI					
@ SHIRE LABS	25MG;0.125MG	N12359 004		JUL	DISC

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC					
PAREDRINE					
@ AKORN	1%	N00004 004		JUN	DISC

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION					
HYDROXYPROGESTERONE CAPROATE					
@ STERIS	250MG/ML	N17439 002		JUN	DISC

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HCL

AA VINTAGE PHARMS 10MG/5ML N40391 001 APR 10, 2002 APR NEWA

IBUPROFEN

SUSPENSION/DROPS; ORAL

MOTRIN

@ MCNEIL

40MG/ML

N20476 001 MAY 25, 1995 JUN DISC

TABLET; ORAL

@ MCNEIL CONS SPECLT

100MG

N20418 001 NOV 16, 1994 JUN DISC

TABLET, CHEWABLE; ORAL

@ MCNEIL CONS SPECLT

50MG

N20135 001 NOV 16, 1994 JUN DISC

@

100MG

N20135 002 NOV 16, 1994 JUN DISC

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN

AP +	PHARMACIA AND UPJOHN	5MG/VIAL	N50661 002	SEP 27, 1990	MAY	CFTG
@		5MG/VIAL	N50661 002	SEP 27, 1990	JUN	DISC
AP +		10MG/VIAL	N50661 001	SEP 27, 1990	MAY	CFTG
@		10MG/VIAL	N50661 001	SEP 27, 1990	JUN	DISC
AP +		20MG/VIAL	N50661 003	APR 25, 1995	MAY	CFTG
@		20MG/VIAL	N50661 003	APR 25, 1995	JUN	DISC
IDAMYCIN PFS						
AP +	PHARMACIA AND UPJOHN	1MG/ML	N50734 001	FEB 17, 1997	MAY	CFTG
IDARUBICIN HCL						
AP	GENSIA SICOR PHARMS	5MG/VIAL	N65037 003	MAY 01, 2002	MAY	NEWA
+		10MG/VIAL	N65037 002	MAY 01, 2002	JUN	CRLD
AP		10MG/VIAL	N65037 002	MAY 01, 2002	MAY	NEWA
+		20MG/VIAL	N65037 001	MAY 01, 2002	JUN	CRLD
AP		20MG/VIAL	N65037 001	MAY 01, 2002	MAY	NEWA
IDARUBICIN HCL PFS						
AP	GENSIA SICOR PHARMS	1MG/ML	N65036 001	MAY 01, 2002	MAY	NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

+	AM PHARM PARTNERS	1GM/VIAL	N76078 001	MAY 28, 2002	AUG	CRLD
		1GM/VIAL	N76078 001	MAY 28, 2002	MAY	NEWA
+		3GM/VIAL	N76078 002	MAY 28, 2002	MAY	NEWA

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+	GENSIA SICOR PHARMS	1GM /20ML(50MG/ML);1GM /10ML(100MG/ML)	N75874 001	FEB 26, 2002	FEB	NEWA
+		3GM /60ML(50MG/ML);1GM /10ML(100MG/ML)	N75874 002	FEB 26, 2002	FEB	NEWA

INAMRINONE LACTATE

INJECTABLE; INJECTION
AMRINONE

AP + ABBOTT	EQ 5MG BASE/ML	N74616 001	AUG 03, 1998	JUN	CRLD
INOCOR					
@ SANOFI SYNTHELABO	EQ 5MG BASE/ML	N18700 001	JUL 31, 1984	JUN	DISC

INDOCYANINE GREEN

INJECTABLE; INJECTION
CARDIO-GREEN
@ AKORN

50MG/VIAL N11525 002 JUN DISC

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB PAR PHARM	25MG	N18829 002	AUG 06, 1984	JUL	CAHN
AB	50MG	N18829 001	AUG 06, 1984	JUL	CAHN
CAPSULE, EXTENDED RELEASE; ORAL					
AB ABLE	75MG	N76114 001	FEB 06, 2002	FEB	NEWA
SUPPOSITORY; RECTAL					
INDOCIN					
@ MERCK	50MG	N17814 001	AUG 13, 1984	MAY	DISC
INDOMETHEGAN					
+ G AND W LABS	50MG	N73314 001	AUG 31, 1992	MAY	CRLD

INSULIN PORK

INJECTABLE; INJECTION
ILETIN I
@ LILLY

500 UNITS/ML N17931 001 JUN DISC

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION
CHOLGRAFIN MEGLUMINE
@ BRACCO

10.3% N09321 007 JUN DISC

IODIXANOL

INJECTABLE; INJECTION
VISIPAQUE 270
@ AMERSHAM HLTH

55% N20808 001 AUG 29, 1997 JUN DISC

VISIPAQUE 320 @ AMERSHAM HLTH 65.2% N20808 002 AUG 29, 1997 JUN DISC

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION
HIPPURAN I 131
@ MALLINCKRODT

0.25mCi/ML N16666 001 JUN DISC

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION
SPECTAMINE
@ IMP

1mCi/ML N19432 001 DEC 24, 1987 JUN DISC

IODEXOL

INJECTABLE; INJECTION

OMNIPAQ 210

@ AMERSHAM HLTH

45.3%

N18956 006 JUN 30, 1989 JUN DISC

JUN CRLD

SOLUTION; URETHRAL

OMNIPAQ 70

@ AMERSHAM HLTH

15.1%

N18956 007 JUN 01, 1994 JUN DISC

JUN DISC

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

@ FAULDING

61%

N74734 001 DEC 10, 1996 JUL DISC

@

76%

N74734 002 DEC 10, 1996 JUL DISC

ISOVUE-128

@ BRACCO

26%

N18735 005 OCT 21, 1986 JUN DISC

JUL CAHN

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+ BERLEX LABS

300MG/ML

N21425 001 SEP 20, 2002 SEP NEWA

FEB NEWA

+

370MG/ML

N21425 002 SEP 20, 2002 SEP NEWA

MAY DISC

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

CONRAY 325

@ MALLINCKRODT

54.3%

N17685 001 JUN DISC

MAY CRLD

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

GUERBET

62%

N20316 001 DEC 21, 1995 JUN CAHN

OXILAN-350

GUERBET

73%

N20316 002 DEC 21, 1995 JUN CAHN

JUN DISC

IPODATE SODIUM

CAPSULE; ORAL

ORAGRAFIN SODIUM

@ BRACCO

500MG

N12967 001 JUN DISC

JUN DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPATROPIUM BROMIDE

AN ROXANE

0.02%

N75867 001 JUL 22, 2002 JUL NEWA

JUN DISC

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HCL

@ 3M

0.12MG/INH

N10375 004 JUN DISC

JUN DISC

JUN DISC

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION
MEDIHALER-ISO

@ 3M 0.08MG/INH

N10375 003

JUN DISC

ISOSORBIDE

SOLUTION; ORAL
ISMOTIC

@ ALCON 100GM/220ML

N17063 001

JUN DISC

ISOSORBIDE DINITRATE

TABLET; ORAL
SORBITRATE

@ ASTRazeneca 5MG
@ 10MG

N16192 001 APR 01, 1996 SEP DISC
N16192 002 APR 01, 1996 SEP DISC

TABLET, CHEWABLE; ORAL
@ ASTRazeneca 5MG

N16776 002 APR 01, 1996 SEP DISC

ISOSORBIDE MONONITRATE

TABLET; ORAL
ISMO

AB ESP PHARMA 20MG

N19091 001 DEC 30, 1991 JUL CAHN

ISOTRETINOIN

CAPSULE; ORAL
ACCUTANE

>D>	HLR	10MG	N18662 002 MAY 07, 1982 NOV CFTG
>A>	AB	10MG	N18662 002 MAY 07, 1982 NOV CFTG
>D>	+	20MG	N18662 004 MAR 28, 1983 NOV CFTG
>A>	AB +	20MG	N18662 004 MAR 28, 1983 NOV CFTG
>D>	+	40MG	N18662 003 MAY 07, 1982 NOV CFTG
>A>	AB +	40MG	N18662 003 MAY 07, 1982 NOV CFTG
>A>	AMNESTEEM		
>A>	AB GENPHARM	10MG	N75945 001 NOV 08, 2002 NOV NEWA
>A>	AB	20MG	N75945 002 NOV 08, 2002 NOV NEWA
>A>	AB	40MG	N75945 003 NOV 08, 2002 NOV NEWA

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETAMINE HCL

AP BIONICHE (CANADA) EQ 100MG BASE/ML

N76092 003 OCT 25, 2002 OCT NEWA

KETOCONAZOLE

TABLET; ORAL
KETOCONAZOLE

AB NEOSAN PHARMS 200MG
AB TORPHARM 200MG

N75341 001 JUL 27, 1999 JUL CAHN
N75912 001 JAN 10, 2002 JAN NEWA

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
KETOPROFEN

AB MYLAN 100MG

N75679 003 FEB 20, 2002 FEB NEWA

AB	150MG	N75679 002 FEB 20, 2002 FEB NEWA
AB	200MG	N75679 001 FEB 20, 2002 FEB NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	AM PHARM PARTNERS	15MG/ML	N75784 001 JAN 11, 2002 JAN NEWA
AP		30MG/ML	N75784 002 JAN 11, 2002 JAN NEWA

KRYPTON, KR-81M

GAS; INHALATION

MPI KRYPTON 81M GAS GENERATOR

@ AMERSHAM HLTH

N/A

N18088 001 JUL DISC

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL

AP	APOTEX	5MG/ML	N76051 001 JUL 05, 2002 JUL NEWA
----	--------	--------	----------------------------------

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA	NOVEX	10GM/15ML	N75911 001 FEB 21, 2002 FEB NEWA
----	-------	-----------	----------------------------------

SOLUTION; ORAL, RECTAL

CEPHULAC

@ AVENTIS PHARMS

10GM/15ML

N17657 001 JUL DISC

ENULOSE

AA	+ ALPHARMA	10GM/15ML	N71548 001 AUG 15, 1988 JUL CRLD
----	------------	-----------	----------------------------------

LAMOTRIGINE

TABLET, CHEWABLE; ORAL

LAMICTAL CD

+ GLAXOSMITHKLINE

25MG

N20764 002 AUG 24, 1998 MAR CRLD

@

100MG

N20764 003 AUG 24, 1998 MAR DISC

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL

PREVACID

TAP PHARM

15MG

N21428 001 AUG 30, 2002 AUG NEWA

+

30MG

N21428 002 AUG 30, 2002 AUG NEWA

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

BX	XANODYNE PHARM	EQ 5MG BASE	N18459 001 JAN 30, 1986 AUG CAHN
AB		EQ 10MG BASE	N71962 001 NOV 19, 1987 AUG CAHN
AB		EQ 15MG BASE	N71104 001 MAR 04, 1987 JUN CAHN

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

ELIGARD

+ ATRIX

7.5MG/VIAL

N21343 001 JAN 23, 2002 JAN NEWA

+

22.5MG/VIAL

N21379 001 JUL 24, 2002 JUL NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

XOPENEX

+ SEPRACOR EQ 0.0105% BASE

N20837 003 JAN 30, 2002 JUN NEWA

LEVOCARNITINE

SOLUTION; ORAL

CARNITOR

@ SIGMA TAU 1GM/10ML

+ 1GM/10ML

@ 1GM/10ML

N18948 002 APR 27, 1988 JUN DISC
N19257 001 APR 10, 1986 JUL CMFD
N19257 001 APR 10, 1986 JUN DISCLEVODOPA

TABLET; ORAL

LARODOPA

@ ROCHE 100MG

@ 250MG

@ 500MG

N16912 005 JUN DISC
N16912 003 JUN DISC
N16912 004 JUN DISCLEVOTHYROXINE SODIUM

TABLET; ORAL

LEVO-T

BX	MOVA	0.025MG
BX		0.05MG
BX		0.075MG
BX		0.088MG
BX		0.1MG
BX		0.112MG
BX		0.125MG
BX		0.15MG
BX		0.175MG
BX		0.2MG
BX +		0.3MG

N21342 001	MAR 01, 2002	MAR	NEWA
N21342 002	MAR 01, 2002	MAR	NEWA
N21342 003	MAR 01, 2002	MAR	NEWA
N21342 004	MAR 01, 2002	MAR	NEWA
N21342 005	MAR 01, 2002	MAR	NEWA
N21342 006	MAR 01, 2002	MAR	NEWA
N21342 007	MAR 01, 2002	MAR	NEWA
N21342 008	MAR 01, 2002	MAR	NEWA
N21342 009	MAR 01, 2002	MAR	NEWA
N21342 010	MAR 01, 2002	MAR	NEWA
N21342 011	MAR 01, 2002	MAR	NEWA

LEVOTHYROXINE SODIUM

AB	MYLAN	0.025MG
AB		0.05MG
AB		0.075MG
AB		0.088MG
AB		0.1MG
AB		0.112MG
AB		0.125MG
AB		0.15MG
AB		0.175MG
AB		0.2MG
AB		0.3MG

N76187 001	JUN 05, 2002	JUN	NEWA
N76187 002	JUN 05, 2002	JUN	NEWA
N76187 003	JUN 05, 2002	JUN	NEWA
N76187 004	JUN 05, 2002	JUN	NEWA
N76187 005	JUN 05, 2002	JUN	NEWA
N76187 006	JUN 05, 2002	JUN	NEWA
N76187 007	JUN 05, 2002	JUN	NEWA
N76187 008	JUN 05, 2002	JUN	NEWA
N76187 009	JUN 05, 2002	JUN	NEWA
N76187 010	JUN 05, 2002	JUN	NEWA
N76187 011	JUN 05, 2002	JUN	NEWA

NOVOTHYROX

BX	GENPHARM	0.025MG
BX		0.05MG
BX		0.075MG
BX		0.088MG
BX		0.1MG
BX		0.112MG

N21292 001	MAY 31, 2002	MAY	NEWA
N21292 002	MAY 31, 2002	MAY	NEWA
N21292 003	MAY 31, 2002	MAY	NEWA
N21292 004	MAY 31, 2002	MAY	NEWA
N21292 005	MAY 31, 2002	MAY	NEWA
N21292 006	MAY 31, 2002	MAY	NEWA

BX		0.125MG	N21292 007	MAY 31, 2002	MAY	NEWA
BX		0.137MG	N21292 008	MAY 31, 2002	MAY	NEWA
BX		0.15MG	N21292 009	MAY 31, 2002	MAY	NEWA
BX		0.175MG	N21292 010	MAY 31, 2002	MAY	NEWA
BX		0.2MG	N21292 011	MAY 31, 2002	MAY	NEWA
BX +		0.3MG	N21292 012	MAY 31, 2002	MAY	NEWA
SYNTHROID						
BX	ABBOTT	0.025MG	N21402 001	JUL 24, 2002	JUL	NEWA
BX		0.05MG	N21402 002	JUL 24, 2002	JUL	NEWA
BX		0.075MG	N21402 003	JUL 24, 2002	JUL	NEWA
BX		0.088MG	N21402 004	JUL 24, 2002	JUL	NEWA
BX		0.1MG	N21402 005	JUL 24, 2002	JUL	NEWA
BX		0.112MG	N21402 006	JUL 24, 2002	JUL	NEWA
BX		0.125MG	N21402 007	JUL 24, 2002	JUL	NEWA
BX		0.137MG	N21402 008	JUL 24, 2002	JUL	NEWA
BX		0.15MG	N21402 009	JUL 24, 2002	JUL	NEWA
BX		0.175MG	N21402 010	JUL 24, 2002	JUL	NEWA
BX		0.2MG	N21402 012	JUL 24, 2002	AUG	NEWA
BX +		0.3MG	N21402 011	JUL 24, 2002	JUL	NEWA
THYRO-TABS						
BX	LLOYD	0.025MG	N21116 001	OCT 24, 2002	OCT	NEWA
BX		0.05MG	N21116 002	OCT 24, 2002	OCT	NEWA
BX		0.075MG	N21116 003	OCT 24, 2002	OCT	NEWA
BX		0.088MG	N21116 010	OCT 24, 2002	OCT	NEWA
BX		0.1MG	N21116 004	OCT 24, 2002	OCT	NEWA
BX		0.112MG	N21116 011	OCT 24, 2002	OCT	NEWA
BX		0.125MG	N21116 005	OCT 24, 2002	OCT	NEWA
BX		0.15MG	N21116 006	OCT 24, 2002	OCT	NEWA
BX		0.175MG	N21116 007	OCT 24, 2002	OCT	NEWA
BX		0.2MG	N21116 008	OCT 24, 2002	OCT	NEWA
BX +		0.3MG	N21116 009	OCT 24, 2002	OCT	NEWA
UNITHROID						
AB	STEVENS J	0.025MG	N21210 001	AUG 21, 2000	JUN	CRLD
AB		0.05MG	N21210 002	AUG 21, 2000	JUN	CRLD
AB		0.075MG	N21210 003	AUG 21, 2000	JUN	CRLD
AB		0.088MG	N21210 004	AUG 21, 2000	JUN	CRLD
AB		0.1MG	N21210 005	AUG 21, 2000	JUN	CRLD
AB		0.112MG	N21210 006	AUG 21, 2000	JUN	CRLD
AB		0.125MG	N21210 007	AUG 21, 2000	JUN	CRLD
AB		0.15MG	N21210 008	AUG 21, 2000	JUN	CRLD
AB		0.175MG	N21210 009	AUG 21, 2000	JUN	CRLD
AB		0.2MG	N21210 010	AUG 21, 2000	JUN	CRLD
AB +		0.3MG	N21210 011	AUG 21, 2000	JUN	CRLD

LIDOCAINE

AEROSOL; ORAL						
XYLOCAINE						
@ ASTRazeneca	10%		N14394 001		JUN	DISC
FILM, EXTENDED RELEASE; Buccal						
LIDOCAINE						
@ NOVEN	23MG/PATCH		N20575 001	MAY 21, 1996	JUN	DISC
OINTMENT; TOPICAL						
AT + FOUGERA	5%		N80198 001		SEP	CRLD

LIDOCAINE

OINTMENT; TOPICAL

XYLOCAINE

@ ASTRazeneca

5%

N08048 001

SEP DISC

LIDOCAINE HYDROCHLORIDE

INJECTABLE; SPINAL

LIDOCAINE HCL 5% AND DEXTROSE 7.5%

+ ABBOTT 5%

N83914 001

SEP CRLD

XYLOCAINE 5% W/ GLUCOSE 7.5%

@ ASTRazeneca 5%

N10496 002 JUL 07, 1982 SEP DISC

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN

@ PHARMACIA AND UPJOHN EQ 250MG BASE

N50316 001

JUN DISC

@ EQ 500MG BASE

N50316 002

JUN DISC

LINEZOLID

TABLET; ORAL

ZYVOX

@ PHARMACIA AND UPJOHN 400MG

N21130 001 APR 18, 2000 JUN DISC

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	APOTEX	2.5MG	N76102 001	SEP 30, 2002	SEP	NEWA
AB		5MG	N76102 002	SEP 30, 2002	SEP	NEWA
AB		10MG	N76102 003	SEP 30, 2002	SEP	NEWA
AB		20MG	N76102 004	SEP 30, 2002	SEP	NEWA
AB		30MG	N76102 005	SEP 30, 2002	SEP	NEWA
AB		40MG	N76102 006	SEP 30, 2002	SEP	NEWA
AB	EON	2.5MG	N75994 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75994 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75994 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75994 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75994 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75994 006	JUL 01, 2002	JUL	NEWA
AB	GENEVA PHARMS TECH	2.5MG	N75903 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75903 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75903 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75903 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75903 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75903 006	JUL 01, 2002	JUL	NEWA
AB	IVAX PHARMS	2.5MG	N75752 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75752 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75752 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75752 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75752 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75752 006	JUL 01, 2002	JUL	NEWA
AB	LEK PHARM	2.5MG	N75999 001	JUL 01, 2002	AUG	NEWA

AB		5MG	N75999 002	JUL 01, 2002	AUG	NEWA
AB		10MG	N75999 003	JUL 01, 2002	AUG	NEWA
AB		20MG	N75999 004	JUL 01, 2002	AUG	NEWA
AB		30MG	N75999 005	JUL 01, 2002	AUG	NEWA
AB		40MG	N75999 006	JUL 01, 2002	AUG	NEWA
AB	MYLAN	2.5MG	N76071 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76071 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N76071 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76071 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N76071 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N76071 006	JUL 01, 2002	JUL	NEWA
AB	PAR PHARM	2.5MG	N75743 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75743 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75743 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75743 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75743 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75743 006	JUL 01, 2002	JUL	NEWA
AB	PUREPAC PHARM	2.5MG	N76180 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76180 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N76180 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76164 001	JUL 01, 2002	JUL	NEWA
AB		30MG	N76164 002	JUL 01, 2002	JUL	NEWA
AB		40MG	N76164 003	JUL 01, 2002	JUL	NEWA
AB	RANBAXY	2.5MG	N75944 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75944 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75944 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75944 004	JUL 01, 2002	JUL	NEWA
AB		40MG	N75944 005	JUL 01, 2002	JUL	NEWA
AB	TEVA	2.5MG	N75783 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75783 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75783 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75783 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75783 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75783 006	JUL 01, 2002	JUL	NEWA
AB	WATSON LABS	2.5MG	N76059 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76059 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N76059 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76059 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N76059 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N76059 006	JUL 01, 2002	JUL	NEWA
AB	WEST WARD	2.5MG	N76063 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76063 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N76063 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76063 004	JUL 01, 2002	JUL	NEWA
AB		40MG	N76063 005	JUL 01, 2002	JUL	NEWA
ZESTRIL						
AB + ASTRazeneca		30MG	N19777 006	JAN 20, 1999	JUL	CFTG

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	WEST WARD	300MG	N76243 001	JUN 27, 2002	JUN	NEWA
----	-----------	-------	------------	--------------	-----	------

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE
AB BARR 300MG N76170 001 JUN 10, 2002 JUN NEWA
LITHOBID
AB + SOLVAY 300MG N18027 001 JUN CFTG

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL
MAXAQUIN
+ PHARMACIA EQ 400MG BASE N20013 001 FEB 21, 1992 JUL CAHN

LORATADINE

TABLET; ORAL
CLARITIN
+ SCHERING 10MG N19658 001 APR 12, 1993 JUL CTEC

LOVASTATIN

TABLET; ORAL
LOVASTATIN
AB CARLSBAD 10MG N75991 001 JUN 05, 2002 JUN NEWA
AB 20MG N75991 002 JUN 05, 2002 JUN NEWA
AB 40MG N75991 003 JUN 05, 2002 JUN NEWA
TABLET, EXTENDED RELEASE; ORAL
ALTOCOR
ANDRX 10MG N21316 001 JUN 26, 2002 JUL CAHN
20MG N21316 002 JUN 26, 2002 JUL CAHN
40MG N21316 003 JUN 26, 2002 JUL CAHN
+ 60MG N21316 004 JUN 26, 2002 JUL CAHN
AURA LABS 10MG N21316 001 JUN 26, 2002 JUN NEWA
20MG N21316 002 JUN 26, 2002 JUN NEWA
40MG N21316 003 JUN 26, 2002 JUN NEWA
+ 60MG N21316 004 JUN 26, 2002 JUN NEWA

LOXPINE HYDROCHLORIDE

CONCENTRATE; ORAL
LOXITANE C
@ WATSON LABS EQ 25MG BASE/ML N17658 001 JUL DISC
INJECTABLE; INJECTION
LOXITANE IM
@ WATSON LABS EQ 50MG BASE/ML N18039 001 JUL DISC

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL
LUMENHANCE
@ BRACCO 3.49MG/GM N20686 001 DEC 19, 1997 JUN DISC

MANNITOL

INJECTABLE; INJECTION
MANNITOL 25%
>D> AP ASTRazeneca 12.5GM/50ML N89239 001 MAY 06, 1987 NOV WDAG

>A>	a	12.5GM/50ML	N89239 001 MAY 06, 1987 NOV WDAG
<u>MASOPROCOL</u>			
CREAM; TOPICAL			
ACTINEX			
JUN NEWA	@ UNIV AZ CANCER CTR	10%	N19940 001 SEP 04, 1992 JUN DISC
<u>MAZINDOL</u>			
TABLET; ORAL			
MAZANOR			
JUN CFTG	@ WYETH AYERST	1MG	N17980 002 APR DISC
SANOREX			
JUL CAHN	NOVARTIS	1MG	N17247 001 APR CTEC
	@	1MG	N17247 001 JUN DISC
	@	2MG	N17247 002 JUN DISC
<u>MEDROXYPROGESTERONE ACETATE</u>			
JUL CTEC	TABLET; ORAL		
AMEN			
	@ AMARIN PHARMS	10MG	N83242 001 SEP DISC
<u>MEFLOQUINE HYDROCHLORIDE</u>			
JUN NEWA	TABLET; ORAL		
JUN NEWA	LARIAM		
JUN NEWA	AB + ROCHE	250MG	N19591 001 MAY 02, 1989 FEB CFTG
	MEFLOQUINE HCL		
	AB GENEVA PHARMS TECH	250MG	N76175 001 FEB 20, 2002 FEB NEWA
JUL CAHN			
JUL CAHN	<u>MEGESTROL ACETATE</u>		
JUL CAHN	SUSPENSION; ORAL		
JUL CAHN	MEGESTROL ACETATE		
JUN NEWA	AB ROXANE	40MG/ML	N75997 001 FEB 15, 2002 FEB NEWA
JUN NEWA			
JUN NEWA	<u>MENOTROPINS (FSH;LH)</u>		
JUN NEWA	INJECTABLE; INJECTION		
PERGONAL			
	BX + SERONO	75 IU/AMP;75 IU/AMP	N17646 001 AUG CMFD
		75 IU/AMP;75 IU/AMP	N17646 001 JUN DISC
	@	150 IU/AMP;150 IU/AMP	N17646 002 MAY 20, 1985 JUN DISC
JUL DISC	REPRONEX		
	+ FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001 AUG 27, 1999 JUN CRLD
	BX	75 IU/VIAL;75 IU/VIAL	N21047 001 AUG 27, 1999 AUG CRLD
JUL DISC	+	150 IU/VIAL;150 IU/VIAL	N21047 002 AUG 27, 1999 JUN CRLD
<u>MEPERIDINE HYDROCHLORIDE</u>			
TABLET; ORAL			
MEPERIDINE HCL			
JUN DISC	AA CARACO	50MG	N40446 001 AUG 08, 2002 AUG NEWA
	AA	100MG	N40446 002 AUG 08, 2002 AUG NEWA

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

@ WYETH AYERST

25MG/ML;25MG/ML

N11730 001

JUN DISC

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

@ WYETH AYERST

EQ 15MG BASE/ML

N08248 002

JUN DISC

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

@ NOVARTIS

100MG

N06008 001

JUN DISC

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+ GALDERMA LABS

2%;0.01%

N20922 001 DEC 10, 1999 APR CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNEX

AP + BAXTER HLTHCARE

100MG/ML

N19884 001 DEC 30, 1988 MAR CAHN

TABLET; ORAL

+ BAXTER HLTHCARE

400MG

N20855 001 MAR 21, 2002 JUN CAHN

+ BRISTOL MYERS SQUIBB

400MG

N20855 001 MAR 21, 2002 MAR NEWA

MESORIDAZINE BESYLATE

INJECTABLE; INJECTION

SERENTIL

@ NOVARTIS

EQ 25MG BASE/ML

N16775 001

JUN DISC

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORINYL 1+50 28-DAY

AB WATSON LABS

0.05MG;1MG

N16659 001

JAN CAHN

METAPROTERENOL SULFATE

SOLUTION; INHALATION

ALUPENT

@ BOEHRINGER INGELHEIM

5%

N17659 001

JUN DISC

METAPROTERENOL SULFATE

AN MORTON GROVE

0.4%

N75586 001 MAY 30, 2002 MAY NEWA

AN MORTON GROVE

0.6%

N75586 002 MAY 30, 2002 MAY NEWA

TABLET; ORAL

ALUPENT

>D> AB BOEHRINGER INGELHEIM

10MG

N15874 002

NOV WDAG

>A> @

10MG

N15874 002

NOV WDAG

>D> AB +

20MG

N15874 001

NOV WDAG

>A> @

20MG

N15874 001

NOV WDAG

METAPROTERENOL SULFATE

TABLET; ORAL

JUN DISC METAPROTERENOL SULFATE

>D>	AB	PAR PHARM	20MG	N72025 001 JUN 28, 1988 NOV CRLD
>A>	AB	+	20MG	N72025 001 JUN 28, 1988 NOV CRLD

METAXALONE

TABLET; ORAL

JUN DISC SKELAXIN

+ ELAN PHARMS	400MG	N13217 001 JUN CAHN
	400MG	N13217 001 AUG CRLD
+	800MG	N13217 003 AUG 30, 2002 AUG NEWA

METFORMIN HYDROCHLORIDE

TABLET; ORAL

APR CAHN GLUCOPHAGE

AB BRISTOL MYERS SQUIBB	500MG	N20357 001 MAR 03, 1995 JAN CFTG
AB	850MG	N20357 002 MAR 03, 1995 JAN CFTG
AB +	1GM	N20357 005 NOV 05, 1998 JAN CFTG

JUN DISC METFORMIN HCL

AB ALPHAPHARM	500MG	N75969 001 JAN 29, 2002 JAN NEWA
AB	850MG	N75969 002 JAN 29, 2002 JAN NEWA
AB	1GM	N75969 003 JAN 29, 2002 JAN NEWA

MAR CAHN ANDRX PHARMS

AB	500MG	N75961 001 JAN 25, 2002 JAN NEWA
AB	850MG	N75961 002 JAN 25, 2002 JAN NEWA
AB	1GM	N75961 003 JAN 25, 2002 JAN NEWA

JUN DISC BARR

AB	500MG	N75971 001 JAN 25, 2002 JAN NEWA
AB	850MG	N75971 002 JAN 25, 2002 JAN NEWA
AB	1GM	N75971 003 JAN 25, 2002 JAN NEWA

JUN DISC CARACO

AB	500MG	N75967 001 JAN 29, 2002 JAN NEWA
AB	850MG	N75967 002 JAN 29, 2002 JAN NEWA
AB	1GM	N75967 003 JAN 29, 2002 JAN NEWA

JUN DISC EON

AB	500MG	N75965 001 JAN 25, 2002 JAN NEWA
AB	850MG	N75965 002 JAN 25, 2002 JAN NEWA
AB	1GM	N75965 003 JAN 25, 2002 JAN NEWA

JAN CAHN GENEVA PHARMS

AB	500MG	N75985 001 JAN 25, 2002 MAY CAHN
AB	850MG	N75985 002 JAN 25, 2002 MAY CAHN
AB	1GM	N75985 003 JAN 25, 2002 MAY CAHN

JUN DISC GENEVA PHARMS TECH

AB	500MG	N75985 001 JAN 25, 2002 JAN NEWA
AB	850MG	N75985 002 JAN 25, 2002 JAN NEWA
AB	1GM	N75985 003 JAN 25, 2002 JAN NEWA

JUN DISC GENPHARM

AB	500MG	N75973 001 JAN 25, 2002 JAN NEWA
AB	850MG	N75973 002 JAN 25, 2002 JAN NEWA
AB	1GM	N75973 003 JAN 25, 2002 JAN NEWA

MAY NEWA GOLDLINE

AB	500MG	N75972 001 JAN 24, 2002 JAN NEWA
----	-------	----------------------------------

NOV WDAG AB 625MG

AB	750MG	N75972 004 JAN 24, 2002 JAN NEWA
----	-------	----------------------------------

NOV WDAG AB 850MG

AB	1GM	N75972 002 JAN 24, 2002 JAN NEWA
----	-----	----------------------------------

NOV WDAG AB 500MG

AB	850MG	N76038 003 JAN 24, 2002 JAN NEWA
----	-------	----------------------------------

AB	500MG	N76038 001 FEB 21, 2002 FEB NEWA
----	-------	----------------------------------

AB	850MG	N76038 002 FEB 21, 2002 FEB NEWA
----	-------	----------------------------------

AB		1GM	N76038 003	FEB 21, 2002	FEB	NEWA
AB	MYLAN	500MG	N75976 001	JAN 24, 2002	JAN	NEWA
AB		850MG	N75976 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75976 003	JAN 24, 2002	JAN	NEWA
AB	PUREPAC PHARM	500MG	N76033 001	JAN 24, 2002	JAN	NEWA
AB		850MG	N76033 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N76033 003	JAN 24, 2001	JAN	NEWA
AB	TEVA	500MG	N75978 001	JAN 25, 2002	JAN	NEWA
AB		850MG	N75978 002	JAN 25, 2002	JAN	NEWA
>A>	AB	1GM	N75978 003	NOV 05, 2002	NOV	NEWA
AB	TORPHARM	500MG	N75984 001	APR 23, 2002	APR	NEWA
AB		850MG	N75984 002	APR 23, 2002	APR	NEWA
AB		1GM	N75984 003	APR 23, 2002	APR	NEWA
AB	WATSON LABS	500MG	N75979 001	JAN 24, 2002	JAN	NEWA
AB		850MG	N75979 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75979 003	JAN 24, 2002	JAN	NEWA
AB	ZENITH GOLDLINE	500MG	N75975 001	JAN 24, 2002	JAN	NEWA
AB		625MG	N75975 004	JAN 24, 2002	JAN	NEWA
AB		750MG	N75975 005	JAN 24, 2002	JAN	NEWA
AB		850MG	N75975 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75975 003	JAN 24, 2002	JAN	NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

GLAXOSMITHKLINE	500MG;EQ 1MG BASE	N21410 001	OCT 10, 2002	OCT	NEWA
	500MG;EQ 2MG BASE	N21410 002	OCT 10, 2002	OCT	NEWA
+	500MG;EQ 4MG BASE	N21410 003	OCT 10, 2002	OCT	NEWA

METHADONE HYDROCHLORIDE

SYRUP; ORAL

DOLOPHINE HCL

@ ROXANE 10MG/30ML

N06134 004

JUL DISC

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

+	OVATION PHARMS	5MG	N05378 002	SEP	CAHN
TABLET, EXTENDED RELEASE; ORAL					
@ ABBOTT	5MG	N05378 004	JUN	DISC	
@	10MG	N05378 003	JUN	DISC	
@	15MG	N05378 005	JUN	DISC	
@ OVATION PHARMS	5MG	N05378 004	SEP	CAHN	
@	10MG	N05378 003	SEP	CAHN	
@	15MG	N05378 005	SEP	CAHN	

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

@ SHIRE LABS 50MG

N07390 001

JUL DISC

METHOHEXITAL SODIUM

INJECTABLE; INJECTION
BREVITAL SODIUM

+ KING PHARMS	500MG/VIAL	N11559 001	FEB CAHN
+	2.5GM/VIAL	N11559 002	FEB CAHN
+	5GM/VIAL	N11559 003	FEB CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION
FOLEX

+ PHARMACIA AND UPJOHN	EQ 50MG BASE/VIAL	N87695 002	APR 08, 1983	JUN CRLD
+	EQ 100MG BASE/VIAL	N87695 003	APR 08, 1983	JUN CRLD
METHOTREXATE SODIUM				
@ LEDERLE	EQ 2.5MG BASE/ML	N11719 004	JUN DISC	
@	EQ 50MG BASE/VIAL	N11719 003	JUN DISC	
@	EQ 100MG BASE/VIAL	N11719 006	JUN DISC	
TABLET; ORAL				
AB + CLONMEL HLTHCARE	EQ 2.5MG BASE	N08085 002	JUL CAHN	

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL
DIUTENSEN-R

@ WALLACE LABS	2.5MG;0.1MG	N12708 005	OCT DISC
----------------	-------------	------------	----------

METHYLDOPA

SUSPENSION; ORAL
ALDOMET

@ MERCK	250MG/5ML	N18389 001	JUN DISC
---------	-----------	------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD

BX + CELLTECH PHARMS	20MG	N21259 001	APR 03, 2001	JUN CTEC
RITALIN LA				
BX NOVARTIS	20MG	N21284 001	JUN 05, 2002	JUN NEWA
	30MG	N21284 002	JUN 05, 2002	JUN NEWA
+	40MG	N21284 003	JUN 05, 2002	JUN NEWA
TABLET; ORAL				
METHYLPHENIDATE HCL				
AB PUREPAC PHARM	5MG	N40321 001	FEB 05, 2002	FEB NEWA
AB	10MG	N40321 002	FEB 05, 2002	FEB NEWA
AB	20MG	N40321 003	FEB 05, 2002	FEB NEWA
TABLET, EXTENDED RELEASE; ORAL				
CONCERTA				
+ ALZA	27MG	N21121 004	APR 01, 2002	JUN NEWA

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

AB GENEVA PHARMS	4MG	N40194 001	OCT 31, 1997	MAY CAHN
------------------	-----	------------	--------------	----------

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION
DEPO-MEDROL
+ PHARMACIA AND UPJOHN 80MG/ML
METHYLPREDNISOLONE ACETATE
@ STERIS 20MG/ML
@ 80MG/ML

N11757 004 SEP CTEC
N85597 001 SEP DISC
N85595 001 SEP DISC

METHYLTESTOSTERONE

TABLET; ORAL
METHYLTESTOSTERONE
@ LANNETT 10MG
@ 25MG

N87092 001 NOV 05, 1982 SEP DISC
N87111 001 JAN 27, 1983 SEP DISC

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL
METOCLOPRAMIDE HCL
>D AA TEVA EQ 5MG BASE/5ML
>A AA + EQ 5MG BASE/5ML
>D REGLAN
>D AA + ROBINS AH EQ 5MG BASE/5ML
>A @ EQ 5MG BASE/5ML

N70819 001 JUL 10, 1987 NOV CRLD
N70819 001 JUL 10, 1987 NOV CRLD
N18821 001 MAR 25, 1983 NOV WDAG
N18821 001 MAR 25, 1983 NOV WDAG

METRONIDAZOLE

INJECTABLE; INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER
AP + GD SEARLE LLC 500MG/100ML

N18353 002 JUL CAHN

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
FLAGYL I.V.
+ GD SEARLE LLC EQ 500MG BASE/VIAL

N18353 001 JUL CAHN

MICONAZOLE NITRATE

CREAM, INSERT; TOPICAL, VAGINAL
MONISTAT DUAL- PAK
@ PERSONAL PRODS 1.2GM;2%

N20968 001 JUN 30, 1999 JUN DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL
AP + ABBOTT EQ 1MG BASE/ML
AP EQ 1MG BASE/ML
AP + EQ 5MG BASE/ML
AP EQ 5MG BASE/ML
AP ROSS LABS EQ 1MG BASE/ML
AP EQ 5MG BASE/ML
VERSED
@ HLR EQ 1MG BASE/ML
@ EQ 5MG BASE/ML

N75293 001 JUN 20, 2000 OCT CRLD
N75857 001 JUL 22, 2002 JUL NEWA
N75293 002 JUN 20, 2000 OCT CRLD
N75857 002 JUL 22, 2002 JUL NEWA
N75856 001 JUN 13, 2002 JUN NEWA
N75856 002 JUN 13, 2002 JUN NEWA
N18654 002 MAY 26, 1987 OCT DISC
N18654 001 DEC 20, 1985 OCT DISC

MIDAZOLAM HYDROCHLORIDE

SYRUP; ORAL

MIDAZOLAM HCL

SEP CTEC	AA RANBAXY	EQ 2MG BASE/ML	N76058 001	MAR 15, 2002	MAR	NEWA
SEP DISC	AA + ROXANE	EQ 2MG BASE/ML	N75873 001	APR 30, 2002	SEP	CRLD
SEP DISC	AA	EQ 2MG BASE/ML	N75873 001	APR 30, 2002	APR	NEWA
	VERSED					
	AA + ROCHE	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998	MAR	CFTG
	@	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998	AUG	DISC

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

	SHIRE LABS	10MG	N19815 003	MAR 20, 2002	JUL	CRLD
	+	10MG	N19815 003	MAR 20, 2002	JUN	NEWA
	SHIRE PHARM	2.5MG	N19815 001	SEP 06, 1996	SEP	CMD
NOV CRLD		5MG	N19815 002	SEP 06, 1996	JUN	CRLD
NOV CRLD	+	5MG	N19815 002	SEP 06, 1996	OCT	CRLD
NOV WDAG		10MG	N19815 003	MAR 20, 2002	OCT	CRLD

MIFEPRISTONE

TABLET; ORAL

MIFEPREX

NOV WDAG	+	DANCO LABS LLC	200MG	N20687 001	SEP 28, 2000	OCT	CAHN
----------	---	----------------	-------	------------	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

	AP ABBOTT	EQ 1MG BASE/ML	N75884 001	MAY 28, 2002	MAY	NEWA
	AP AM PHARM PARTNERS	EQ 1MG BASE/ML	N75936 001	MAY 28, 2002	MAY	NEWA
	AP BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	N75852 001	MAY 28, 2002	MAY	NEWA
JUL CAHN	>D> AP BEDFORD	EQ 10MG 10ML (10MG/ML)	N75660 001	MAY 28, 2002	NOV	CPT
	>A> AP	EQ 10MG /10ML (10MG/ML)	N75660 001	MAY 28, 2002	NOV	CPT
	AP	EQ 10MG 10/ML (10MG/ML)	N75660 001	MAY 28, 2002	MAY	NEWA
	AP	EQ 20MG /20ML (1MG/ML)	N75660 002	MAY 28, 2002	MAY	NEWA
	AP	EQ 50MG /50ML (1MG/ML)	N75660 003	MAY 28, 2002	MAY	NEWA
JUN DISC	AP ESI LEDERLE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	MAY	NEWA
	AP FAULDING	EQ 1MG BASE/ML	N75830 001	MAY 28, 2002	MAY	NEWA
	AP INTL MEDICATED	EQ 1MG BASE/ML	N76013 001	AUG 02, 2002	AUG	NEWA

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

OCT CRLD	AP ABBOTT	EQ 20MG BASE/100ML	N75885 001	MAY 28, 2002	MAY	NEWA
JUL NEWA	AP +	EQ 40MG BASE/200ML	N75885 002	MAY 28, 2002	MAY	NEWA
OCT CRLD	AP BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75834 001	MAY 28, 2002	MAY	NEWA
JUL NEWA	AP	EQ 40MG BASE/100ML	N75834 002	MAY 28, 2002	MAY	NEWA
JUN NEWA	AP	EQ 40MG BASE/200ML	N75834 002	MAY 28, 2002	JUN	NEWA
JUN NEWA	AP ESI LEDERLE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002	MAY	NEWA

MILRINONE LACTOSE IN 5% DEXTROSE

OCT DISC	AP ESI LEDERLE	EQ 20MG BASE/100ML	N76259 001	AUG 08, 2002	AUG	NEWA
OCT DISC	PRIMACOR					
	AP + SANOFI SYNTHELABO	EQ 1MG BASE/ML	N19436 001	DEC 31, 1987	MAY	CFTG

MILRINONE LACTATE

INJECTABLE; INJECTION

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CFTG
AP +		EQ 40MG BASE/100ML	N20343 004	AUG 09, 1994	MAY	CFTG
AP +		EQ 40MG BASE/200ML	N20343 004	AUG 09, 1994	JUN	CFTG

MINOCYCLINE HYDROCHLORIDE

SUSPENSION; ORAL

MINOCIN

@ LEDERLE EQ 50MG BASE/5ML

N50445 001

JUN DISC

MISOPROSTOL

TABLET; ORAL

CYTOTEC

AB	GD SEARLE LLC	0.1MG	N19268 003	SEP 21, 1990	JUL	CFTG
AB +		0.2MG	N19268 001	DEC 27, 1988	JUL	CFTG
MISOPROSTOL						
AB	IVAX PHARMS	0.1MG	N76095 001	JUL 10, 2002	JUL	NEWA
AB		0.2MG	N76095 002	JUL 10, 2002	JUL	NEWA

MITOMYCIN

INJECTABLE; INJECTION

>A> MYTOZYTREX

>A> + SUPERGEN 5MG/VIAL

N50763 001 NOV 14, 2002 NOV NEWA

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ABBOTT EQ 0.5MG BASE/ML

N20098 002 JAN 22, 1992 JUN DISC

MOMETASONE FUROATE

OINTMENT; TOPICAL

ELOCON

AB +	SCHERING	0.1%	N19543 001	APR 30, 1987	MAR	CFTG
MOMETASONE FUROATE						
AB	CLAY PARK	0.1%	N76067 001	MAR 18, 2002	MAR	NEWA

MONOCTANOIN

LIQUID; PERfusion, BILIARY

MOCTANIN

@ ETHITEK 100%

N19368 001 OCT 29, 1985 JUN DISC

MONTELUKAST SODIUM

GRANULE; ORAL

SINGULAIR

+ MERCK EQ 4MG BASE/PACKET

N21409 001 JUL 26, 2002 JUL NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

MAY	CFTG	BX	+	ELAN PHARM	30MG	N21260 001	MAR 20, 2002	SEP	CTEC
MAY	CFTG				30MG	N21260 001	MAR 20, 2002	MAR	NEWA
JUN	CFTG	BX	+		60MG	N21260 002	MAR 20, 2002	SEP	CTEC
					60MG	N21260 002	MAR 20, 2002	MAR	NEWA
			+		90MG	N21260 003	MAR 20, 2002	SEP	CRLD
					90MG	N21260 003	MAR 20, 2002	MAR	NEWA
			+		120MG	N21260 004	MAR 20, 2002	MAR	NEWA

KADIAN

JUN	DISC	BX	+	FAULDING PHARMS	30MG	N20616 004	MAR 09, 2001	SEP	CTEC
		BX	+		60MG	N20616 005	MAR 09, 2001	SEP	CTEC

TABLET, EXTENDED RELEASE; ORAL

MS CONTIN

JUL	CFTG	AB		PURDUE FREDERICK	15MG	N19516 003	SEP 12, 1989	OCT	CRLD
JUL	CFTG	AB			30MG	N19516 001	MAY 29, 1987	OCT	CRLD
		AB			100MG	N19516 004	JAN 16, 1990	OCT	CRLD
		AB			200MG	N19516 005	NOV 08, 1993	OCT	CRLD

JUL NEWA

JUL NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

NOV	NEWA	AB		EON	500MG	N75280 001	FEB 25, 2002	FEB	NEWA
		AB			750MG	N75280 002	FEB 25, 2002	FEB	NEWA
		AB		INVAMED	500MG	N75590 001	FEB 25, 2002	FEB	NEWA
		AB			750MG	N75590 002	FEB 25, 2002	FEB	NEWA

NAFCILLIN SODIUM

CAPSULE; ORAL

UNIPEN

@ WYETH AYERST

EQ 250MG BASE

N50111 001

JUN DISC

JUN DISC

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

@ ABBOTT

1.5MG/ML

N20200 001 MAR 12, 1993 JUL DISC

MAR CFTG

MAR NEWA

NALIDIXIC ACID

SUSPENSION; ORAL

NEGRAM

@ SANOFI SYNTHELABO

250MG/5ML

N17430 001

JUN DISC

JUN DISC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HCL

MALLINCKRODT

25MG

N76264 001 MAR 22, 2002 MAR NEWA

JUL NEWA

		AB			50MG	N76264 002	MAR 22, 2002	MAR	NEWA
			+		100MG	N76264 003	MAR 22, 2002	MAR	NEWA
				REVIA					
		>A>	AB	+	BARR PHARMS	N18932 001	NOV 20, 1984	NOV	CAHN
		>D>	AB	+	BRISTOL MYERS SQUIBB	N18932 001	NOV 20, 1984	NOV	CAHN
					50MG				
					50MG				

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

@ ELAN PHARM

EQ 750MG BASE

N20353 003 JAN 05, 1996 JUN DISC

NEOMYCIN SULFATE

SOLUTION; ORAL

MYCIFRADIN

AA + PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N50285 001	MAY CFTG
@	EQ 87.5MG BASE/5ML	N50285 001	JUN DISC
NEO-FRADIN			
+ PHARMATEK	EQ 87.5MG BASE/5ML	N65010 001	MAY 23, 2002 JUN CRLD
AA	EQ 87.5MG BASE/5ML	N65010 001	MAY 23, 2002 MAY NEWA

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

STATROL

@ ALCON EQ 3.5MG BASE/GM;10,000 UNITS/GM N50344 002

JUN DISC

SOLUTION/DROPS; OPHTHALMIC

@ ALCON EQ 3.5MG BASE/ML;16,250 UNITS/ML N50456 001

JUN DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

@ KOS 375MG N20381 001 JUL 28, 1997 AUG DISC

+ 500MG N20381 002 JUL 28, 1997 AUG CMFD

@ 500MG N20381 002 JUL 28, 1997 JUN DISC

NIASPAN TITRATION STARTER PACK

@ KOS 375MG;500MG;750MG N20381 005 JUL 28, 1997 JUN DISC

NICOTINE

INHALANT; INHALATION

>D> NICOTROL

>D> + PHARMACIA AND UPJOHN 4MG/CARTRIDGE

N20714 001 MAY 02, 1997 NOV WDAG

>A> @ 4MG/CARTRIDGE N20714 001 MAY 02, 1997 NOV WDAG

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

AB1 + BAYER 90MG N20198 003 APR 21, 1993 AUG CTEC

NIFEDIPINE

AB1 BIOVAIL 90MG N76070 001 AUG 16, 2002 AUG NEWA

NILUTAMIDE

TABLET; ORAL

NILANDRON

@ AVENTIS PHARMS 50MG N20169 001 SEP 19, 1996 JUN DISC

+ 150MG N20169 002 APR 30, 1999 JUL CMFD

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

JUN	DISC	+ FIRST HORIZON	10MG 20MG 30MG 40MG	N20356 001 N20356 002 N20356 003 N20356 004	FEB 02, 1995 FEB 02, 1995 FEB 02, 1995 FEB 02, 1995	MAR	CAHN
MAY	CFTG	+ WHITEHALL ROBINS	10MG 20MG 40MG	N20356 001 N20356 002 N20356 004	FEB 02, 1995 FEB 02, 1995 FEB 02, 1995	FEB	CAHN
JUN	DISC	+					

NITAZOXANIDE

FOR SUSPENSION; ORAL

ALINIA

>A>	+ ROMARK	100MG/5ML
-----	----------	-----------

N21498 001 NOV 22, 2002 NOV NEWA

NITISINONE

CAPSULE; ORAL

ORFADIN

JUN	DISC	R R REGISTRATIONS	2MG 5MG 10MG	N21232 001 N21232 002 N21232 003	JAN 18, 2002 JAN 18, 2002 JAN 18, 2002	JAN	NEWA
AUG	DISC	SWEDISH ORPHAN	2MG 5MG 10MG	N21232 001 N21232 002 N21232 003	JAN 18, 2002 JAN 18, 2002 JAN 18, 2002	MAY	CAHN
AUG	CMFD	+					
JUN	DISC	+					

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

JUN	DISC	+ FIRST HORIZON	25MG/5ML
-----	------	-----------------	----------

N09175 001 JAN CAHN

NITROFURAZONE

CREAM; TOPICAL

FURACIN

NOV	WDAG	@ SHIRE LABS	0.2%	N83789 001	JUL	DISC
		OINTMENT; TOPICAL		N05795 001	JUL	DISC
		@ SHIRE LABS	0.2%	N05795 001	SEP	CMFD

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

AUG	CTEC	@ FIRST HORIZON	0.4MG/SPRAY	N18705 001	OCT 31, 1985	APR	CAHN
		@ POHL BOSKAMP	0.4MG/SPRAY	N18705 001	OCT 31, 1985	JUN	CAHN

SPRAY, METERED; SUBLINGUAL

NITROLINGUAL PUMPSPRAY

JUN	DISC	+ FIRST HORIZON	0.4MG/SPRAY	N18705 002	JAN 10, 1997	APR	CAHN
JUL	CMFD	+ POHL BOSKAMP	0.4MG/SPRAY	N18705 002	JAN 10, 1997	JUN	CAHN

TABLET; SUBLINGUAL

NITROSTAT

		Pfizer Pharmas	0.4MG	N21134 002	MAY 01, 2000	JUN	CAHN
--	--	----------------	-------	------------	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL
AXID

AB	LILLY	150MG	N19508 001	APR 12, 1988	JUL	CFTG
AB	+	300MG	N19508 002	APR 12, 1988	JUL	CFTG
AB	RELIANT PHARMS	150MG	N19508 001	APR 12, 1988	AUG	CAHN
AB	+	300MG	N19508 002	APR 12, 1988	AUG	CAHN
NIZATIDINE						
AB	EON	150MG	N76178 001	JUL 05, 2002	JUL	NEWA
AB		300MG	N76178 002	JUL 05, 2002	JUL	NEWA
AB	GENPHARM	150MG	N75934 001	JUL 09, 2002	JUL	NEWA
AB		300MG	N75934 002	JUL 09, 2002	JUL	NEWA
AB	MYLAN	150MG	N75806 001	JUL 05, 2002	JUL	NEWA
AB		300MG	N75806 002	JUL 05, 2002	JUL	NEWA
AB	TEVA	150MG	N75668 001	SEP 12, 2002	SEP	NEWA
AB		300MG	N75668 002	SEP 12, 2002	SEP	NEWA
AB	WATSON LABS	150MG	N75616 001	JUL 09, 2002	JUL	NEWA
AB		300MG	N75616 002	JUL 09, 2002	JUL	NEWA
AB	ZENITH GOLDLINE	150MG	N75461 001	JUL 08, 2002	JUL	NEWA
AB		300MG	N75461 002	JUL 08, 2002	JUL	NEWA

NORETHINDRONE

TABLET; ORAL
NOR-QD

+ AB	WATSON LABS (UTAH)	0.35MG	N17060 001		MAY	CAHN
TABLET; ORAL-28						
CAMILA						
AB1	BARR	0.35MG	N76177 001	OCT 21, 2002	OCT	NEWA
	ERRIN					
AB2	BARR	0.35MG	N76225 001	OCT 21, 2002	OCT	NEWA
	MICRONOR					
AB2 + AB1	ORTHO MCNEIL PHARM	0.35MG	N16954 001		OCT	CFTG
	NOR-QD					
AB1 + AB2	WATSON LABS (UTAH)	0.35MG	N17060 001		OCT	CFTG

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL
AVENTYL HCL

AA +	RANBAXY	EQ 10MG BASE/5ML	N14685 001		JUN	CAHN
------	---------	------------------	------------	--	-----	------

NOVOBIOCIN SODIUM

CAPSULE; ORAL
ALBAMYCIN

AA	@ PHARMACIA AND UPJOHN	EQ 250MG BASE	N50339 001		JUN	DISC
----	------------------------	---------------	------------	--	-----	------

NYSTATIN

TABLET; ORAL
NILSTAT

@ LEDERLE		500,000 UNITS	N61151 001		JUN	DISC
TABLET; VAGINAL						
@ LEDERLE		100,000 UNITS	N61325 001		JUL	DISC

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
SANDOSTATIN LAR

>D>	+ NOVARTIS	EQ 10MG BASE/VIAL	N21008 001	NOV 25, 1998	NOV	CRLD
>A>		EQ 10MG BASE/VIAL	N21008 001	NOV 25, 1998	NOV	CRLD
>D>	+	EQ 20MG BASE/VIAL	N21008 002	NOV 25, 1998	NOV	CRLD
>A>		EQ 20MG BASE/VIAL	N21008 002	NOV 25, 1998	NOV	CRLD

OFLOXACIN

INJECTABLE; INJECTION
FLOXIN

AP +	JOHNSON RW	40MG/ML	N20087 003	MAR 31, 1992	JAN	CFTG
	@ ORTHO MCNEIL PHARM	20MG/ML	N20087 002	MAR 31, 1992	JUL	DISC
	OFLOXACIN					
AP	BEDFORD	40MG/ML	N75762 001	JAN 16, 2002	JAN	NEWA

OLANZAPINE

TABLET; ORAL
ZYPREXA
LILLY

		2.5MG	N20592 001	SEP 30, 1996	OCT	CRLD
--	--	-------	------------	--------------	-----	------

OLMESARTAN MEDOXOMIL

TABLET; ORAL
BENICAR

	SANKYO	5MG	N21286 001	APR 25, 2002	APR	NEWA
		20MG	N21286 003	APR 25, 2002	APR	NEWA
+		40MG	N21286 004	APR 25, 2002	APR	NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

>A>	AB AB	IMPAX LABS	10MG	N75785 001	NOV 08, 2002	NOV	NEWA
>A>	AB AB		20MG	N75785 002	NOV 08, 2002	NOV	NEWA
>A>	AB AB	KREMERS URBAN DEV	10MG	N75410 001	NOV 01, 2002	NOV	NEWA
>A>	AB AB		20MG	N75410 002	NOV 01, 2002	NOV	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)
ELOXATIN

	SANOFI	50MG/VIAL	N21492 001	AUG 09, 2002	AUG	NEWA
+		100MG/VIAL	N21492 002	AUG 09, 2002	AUG	NEWA

OXANDROLONE

TABLET; ORAL
OXANDRIN

	BIO TECH GEN	2.5MG	N13718 001		JUN	CRLD
+		10MG	N13718 002	NOV 05, 2001	JUN	NEWA

OXAPROZIN

TABLET; ORAL
OXAPROZIN

AB	CARACO	600MG	N75844 001	JAN 03, 2002	JAN	NEWA
----	--------	-------	------------	--------------	-----	------

AB	IVAX PHARMS	600MG	N75846 001	MAY 13, 2002	MAY	NEWA
AB	TEVA	600MG	N75849 001	JUL 03, 2002	JUL	NEWA

OXaprozin Potassium

TABLET; ORAL						
DAYRO ALTA						
+ PHARMACIA	600MG		N20776 001	OCT 17, 2002	OCT	NEWA

Paclitaxel

INJECTABLE; INJECTION						
PACLITAXEL						
AP ABBOTT	6MG/ML		N76131 001	MAY 08, 2002	MAY	NEWA
AP NAPRO	6MG/ML		N76233 001	AUG 01, 2002	AUG	NEWA

Pamidronate Disodium

INJECTABLE; INJECTION						
PAMIDRONATE DISODIUM						
AP AESGEN	30MG/VIAL		N75594 001	MAY 06, 2002	MAY	NEWA
AP	90MG/VIAL		N75594 002	MAY 06, 2002	MAY	NEWA
AP AM PHARM PARTNERS	30MG/VIAL		N75773 001	MAY 06, 2002	MAY	NEWA
AP	30MG /10ML(3MG/ML)		N76207 001	MAY 17, 2002	MAY	NEWA
AP	90MG/VIAL		N75773 002	MAY 06, 2002	MAY	NEWA
AP	90MG /10ML(9MG/ML)		N76207 002	MAY 17, 2002	MAY	NEWA
AP BEDFORD	30MG /10ML(3MG/ML)		N21113 001	MAR 04, 2002	MAY	CDFR
AP +	90MG /10ML(9MG/ML)		N21113 002	MAR 04, 2002	MAY	CDFR
AP FAULDING	30MG /10ML(3MG/ML)		N75841 001	JUN 27, 2002	JUN	NEWA
AP	60MG /10ML(6MG/ML)		N75841 002	JUN 27, 2002	JUN	NEWA
AP	90MG /10ML(9MG/ML)		N75841 003	JUN 27, 2002	JUN	NEWA
AP GENESIA SICOR PHARMS	30MG /10ML(3MG/ML)		N76153 001	MAR 27, 2002	MAY	CDFR
AP	90MG /10ML(9MG/ML)		N76153 002	MAR 27, 2002	MAY	CDFR
INJECTABLE; IV (INFUSION)						
AP BEDFORD	30MG /10ML(3MG/ML)		N21113 001	MAR 04, 2002	MAR	NEWA
AP +	90MG /10ML(9MG/ML)		N21113 002	MAR 04, 2002	MAR	NEWA
AP GENESIA SICOR PHARMS	30MG /10ML(3MG/ML)		N76153 001	MAR 27, 2002	MAR	NEWA
AP	90MG /10ML(9MG/ML)		N76153 002	MAR 27, 2002	MAR	NEWA

Pancrelipase (Amylase; Lipase; Protease)

CAPSULE; ORAL						
COTAZYM						
@ ORGANON	30,000USP UNITS;8,000USP UNITS;30,000USP UNITS		N20580 001	DEC 09, 1996	JUN	DISC

Paramethadione

CAPSULE; ORAL						
PARADIONE						
@ ABBOTT	150MG		N06800 003		JUN	DISC
@	300MG		N06800 001		JUN	DISC

Paroxetine Hydrochloride

TABLET, EXTENDED RELEASE; ORAL						
PAXIL CR						
GLAXOSMITHKLINE	EQ 12.5MG BASE		N20936 001	FEB 16, 1999	OCT	CRLD
	EQ 25MG BASE		N20936 002	FEB 16, 1999	OCT	CRLD

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM

AP	GENEVA PHARMS	1,000,000 UNITS/VIAL	N65079 001	AUG 30, 2002	AUG	NEWA
AP		5,000,000 UNITS/VIAL	N65079 002	AUG 30, 2002	AUG	NEWA
AP		20,000,000 UNITS/VIAL	N65079 003	AUG 30, 2002	AUG	NEWA

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL
PEN-VEE K

@ WYETH AYERST	EQ 125MG BASE/5ML	N60007 001	MAY	DISC
@	EQ 250MG BASE/5ML	N60007 002	MAY	DISC

PENTAGASTRIN

INJECTABLE; INJECTION
PEPTAVLON

@ WYETH AYERST	0.25MG/ML	N17048 001	APR	DISC
----------------	-----------	------------	-----	------

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
ELMIRON

+ JOHNSON AND JOHNSON	100MG	N20193 001	SEP 26, 1996	JUL	CAHN
-----------------------	-------	------------	--------------	-----	------

PERGOLIDE MESYLATE

TABLET; ORAL
PERGOLIDE MESYLATE

>A>	AB	TEVA	EQ 0.05MG BASE	N76061 001	NOV 27, 2002	NOV	NEWA
>A>	AB		EQ 0.25MG BASE	N76061 002	NOV 27, 2002	NOV	NEWA
>A>	AB		EQ 1MG BASE	N76061 003	NOV 27, 2002	NOV	NEWA
		PERMAX					
>D>	+	LILLY	EQ 0.05MG BASE	N19385 001	DEC 30, 1988	NOV	CFTG
>A>	AB	+	EQ 0.05MG BASE	N19385 001	DEC 30, 1988	NOV	CFTG
>D>			EQ 0.25MG BASE	N19385 002	DEC 30, 1988	NOV	CFTG
>A>	AB		EQ 0.25MG BASE	N19385 002	DEC 30, 1988	NOV	CFTG
>D>			EQ 1MG BASE	N19385 003	DEC 30, 1988	NOV	CFTG
>A>	AB		EQ 1MG BASE	N19385 003	DEC 30, 1988	NOV	CFTG

PHENACEMIDE

TABLET; ORAL
PHENURONE

@ ABBOTT	500MG	N07707 001	JUN	DISC
----------	-------	------------	-----	------

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL

@ ABLE	200MG;800MG;160MG	N21105 001	JUN 26, 2001	JUN	DISC
--------	-------------------	------------	--------------	-----	------

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	MIKART	35MG	N89452 001	OCT 30, 1991	MAR	CMFD
----	--------	------	------------	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL
AA VINTAGE PHARMS 37.5MG N40377 001 JAN 04, 2002 JAN NEWA

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
PREFRIN-A
@ ALLERGAN 0.12%;0.1% N07953 001 JUN DISC

PHENYTOIN

SUSPENSION; ORAL
PHENYTOIN
AB MORTON GROVE 125MG/5ML N40420 001 APR 19, 2002 APR NEWA

PILOCARPINE

DRUG DELIVERY SYSTEM; OPHTHALMIC
OCUSERT PILO-40
@ AKORN 11MG N17548 001 JUN DISC
INSERT, EXTENDED RELEASE; OPHTHALMIC
OCUSERT PILO-20
@ AKORN 5MG N17431 001 JUN DISC

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION
ARDUAN
@ ORGANON 10MG/VIAL N19638 001 JUN 26, 1990 JUN DISC

PODOFILOX

SOLUTION; TOPICAL
CONDYLOX
AT + PADDICK 0.5% N19795 001 DEC 13, 1990 JAN CFTG
PODOFILOX
AT PADDICK 0.5% N75600 001 JAN 29, 2002 JAN NEWA

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE
AB ANDRX PHARMS 10MEQ N75604 001 APR 10, 2002 APR NEWA
AB 20MEQ N75604 002 APR 10, 2002 APR NEWA
AB KV PHARM 20MEQ N76044 001 APR 05, 2002 APR NEWA

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVACHOL
BRISTOL MYERS SQUIBB 40MG N19898 004 MAR 22, 1993 MAR CRLD
+ 80MG N19898 008 DEC 18, 2001 MAR NEWA

PREDNICARBATE

CREAM; TOPICAL
DERMATOP
+ DERMIC LABS 0.1% N20279 001 OCT 29, 1993 JUN CAHN

PREDNICARBATE

OINTMENT; TOPICAL

DERMATOP

OINTMENT; TOPICAL

+ DERMIC LABS

0.1%

N19568 001 SEP 23, 1991 JUN CAHN

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA KV PHARM

15MG/5ML

N40364 001 APR 10, 2002 APR NEWA

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

METIMYD

@ SCHERING

0.5%;10%

N10210 002 SEP 09, 1984 JUL DISC

VASOCIDIN

+ NOVARTIS

0.5%;10%

N88791 001 OCT 05, 1984 AUG CRLD

SUSPENSION; OPHTHALMIC

ISOPTO CETAPRED

@ ALCON

0.25%;10%

N87547 001 JUN DISC

SUSPENSION/DROPS; OPHTHALMIC

METIMYD

@ SCHERING

0.5%;10%

N10210 001 JUL DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

AA + ASCENT PEDS

EQ 15MG BASE/5ML

N75117 001 DEC 14, 2000 JUL CFTG

PEDIAPRED

AA + CELLTECH PHARMS

EQ 5MG BASE/5ML

N19157 001 MAY 28, 1986 JUN CFTG

PREDNISOLONE SODIUM PHOSPHATE

AA MORTON GROVE

EQ 5MG BASE/5ML

N75099 001 JUN 28, 2002 JUN NEWA

AA WE PHARMS

EQ 15MG BASE/5ML

N75250 001 JUL 12, 2002 JUL NEWA

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

@ MERCK

20MG/ML

N10562 001 JUN DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

@ LANNETT

5MG

N80514 001 SEP DISC

AB VINTAGE PHARMS

5MG

N40256 001 JUL 12, 2002 JUL NEWA

AB

10MG

N40256 002 JUL 12, 2002 JUL NEWA

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

@ XCEL PHARMS

250MG/5ML

N10401 001 JUL DISC

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL					
COMPAZINE					
@ GLAXOSMITHKLINE	EQ 10MG BASE	N11000 001	JUN	DISC	
+	EQ 10MG BASE	N21019 001	OCT 06, 1999	JUN	CRLD
@	EQ 15MG BASE	N11000 002		JUN	DISC
+	EQ 15MG BASE	N21019 002	OCT 06, 1999	JUN	CRLD
@	EQ 30MG BASE	N11000 003		JUN	DISC

PROGESTERONE

INSERT, EXTENDED RELEASE; INTRAUTERINE				
PROGESTASERT				
@ ALZA	38MG	N17553 001	JUN	DISC

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION				
SPARINE				
@ WYETH AYERST	50MG/ML	N10349 006	JUN	DISC
TABLET; ORAL				
@ WYETH AYERST	25MG	N10348 001	JUN	DISC
@	50MG	N10348 002	JUN	DISC

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION							
PROMETHAZINE HCL							
AP	GENSIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002	AUG	NEWA	
AP		50MG/ML	N40454 002	AUG 22, 2002	AUG	NEWA	
>A>	AP	PHARMAFORCE	25MG/ML	N40471 001	NOV 21, 2002	NOV	NEWA
		SUPPOSITORY; RECTAL					
		PHENERGAN					
AB	+	WYETH AYERST	25MG	N10926 001		FEB	CTEC
		PROMETHAZINE HCL					
AB		G AND W LABS	25MG	N40428 001	FEB 05, 2002	FEB	NEWA
		SYRUP; ORAL					
		PHENERGAN FORTIS					
		@ WYETH AYERST	25MG/5ML	N08381 003		JUN	DISC

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL						
PROPAFENONE HCL						
AB	KV PHARM	150MG	N76193 001	FEB 07, 2002	FEB	NEWA
AB		225MG	N76193 002	FEB 07, 2002	FEB	NEWA
AB		300MG	N76193 003	FEB 07, 2002	FEB	NEWA
AB	VINTAGE PHARMS	150MG	N75938 001	OCT 17, 2002	OCT	NEWA
AB		225MG	N75938 002	OCT 17, 2002	OCT	NEWA
AB		300MG	N75938 003	OCT 17, 2002	OCT	NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL					
DARVON					
AA +	AAI PHARMA	32MG	N10997 001	JUN	CAHN
AA +		65MG	N10997 003	JUN	CAHN

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL DARVON-N			
+ NEOSAN PHARMS	50MG/5ML	N16861 001	JUN CAHN
TABLET; ORAL + AAIPHARMA LLC	100MG	N16862 002	JUN CAHN

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL PROPRANOLOL HCL					
@ LEDERLE	60MG	N71495 001	DEC 31, 1987	FEB	DISC
@	80MG	N70128 001	JUL 30, 1985	MAY	CAHN
@	90MG	N71496 001	DEC 31, 1987	FEB	DISC
@ PUREPAC PHARM	10MG	N70814 001	NOV 03, 1986	MAY	DISC
@	20MG	N70815 001	NOV 03, 1986	MAY	DISC
@	40MG	N70816 001	NOV 03, 1986	MAY	DISC
@	60MG	N70817 001	NOV 03, 1986	MAY	DISC
@	80MG	N70757 001	NOV 03, 1986	MAY	DISC

PYRAZINAMIDE

TABLET; ORAL PYRAZINAMIDE				
AB + CLONMEL	500MG	N80157 001	JUL	CAHN

QUINETHAZONE

TABLET; ORAL HYDROMOX				
@ LEDERLE	50MG	N13264 001	APR	DISC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL ACIPHEX					
@ EISAI MEDCL RES	10MG	N20973 001	MAY 29, 2002	JUL	DISC
+	20MG	N20973 002	AUG 19, 1999	MAY	CAHN
+	20MG	N20973 002	AUG 19, 1999	JUL	CMFD
@	20MG	N20973 002	AUG 19, 1999	JUN	DISC

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL RANITIDINE HCL					
AB + GENEVA PHARMS	EQ 300MG BASE	N74655 002	OCT 22, 1997	AUG	CRLD
ZANTAC 300					
@ GLAXOSMITHKLINE	EQ 300MG BASE	N20095 002	MAR 08, 1994	AUG	DISC

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION RAPLON					
@ ORGANON	100MG/VIAL	N20984 001	AUG 18, 1999	JUN	DISC
@	200MG/VIAL	N20984 002	AUG 18, 1999	JUN	DISC

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL
RIMANTADINE HCL
AB IMPAX LABS 100MG N76132 001 AUG 30, 2002 AUG NEWA

RISEDRONATE SODIUM

TABLET; ORAL
ACTONEL
PROCTER AND GAMBLE 30MG N20835 001 MAR 27, 1998 JUL CRLD
+ 35MG N20835 003 MAY 25, 2002 JUL NEWA

RITONAVIR

CAPSULE; ORAL
NORVIR
@ ABBOTT 100MG N20680 001 MAR 01, 1996 JUN DISC
+ 100MG N20945 001 JUN 29, 1999 JUN CRLD

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ZEMURON
@ ORGANON 10MG/ML N20214 002 MAR 17, 1994 JUN DISC

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECONAL SODIUM
+ RANBAXY 50MG N86101 001 OCT 03, 1983 JUN CAHN
AA + 100MG N86101 002 OCT 03, 1983 JUN CAHN

SECRETIN

FOR SOLUTION; INTRAVENOUS
SECREFLO
+ CHIRHOCLIN 16UGM/VIAL N21209 001 APR 04, 2002 APR NEWA

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
SELEGILINE HCL
AB CLONMEL HLTHCARE 5MG N75352 001 NOV 30, 1998 JUN CAHN
TABLET; ORAL
AB CLONMEL HLTHCARE 5MG N74641 001 AUG 02, 1996 APR CAHN
AB SIEGFRIED 5MG N74672 001 APR 01, 1997 AUG CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELSUN
AT + CHATTEM 2.5% N07936 001 AUG CAHN

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION
SELENOMETHIONINE SE 75
@ CIS 500uCi/ML N17322 001 JUN DISC

SEVOFLURANE

LIQUID; INHALATION
 SEVOFLURANE
 AN BAXTER HLTHCARE 100% N75895 001 JUL 02, 2002 SEP NEWA
 ULTANE
 AN + ABBOTT 100% N20478 001 JUN 07, 1995 SEP CFTG

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL
 SONORX
 @ BRACCO 7.5MG/ML N20773 001 OCT 29, 1998 JUN DISC

SIROLIMUS

TABLET; ORAL
 RAPAMUNE
 + WYETH AYERST 1MG N21110 001 AUG 25, 2000 JUN NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL
 UCEPHAN
 @ B BRAUN 100MG/ML;100MG/ML N19530 001 DEC 23, 1987 JUN DISC

SODIUM IODIDE, I-131

CAPSULE; ORAL
 IODOTOPE
 @ BRACCO 1-150mCi N10929 003 JUN DISC
 SOLUTION; ORAL
 @ BRACCO 7-106mCi/BOT N10929 002 JUN DISC

SODIUM OXYBATE

SOLUTION; ORAL
 XYREM
 + ORPHAN MEDCL 500MG/ML N21196 001 JUL 17, 2002 JUL NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
 NORDITROPIN
 @ NOVO NORDISK 4MG/VIAL N19721 001 MAY 08, 1995 JUN DISC
 @ 8MG/VIAL N19721 002 MAY 08, 1995 JUN DISC
 NUTROPIN AQ PEN
 BX + GENENTECH 5MG/ML N20522 002 APR 22, 2002 JUN NEWA
 SAIZEN
 >D> BX + SERONO 8.8MG/VIAL N19764 003 AUG 29, 2000 NOV CTEC
 >A> + 8.8MG/VIAL N19764 003 AUG 29, 2000 NOV CTEC
 BX + 8.8MG/VIAL N19764 003 AUG 29, 2000 SEP CDFR
 SEROSTIM
 BX + SERONO 4MG/VIAL N20604 003 JUL 25, 1997 JUN CRLD
 BX 6MG/VIAL N20604 001 AUG 23, 1996 JUN CRLD
 >D> BX + 8.8MG/VIAL N20604 004 SEP 06, 2001 NOV CTEC
 >A> + 8.8MG/VIAL N20604 004 SEP 06, 2001 NOV CTEC
 BX + 8.8MG/VIAL N20604 004 SEP 06, 2001 SEP CTNA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
 SEROSTIM IN PLASTIC CONTAINER

BX + SERONO	8.8MG/VIAL	N20604 004	SEP 06, 2001	JUN	NEWA
TEV-TROVIN					
BX + BIO TECH GEN	5MG/ML	N19774 002	JAN 04, 2002	JUN	NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL
 SOTALOL HCL

AB APOTEX	80MG	N76140 001	SEP 26, 2002	SEP	NEWA
AB	120MG	N76140 002	SEP 26, 2002	SEP	NEWA
AB	160MG	N76140 003	SEP 26, 2002	SEP	NEWA
AB	240MG	N76140 004	SEP 26, 2002	SEP	NEWA

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
 TROBICIN
 @ PHARMACIA AND UPJOHN EQ 4GM BASE/VIAL

		N50347 002		JUN	DISC
--	--	------------	--	-----	------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
 QUELICIN PRESERVATIVE FREE
 @ ABBOTT 50MG/ML

		N08845 002		JUN	DISC
--	--	------------	--	-----	------

SULFAMETHIZOLE

TABLET; ORAL
 THIOSULFIL
 @ WYETH AYERST 500MG

		N08565 004		JUN	DISC
--	--	------------	--	-----	------

SULFAMETHOXAZOLE

TABLET; ORAL
 GANTANOL
 @ ROCHE 500MG

		N12715 002		MAY	CTEC
--	--	------------	--	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
 BACTRIM PEDIATRIC
 @ WOMEN FIRST HLTHCARE 200MG/5ML;40MG/5ML

		N17560 002		APR	DISC
SEPTRA					
AB + MONARCH PHARMS	200MG/5ML;40MG/5ML	N17598 001		APR	CRLD

SULFAPYRIDINE

TABLET; ORAL
 SULFAPYRIDINE
 @ LILLY 500MG

		N00159 001		JUN	DISC
--	--	------------	--	-----	------

SULFASALAZINE

TABLET; ORAL
 SULFASALAZINE
 AB VINTAGE PHARMS 500MG

		N40349 001	JAN 11, 2002	JAN	NEWA
--	--	------------	--------------	-----	------

SULFASALAZINE

TABLET, DELAYED RELEASE; ORAL					
AZULFIDINE EN-TABS					
AB + PHARMACIA AND UPJOHN	500MG		N07073	002 APR 06, 1983	JAN CFTG
SULFASALAZINE					
AB VINTAGE PHARMS	500MG		N75339	001 JAN 11, 2002	JAN NEWA

SULFISOXAZOLE ACETYL

SYRUP; ORAL					
GANTRISIN					
@ ROCHE	EQ 500MG BASE/5ML		N09182	002	JUN DISC

SUMATRIPTAN SUCCINATE

TABLET; ORAL					
IMITREX					
GLAXOSMITHKLINE	EQ 50MG BASE		N20132	003 JUN 01, 1995	JUN CRLD
+	EQ 100MG BASE		N20132	001 JUN 01, 1995	JUN CMFD

SUPROFEN

SOLUTION/DROPS; OPHTHALMIC					
PROFENAL					
@ ALCON	1%		N19387	001 DEC 23, 1988	JUN DISC

TAMOXIFEN CITRATE

TABLET; ORAL					
NOLVADEX					
+ ASTRazeneca	EQ 20MG BASE		N17970	002 MAR 21, 1994	AUG CTEC

TAZAROTENE

CREAM; TOPICAL					
AVAGE					
+ ALLERGAN	0.1%		N21184	003 SEP 30, 2002	OCT NEWA

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION					
MICROLITE					
@ CIS	N/A		N18263	001 MAR 25, 1983	JUN DISC

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION					
TECHNETIUM TC 99M HSA					
@ AMERSHAM HLTH	N/A		N17775	001	JUL DISC

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION					
RBC-SCAN					
@ CADEMA	N/A		N20063	001 JUN 11, 1992	JUN DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M
© MALLINCKRODT 10-60mCi/ML

N17725 001

JUN DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNETIUM TC 99M GENERATOR
© AMERSHAM HLTH 830-16600mCi/GENERATOR

N17693 001

JUN DISC

TEGASEROD MALEATE

TABLET; ORAL
ZELNORM
NOVARTIS EQ 2MG BASE
2MG
+ EQ 6MG BASE
+ 6MG

N21200 001 JUL 24, 2002 AUG CPOT
N21200 001 JUL 24, 2002 JUL NEWA
N21200 002 JUL 24, 2002 AUG CPOT
N21200 002 JUL 24, 2002 JUL NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HCL
AB RANBAXY EQ 1MG BASE
AB EQ 2MG BASE
AB EQ 5MG BASE
AB EQ 10MG BASE

N76021 001 AUG 22, 2002 AUG NEWA
N76021 002 AUG 22, 2002 AUG NEWA
N76021 003 AUG 22, 2002 AUG NEWA
N76021 004 AUG 22, 2002 AUG NEWA

TERBINAFINE

GEL; TOPICAL
LAMISIL
© NOVARTIS 1%

N20846 001 APR 29, 1998 JUN DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE
+ AAIPHARMA 1MG/ML
+ NEOSAN PHARMS 1MG/ML
TABLET; ORAL
AB AAIPHARMA 2.5MG
AB + 5MG
AB NEOSAN PHARMS 2.5MG
AB + 5MG

N18571 001 JUL CAHN
N18571 001 FEB CAHN
N17849 001 JUL CAHN
N17849 002 JUL CAHN
N17849 001 FEB CAHN
N17849 002 FEB CAHN

TERIPARATIDE ACETATE

INJECTABLE; SUBCUTANEOUS
>A> FORTERO
>A> + LILLY EQ 0.75MG/3ML (0.25MG/ML)

N21318 001 NOV 26, 2002 NOV NEWA

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
TESTODERM TTS
BX + ALZA 5MG/24HR

N20791 001 DEC 18, 1997 JAN CTNA

TESTOSTERONE

GEL; TOPICAL
 TESTIM
 + AUXILIUM AZ 1% N21454 001 OCT 31, 2002 OCT NEWA

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL
 ACTISITE
 + ALZA 12.7MG/FIBER N50653 001 MAR 25, 1994 FEB CAHN

FOR SOLUTION; TOPICAL
 TOPICYCLINE
 @ SHIRE LABS 2.2MG/ML N50493 001 JUL DISC

INJECTABLE; INJECTION
 ACHROMYCIN
 @ LEDERLE 250MG/VIAL N50273 002 JUN DISC

+ 500MG/VIAL N50273 003 JUN CRLD

@ 500MG/VIAL N50273 003 JUL DISC

SUSPENSION; ORAL
 ACHROMYCIN V
 @ LEDERLE 125MG/5ML N50263 002 APR DISC

SUMYCIN
 + APOTHECON 125MG/5ML N60400 001 APR CTEC

TABLET; ORAL
 @ PAR PHARM 50MG N61147 003 MAY CAHN

@ 100MG N61147 002 MAY CAHN

250MG N61147 001 MAY CAHN

+ 500MG N61147 004 MAY CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
 THEO-DUR
 AB SCHERING 100MG N85328 001 OCT CRLD
 AB 200MG N86998 001 OCT CRLD
 AB 300MG N85328 002 OCT CRLD
 AB 450MG N89131 001 JUN 25, 1986 OCT CRLD

THEOPHYLLINE
 AB + SIDMAK LABS NJ 100MG N89807 001 APR 30, 1990 OCT CRLD
 AB + 200MG N89808 001 APR 30, 1990 OCT CRLD
 AB + 300MG N89763 001 APR 30, 1990 OCT CRLD
 AB + 450MG N81236 001 NOV 09, 1992 OCT CRLD

UNI-DUR
 BC SCHERING 400MG N89822 001 JAN 04, 1995 OCT CRLD
 BC 600MG N89823 001 JAN 04, 1995 OCT CRLD

UNIPHYL
 BC + PURDUE FREDERICK 400MG N87571 001 SEP 01, 1982 OCT CRLD
 BC + 600MG N40086 001 APR 15, 1996 OCT CRLD

THIETHYLPERAZINE MALATE

INJECTABLE; INJECTION
 TORECAN
 @ NOVARTIS 5MG/ML N12754 002 JUN DISC

THIORIDAZINE

SUSPENSION; ORAL

MELLARIL-S

@ NOVARTIS

EQ 25MG HCL/5ML

N17923 001

JUN DISC

@

EQ 100MG HCL/5ML

N17923 002

JUN DISC

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

MELLARIL

@ NOVARTIS

30MG/ML

N11808 012

AUG DISC

@

100MG/ML

N11808 018

AUG DISC

THIORIDAZINE HCL

AA + COBLEY PHARM

30MG/ML

N89602 001 NOV 09, 1987

AUG CRLD

AA +

100MG/ML

N89603 001 NOV 09, 1987

AUG CRLD

TABLET; ORAL

MELLARIL

@ NOVARTIS

10MG

N11808 003

AUG DISC

@

15MG

N11808 016

AUG DISC

@

25MG

N11808 006

AUG DISC

@

50MG

N11808 011

AUG DISC

@

100MG

N11808 009

AUG DISC

@

150MG

N11808 017

AUG DISC

@

200MG

N11808 015

AUG DISC

THIORIDAZINE HCL

AB + GENEVA PHARMS

25MG

N88133 001 AUG 30, 1983

AUG CRLD

AB +

100MG

N88135 001 NOV 20, 1984

AUG CRLD

AB +

200MG

N88137 001 SEP 17, 1986

AUG CRLD

THIOTEPHA

INJECTABLE; INJECTION

THIOTEPHA

AP AM PHARM PARTNERS

15MG/VIAL

N75698 001 SEP 20, 2001 FEB CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

THIOTHIXENE HCL INTENSOL

@ ROXANE

EQ 5MG BASE/ML

N73494 001 JUN 30, 1992 JAN DISC

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

+ CEPHALON

16MG

N20646 003 SEP 30, 1997 JUN CRLD

@

20MG

N20646 004 SEP 30, 1997 JUN DISC

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HCL

AB CARACO

250MG

N75526 001 SEP 26, 2002 SEP NEWA

TIMOLOL MALEATE

SOLUTION; OPHTHALMIC

TIMOLOL MALEATE

AT HI TECH PHARMA EQ 0.5% BASE

N75163 001 SEP 10, 2002 SEP NEWA

JUN DISC

JUN DISC

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

+ LEO PHARM 20,000 IU/ML
+ PHARMION 20,000 IU/MLN20484 001 JUL 14, 2000 APR CAHN
N20484 001 JUL 14, 2000 JUL CAHN

AUG DISC

AUG DISC

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANAFLEX

ELAN PHARMS EQ 2MG BASE
EQ 4MG BASE
EQ 6MG BASEN21447 001 AUG 29, 2002 AUG NEWA
N21447 002 AUG 29, 2002 AUG NEWA
N21447 003 AUG 29, 2002 AUG NEWA

AUG DISC

AUG DISC

TIZANIDINE HCL

AB COREPHARMA EQ 2MG BASE
AB EQ 4MG BASEN76347 001 OCT 11, 2002 OCT NEWA
N76347 002 OCT 11, 2002 OCT NEWA

AUG DISC

AUG DISC

AB DR REDDYS LABS INC EQ 2MG BASE
AB EQ 4MG BASEN76286 001 JUL 03, 2002 JUL NEWA
N76286 002 JUL 03, 2002 JUL NEWA

AUG DISC

AUG DISC

AB EON EQ 2MG BASE
AB EQ 4MG BASEN76399 001 NOV 26, 2002 NOV NEWA
N76280 002 JUN 27, 2002 JUN NEWA

AUG CRLD

AUG CRLD

AB PUREPAC PHARM EQ 2MG BASE
AB EQ 4MG BASEN76283 001 JUL 12, 2002 JUL NEWA
N76283 002 JUL 12, 2002 JUL NEWA

AUG CRLD

AUG CRLD

AB TEVA EQ 2MG BASE
AB EQ 4MG BASEN76284 001 JUL 03, 2002 JUL NEWA
N76284 002 JUL 03, 2002 JUL NEWA

AUG CFTG

AB ZANAFLEX EQ 2MG BASE
AB ELAN PHARMS EQ 4MG BASEN20397 002 FEB 04, 2000 AUG CFTG
N20397 001 NOV 27, 1996 JUN CFTG

FEB CAHN

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT NOVEX 0.3%

N65087 001 FEB 25, 2002 FEB NEWA

JAN DISC

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN

>A AP AM PHARM PARTNERS EQ 10MG BASE/ML
>A AP EQ 40MG BASE/MLN65122 001 NOV 29, 2002 NOV NEWA
N65122 002 NOV 29, 2002 NOV NEWA

JUN CRLD

JUN DISC

TOBRAMYCIN (PHARMACY BULK)

>A AP AM PHARM PARTNERS EQ 40MG BASE/ML

N65120 001 NOV 29, 2002 NOV NEWA

SEP NEWA

TOBRAMYCIN SULFATE

@ ASTRazeneca EQ 40MG BASE/ML

N63120 001 OCT 31, 1994 FEB DISC

@ EQ 40MG BASE/ML

N63122 001 OCT 31, 1994 JAN DISC

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

@ NOVARTIS 25MG/ML

N06403 005 FEB 22, 1985 JUN DISC

TOPIRAMATE

TABLET; ORAL

TOPAMAX

+ JOHNSON AND JOHNSON	25MG	N20505 004	DEC 24, 1996	JAN	CAHN
@	50MG	N20505 005	DEC 24, 1996	JAN	CAHN
	100MG	N20505 001	DEC 24, 1996	JAN	CAHN
	200MG	N20505 002	DEC 24, 1996	JAN	CAHN
@	300MG	N20505 003	DEC 24, 1996	JAN	CAHN
@	400MG	N20505 006	DEC 24, 1996	JAN	CAHN

TORSEMIDE

TABLET; ORAL

DEMADEX

AB ROCHE	5MG	N20136 001	AUG 23, 1993	MAY	CFTG
AB	10MG	N20136 002	AUG 23, 1993	MAY	CFTG
AB +	20MG	N20136 003	AUG 23, 1993	MAY	CFTG
AB	100MG	N20136 004	AUG 23, 1993	MAY	CFTG

TORSEMIDE

AB TEVA	5MG	N76110 001	MAY 14, 2002	MAY	NEWA
AB	10MG	N76110 002	MAY 14, 2002	MAY	NEWA
AB	20MG	N76110 003	MAY 14, 2002	MAY	NEWA
AB	100MG	N76110 004	MAY 14, 2002	MAY	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HCL

AB ABLE	50MG*	N75963 001	JUL 03, 2002	JUL	NEWA
>A> AB ALPHAPHARM	50MG*	N75980 001	NOV 21, 2002	NOV	NEWA
AB ASTA	50MG*	N75974 001	JUL 12, 2002	JUL	NEWA
AB CARACO	50MG*	N75964 001	JUN 19, 2002	JUN	NEWA
AB COREPHARMA	50MG*	N76003 001	JUN 20, 2002	JUN	NEWA
AB EON	50MG*	N75968 001	JUN 25, 2002	JUN	NEWA
AB MALLINCKRODT	50MG*	N75983 001	JUN 25, 2002	JUN	NEWA
AB MUTUAL PHARM	50MG*	N76100 001	JUN 20, 2002	JUN	NEWA
AB MYLAN	50MG*	N75986 001	JUN 21, 2002	JUN	NEWA
AB PUREPAC PHARM	50MG*	N75960 001	JUN 19, 2002	JUN	NEWA
AB SIDMAK LABS	50MG*	N75982 001	JUL 01, 2002	JUL	NEWA
AB TEVA	50MG*	N75977 001	JUN 19, 2002	JUN	NEWA
AB TORPHARM	50MG*	N75981 001	JUL 10, 2002	JUL	NEWA
AB WATSON LABS	50MG*	N75962 001	JUN 24, 2002	JUN	NEWA
ULTRAM					
+ JOHNSON AND JOHNSON	50MG	N20281 002	MAR 03, 1995	FEB	CAHN
@	100MG	N20281 001	MAR 03, 1995	FEB	CAHN
AB + ORTHO MCNEIL PHARM	50MG	N20281 002	MAR 03, 1995	JUN	CTEC

TREPROSTINIL SODIUM

INJECTABLE; SUBCUTANEOUS

REMODULIN

UNITED THERAP	1MG/ML	N21272 001	MAY 21, 2002	MAY	NEWA
	2.5MG/ML	N21272 002	MAY 21, 2002	MAY	NEWA
	5MG/ML	N21272 003	MAY 21, 2002	MAY	NEWA
+	10MG/ML	N21272 004	MAY 21, 2002	MAY	NEWA

* SEE SECTION 1.4 OF INTRODUCTION

TRETINOIN

GEL; TOPICAL
RETIN-A
AB + JOHNSON AND JOHNSON 0.01% N17955 001 JUN CFTG
RETIN-A MICRO
+ JOHNSON AND JOHNSON 0.04% N20475 002 MAY 10, 2002 SEP NEWA
TRETINOIN
AB SPEAR PHARMS 0.01% N75589 001 JUN 11, 2002 JUN NEWA

TRIAMCINOLONE

TABLET; ORAL
ARISTOCORT
@ FUJISAWA HLTHCARE 1MG N11161 009 JUL DISC
@ 2MG N11161 004 JUL DISC
@ 8MG N11161 011 JUL DISC
KENACORT
+ BRISTOL MYERS SQUIBB 8MG N11283 010 AUG CTEC

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

KENALOG-10
APOTHECON 10MG/ML N12041 001 JUN CRLD
KENALOG-40
BP + APOTHECON 40MG/ML N14901 001 JUN CRLD
+ 40MG/ML N14901 001 SEP CTEC
TRIAMCINOLONE ACETONIDE
@ PARRELL 3MG/ML N19503 001 OCT 16, 1987 JUN DISC
@ STERIS 40MG/ML N85825 001 SEP DISC
SPRAY, METERED; NASAL
TRI-NASAL
@ MURO 0.05MG/SPRAY N20120 001 FEB 04, 2000 JUN DISC

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT
+ FUJISAWA HLTHCARE 25MG/ML N11685 003 OCT CAHN
+ 40MG/ML N12802 001 OCT CAHN
+ LEDERLE 40MG/ML N12802 001 SEP CTEC
TRIAMCINOLONE DIACETATE
@ STERIS 40MG/ML N84072 001 SEP DISC
SYRUP; ORAL
ARISTOCORT
@ FUJISAWA HLTHCARE 2MG/5ML N11960 004 JUL DISC

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN
+ FUJISAWA HLTHCARE 5MG/ML N16466 001 OCT CAHN
+ 20MG/ML N16466 002 OCT CAHN

TRIFLUOPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

@ APOTHECON

10MG/ML

N11325 004

JUN DISC

@

20MG/ML

N11325 001

JUN DISC

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

@ BIOENVISION

30MG

N18719 002 DEC 31, 1984 JUN CAHN

@

60MG

N18719 001 DEC 31, 1984 JUN CAHN

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

@ ABBOTT

300MG

N05856 005

JUN DISC

SOLUTION; ORAL

@ ABBOTT

200MG/5ML

N05856 002

JUN DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

+ KING PHARMS

300MG

N17531 006 DEC 13, 2001 JAN NEWA

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL

@ STERIS

100MG/ML

N87939 001 DEC 28, 1982 FEB DISC

TRIMETHOPRIM

TABLET; ORAL

TRIMPEX

@ ROCHE

100MG

N17952 001

AUG DISC

TRIOXSALEN

TABLET; ORAL

TRISORALEN

@ ICN

5MG

N12697 001

JUN DISC

TRIPELENNAMINE CITRATE

ELIXIR; ORAL

PBZ

@ NOVARTIS

EQ 25MG HCL/5ML

N05914 004

JUN DISC

TRIPELENNAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

@ NOVARTIS

100MG

N10533 001

JUN DISC

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

TABLET; VAGINAL

SULTRIN

@ ORTHO MCNEIL PHARM

184MG;143.75MG;172.5MG

N05794 002

JUN DISC

UREA, C-13

FOR SOLUTION; ORAL
PYLORI-CHEK BREATH TEST
@ ALIMENTERICS 100MG/VIAL

N20900 001 FEB 04, 1999 JUL DISC

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
BRAVELLE
BX + FERRING 75 IU/VIAL
INJECTABLE; SUBCUTANEOUS
FERTINEX
BX + SERONO 75 IU/AMP
@ 150 IU/AMP

N21289 001 MAY 06, 2002 MAY NEWA
N19415 005 AUG 23, 1996 MAY CTEC
N19415 004 AUG 23, 1996 JUN DISC

URSODIOL

CAPSULE; ORAL
ACTIGALL
@ WATSON PHARMS 150MG
AB + 300MG

N19594 001 DEC 31, 1987 FEB CAHN
N19594 002 DEC 31, 1987 FEB CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALTREX
@ GLAXOSMITHKLINE EQ 500MG BASE
@ EQ 1GM BASE

N20487 001 JUN 23, 1995 MAR DISC
N20487 002 JUN 23, 1995 MAR DISC

VALPROATE SODIUM

INJECTABLE; INJECTION
DEPACON
>D> + ABBOTT EQ 100MG BASE/ML
>A> AP + EQ 100MG BASE/ML
>A> VALPROATE SODIUM
>A> AP BEDFORD EQ 100MG BASE/ML

N20593 001 DEC 30, 1996 NOV CFTG
N20593 001 DEC 30, 1996 NOV CFTG
N76295 001 NOV 14, 2002 NOV NEWA

VALSARTAN

CAPSULE; ORAL
DIOVAN
@ NOVARTIS 80MG
@ 160MG

N20665 001 DEC 23, 1996 JUN DISC
N20665 002 DEC 23, 1996 JUN DISC

VECURONIUM BROMIDE

INJECTABLE; INJECTION
NORCURON
@ ORGANON 20MG/VIAL

N18776 003 JAN 03, 1992 JUN DISC

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
EFFEXOR XR
WYETH AYERST EQ 37.5MG BASE
EQ 150MG BASE

N20699 001 OCT 20, 1997 MAY CRLD
N20699 004 OCT 20, 1997 MAY CRLD

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN

AB + ELAN DRUG	120MG	N19614 001	MAY 29, 1990	APR	CAHN
AB +	180MG	N19614 003	JAN 09, 1992	APR	CAHN
AB +	240MG	N19614 002	MAY 29, 1990	APR	CAHN
+	360MG	N19614 004	MAY 10, 1996	APR	CAHN

VITAMIN A PALMITATE

INJECTABLE; INJECTION
AQUASOL A
+ AAIPHARMA

EQ 50,000 UNITS BASE/ML

N06823 001

JUL CAHN

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND
+ PFIZER

TABLET; ORAL

PFIZER
+

200MG/VIAL

N21267 001	MAY 24, 2002	MAY	NEWA
N21266 001	MAY 24, 2002	MAY	NEWA
N21266 002	MAY 24, 2002	MAY	NEWA

XENON, XE-127

GAS; INHALATION

XENON XE 127

@ MALLINCKRODT

5mCi/VIAL

@

10mCi/VIAL

N18536 001	OCT 01, 1982	JUN	DISC
N18536 002	OCT 01, 1982	JUN	DISC

XYLOSE

POWDER; ORAL

XYLOSE

@ LYNE

25GM/BOT

N18856 001 MAR 26, 1987 JUL DISC

ZILEUTON

TABLET; ORAL

ZYFLO

+ ABBOTT

300MG

@

300MG

N20471 001	DEC 09, 1996	JUN	CRLD
N20471 001	DEC 09, 1996	JUL	DISC

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

+ PFIZER

EQ 20MG BASE/ML

N20919 001 JUN 21, 2002 JUN NEWA

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT

+ ASTRAZENECA

5MG

N21231 002 SEP 17, 2001 JUN NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER '02

1990 APR CAHN
1992 APR CAHN
1990 APR CAHN
1996 APR CAHN

NO NOVEMBER 2002 APPROVALS

JUL CAHN

2002 MAY NEWA
2002 MAY NEWA
2002 MAY NEWA

1982 JUN DISC
1982 JUN DISC

1987 JUL DISC

1996 JUN CRLD
1996 JUL DISC

2002 JUN NEWA

2001 JUN NEWA

**This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.**

**Orphan Products Designations and Approvals List
November 2002**

albuterol	DD: 3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc. 3 Pine View Road Mount Kisco NY 10549
	MA:		
allantoin	DD: 11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Alwyn Company, Inc. 2301 Highway 60 East Lake Crystal MN 56055
Alwextin	MA:		
antiangiogenic components extracted from marine cartilage Neovastat (AE-941)	DD: 10/16/2002	Treatment of renal cell carcinoma	AEterna Laboratories, Inc. Dr. Claude Hariton, Chief Medical Officer, VP, Clinical & Regulatory Affairs 1405 boul. Du Parc - Technologique Quebec G1P 4P5 CANADA
	MA:		
autologous antigen presenting cells pulsed with autologous tumor Ig idiotype Mylovenge	DD: 4/18/2002	Treatment of multiple myeloma	Dendreon Corporation 3005 First Avenue Seattle WA 98121
	MA:		
autologous tumor-derived gp96 heat shock protein-peptide complex Oncophage	DD: 7/11/2002	Treatment of metastatic melanoma	Antigenics, Inc. 34 Commerce Way Woburn MA 01702
	MA:		
autologous tumor-derived gp96 heat shock protein-peptide complex Oncophage	DD: 5/10/2002	Treatment of renal cell carcinoma	Antigenics, Inc. 34 Commerce Way Woburn MA 01702
	MA:		
aztreonam	DD: 3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Corus Pharma 2025 First Ave., Suite 800 Seattle WA 98121
	MA:		
Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	DD: 2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc. Suite 235 7200 Hudson Blvd. Oakdale MN 55128
	MA:		

Orphan Products Designations and Approvals List
November 2002

capsaicin	DD: 10/23/2002 Treatment of erythromelalgia MA:	NeurogesX, Inc. 981F Industrial Road San Carlos CA 94070
carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-me thyl-ethyl]phenoxy]methyl]phenyl]m ethoxy]-phenyl]iminomethyl]-ethyl ester	DD: 1/15/2002 Management of cystic fibrosis MA:	Boehringer Ingelheim Pharmaceuticals, Inc 900 Ridgebury Road P.O. Box 368 Ridgefield CT 06877
cells produced using the AastromReplicelle System and SC-I Therapy Kit	DD: 7/10/2002 For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor MA:	Aastrom Biosciences Incorporated P.O. Box 376 Ann Arbor MI 48106
clofarabine Clofarex	DD: 2/7/2002 Treatment of acute lymphoblastic leukemia MA:	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
clofarabine Clofarex	DD: 3/14/2002 Treatment of acute myelogenous leukemia MA:	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
creatine Creapure	DD: 2/12/2002 Treatment of amyotrophic lateral sclerosis MA:	Avicena Group, Inc. 580 California St. Suite 1600 San Francisco CA 94104
D-peptide of the sequence AKRHHGYKRKFH - NH ₂ PulmaDex	DD: 10/23/2002 Treatment of cystic fibrosis MA:	Demegen, Inc. 1051 Brinton Road Pittsburgh PA 15221
decitabine	DD: 9/9/2002 Treatment of sickle cell anemia MA:	SuperGen, Inc. 4140 Dublin Blvd., Suite 200 Dublin CA 94568
Deferasirox	DD: 11/21/2002 Treatment of chronic iron overload in patients with transfusion-dependent anemias MA:	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover NJ 07936-1080
DHA-paclitaxel Taxoprexin	DD: 10/10/2002 Treatment of metastatic malignant melanoma MA:	Protarga, Inc. 2200 Renaissance Boulevard Suite 450 King of Prussia PA 19406

Orphan Products Designations and Approvals List
November 2002

G17DT Immunogen	DD: 7/18/2002	Treatment of gastric cancer	Aphton Corporation 26 Harter Avenue Suite 14 Woodland CA 95776
	MA:		
G17DT Immunogen	DD: 7/10/2002	Treatment of adenocarcinoma of the pancreas	Aphton Corporation 26 Harter Avenue Suite 14 Woodland CA 95776
	MA:		
genetically engineered herpes simplex virus (G207)	DD: 4/29/2002	Treatment of malignant glioma	MediGene, Inc. 9880 Campus Point Drive, Suite A San Diego CA 92121
	MA:		
heat killed mycobacterium with immunomodulator CADI Mw	DD: 11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc. 16020 Swingley Ridge Road Suite 145 Chesterfield MO 63017
	MA:		
Hepatitis C virus immune globulin (human)	DD: 11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	NABI 5800 Park of Commerce Blvd., N.W. Boca Raton FL 33487
	MA:		
homoharringtonine	DD: 2/8/2002	Treatment for chronic myelogenous leukemia	American BioScience, Inc. 2730 Wilshire Blvd. #110 Santa Monica CA 90403
	MA:		
human anti-transforming growth factor beta 1 monoclonal antibody	DD: 1/11/2002	Treatment of systemic sclerosis	Genzyme Corporation One Kendall Square Cambridge MA 02139
	MA:		
human gammaglobulin	DD: 9/16/2002	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Protein Therapeutics, Inc. 9040 S. Rita Road Suite 1100 Tucson AZ 85747
	MA:		
hyaluronic acid	DD: 3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	Exhale Therapeutics, Inc. 1301 Shoreway Road Suite 320 Belmont CA 94002
	MA:		
I(131)-TM-601 (chlorotoxin)	DD: 2/14/2002	treatment of malignant glioma	TransMolecular, Inc. 3800 Colonnade Parkway Suite 240 Birmingham AL 35243
	MA:		
infliximab	DD: 10/23/2002	Treatment of juvenile rheumatoid arthritis	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355-1307
Remicade	MA:		

Orphan Products Designations and Approvals List
November 2002

inolimomab	DD: 10/23/2002	Treatment of graft versus host disease	Opi 6, Chemin de l'industrie 69570 DARDILLY - France
Leukotac	MA:		
interferon gamma-1b	DD: 9/12/2002	Treatment of idiopathic pulmonary fibrosis	InterMune, Inc. 3280 Bayshore Boulevard Brisbane CA 94005
Actimmune	MA:		
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococci)	DD: 1/15/2002	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Avenue Gaithersburg MD 20877
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	MA:		
DD: 1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Ave.	
lintuzumab	MA:		Gaithersburg MD 20877
Zamyl	DD: 9/9/2002	Treatment of acute myelogenous leukemia	Protein Design Labs, Inc. 34801 Campus Drive Fremont CA 94555
lipase, amylase, and protease	DD: 1/23/2002	Treatment of pancreatic insufficiency	Altus Biologics Inc. 625 Putnam Avenue Cambridge MA 02139
TheraCLEC-Total	MA:		
meloxicam	DD: 11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road P. O. Box 368 Ridgefield CT 06877-0368
Mobic	MA:		
methylbicyclone	DD: 11/14/2002	Treatment of cystic fibrosis	Sucampo Pharmaceuticals, Inc. 4733 Bethesda Ave. Suite 450 Bethesda MD 20814
N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea	DD: 5/13/2002	Treatment of sickle cell disease	NeuroSearch A/S 93 Pederstrupvej
	MA:		DK-2750 Ballerup Denmark
N-acetylcysteine	DD: 9/9/2002	Treatment of acute liver failure	William M. Lee, MD, FACP University of Texas Southwestern Medical Center at Dallas 5323 Harry Hines Blvd Dallas TX 75390-9151
	MA:		
Natural human lymphoblastoid interferon-alpha	DD: 11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.

Orphan Products Designations and Approvals List
November 2002

nitazoxanide	MA:	DD: 2/14/2002	Treatment of intestinal giardiasis	800 West 9th Avenue Amarillo TX 79101
Cryptaz	MA:			Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607
octavalent Psuedomonas aeruginosa O-polysaccharide-toxin A Aerugen	MA:	DD: 5/16/2002	Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis	Orphan Europe Immeuble "Le Wilson" 70 avenue du General de Gaulle, 92046 Paris La Defense France
phenylephrine	MA:	DD: 2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma Unit 3, Hill Farm Industrial Estate Leavesden, Watford United Kingdom WD25 7SA
polyinosinic-polycytidilic acid	MA:	DD: 11/19/2002	Treatment for orthopox virus infections	Ribopharm, Inc. 3203 Cleveland Ave., NW Washington DC 20008-3450
Poly-ICLC	MA:			Ribopharm, Inc. 3203 Cleveland Ave., NW Washington DC 20008-3450
polyinosinic-polycytidilic acid	MA:	DD: 8/2/2002	As an adjuvant to smallpox vaccination	
Poly-ICLC	MA:			
recombinant human endostatin protein	MA:	DD: 2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850
recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3 SomatoKine	MA:	DD: 5/17/2002	Treatment of growth hormone insensitivity syndrome	Celtrix Pharmaceuticals, Inc. a subsidiary of Insmed, Inc. 4851 Lake Brook Drive Glen Allen VA 23060
recombinant human monoclonal antibody to hsp90 Mycograb	MA:	DD: 9/16/2002	Treatment of invasive candidiasis	NeuTec Pharma plc 2dn floor, Clinical Sciences Bldg. Central Manchester Healthcare Trust, Oxford Rd., Manchester M139WL, UK
recombinant human porphobilinogen deaminase	MA:	DD: 9/9/2002	Treatment of acute intermittent porphyria attacks	HemeBiotech A/S Roskildevej 12C 3400 Hillerod Denmark
retroviral gamma-c cDNA containing vector	MA:	DD: 4/29/2002	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc. 9200 Indian Creek Parkway Building 9, Suite 200 Overland Park KS 66210

Orphan Products Designations and Approvals List
November 2002

rituximab	DD: 3/12/2002	Treatment of immune thrombocytopenic purpura	Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990
Rituxan	MA:		
rubitecan	DD: 7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
	MA:		
S(-)-3-[3-amino-phthalimido]-glutar amide	DD: 3/14/2002	Treatment of multiple myeloma	EntreMed Incorporated 9640 Medical Center Dr. Rockville MD 20850
	MA:		
SS1(dsFv)-PE38	DD: 2/11/2002	Treatment of epithelial ovarian cancer	NeoPharm, Inc. 150 Field Drive Suite 195 Lake Forest IL 60045
	MA:		
SS1(dsFv)-PE38	DD: 2/11/2002	Treatment of malignant mesothelioma	NeoPharm Incorporated 150 Field Drive Suite 195 Lake Forest IL 60045
	MA:		
TGF(beta)2-specific phosphorothioate antisense oligodeoxynucleotide	DD: 6/5/2002	Treatment of malignant glioma	Antisense Pharma GmbH Josef-Engert-Str. 9 93053 Regensburg Germany
Oncomun	MA:		
tinidazole	DD: 4/18/2002	Treatment of giardiasis	Presutti Laboratories, Inc. 1607 N. Douglas Ave. Arlington Heights IL 60004
	MA:		
tirapazamine	DD: 10/23/2002	For the treatment of head and neck cancer	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355
	MA:		
toralizumab	DD: 3/14/2002	Treatment of immune thrombocytopenic purpura	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121
	MA:		

NO NOV

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

080-4990

NO NOVEMBER 2002 ADDITIONS

ration

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUSIVITY CODE	EXCLUSIVITY EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	6417191	MAR 28, 2016	U-248			
021449 001	ADEFOVIR DIPIVOXIL;HEPSERA	6417191*PED 6451340	SEP 28, 2016 JUL 23, 2018	U-248 U-470	NCE		SEP 20, 2007
>ADD>	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	4808716 5663159 4724233 5695743 6352684	APR 25, SEP 02, APR 21, JUL 06, NOV 28,	2006 2014 2006 2010 2009	U-470 U-470	
021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	OCT 15, 2013		NP	JUN 11, 2005	
021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	OCT 15, 2013		NP	JUN 11, 2005	
021212 001	ALPROSTADIL;CAVERJECT				NS	JUN 20, 2005	
021212 002	ALPROSTADIL;CAVERJECT						
020364 005	AMLODIPINE BESSYLATE;LOTREL	4410520 4572909	AUG 11, 2003 JUL 31, 2006	2003 2006			
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 1.0	4879303	MAR 25, 2007				
021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 1.5	6162802	DEC 19, 2017	U-367			
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 2.0	6322819	NOV 27, 2018				
021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 2.5	6322819	NOV 27, 2018				
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 3.0	6322819	NOV 27, 2018				
021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6322819	NOV 27, 2018				
>ADD>	011522 007	AMPHETAMINE ASPARTATE;ADDERALL 10	6384020	JUL 06, 2020			
>ADD>	011522 012	AMPHETAMINE ASPARTATE;ADDERALL 12.5	6384020	JUL 06, 2020			
>ADD>	011522 013	AMPHETAMINE ASPARTATE;ADDERALL 15	6384020	JUL 06, 2020			
>ADD>	011522 008	AMPHETAMINE ASPARTATE;ADDERALL 20	6384020	JUL 06, 2020			
>ADD>	011522 010	AMPHETAMINE ASPARTATE;ADDERALL 30	6384020	JUL 06, 2020			
>ADD>	011522 009	AMPHETAMINE ASPARTATE;ADDERALL 5	6384020	JUL 06, 2020			
>ADD>	011522 011	AMPHETAMINE ASPARTATE;ADDERALL 7.5	6384020	JUL 06, 2020			
020541 001	ANASTROZOLE;ARIMIDEX						
020883 001	ARGATROBAN;ARGATROBAN						
>ADD>	021436 001	ARIPIRAZOLE;ABILITY					
>ADD>	021436 002	ARIPIRAZOLE;ABILITY					
>ADD>	021436 003	ARIPIRAZOLE;ABILITY					
>ADD>	021436 004	ARIPIRAZOLE;ABILITY					
>ADD>	021436 005	ARIPIRAZOLE;ABILITY					
>ADD>	021436 006	ARIPIRAZOLE;ABILITY					
020702 001	ATORVASTATIN CALCIUM;LIPITOR						
020702 002	ATORVASTATIN CALCIUM;LIPITOR	5925760	AUG 04, 2017				
020702 003	ATORVASTATIN CALCIUM;LIPITOR						
D-77							
I-350							
PED							
D-77							
I-350							
PED							
D-77							
I-350							
PED							

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXPIRES
020702 004	ATORVASTATIN CALCIUM;LIPITOR		D-77	APR 22,	2005	
020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	6352684	NOV 28,	2009	I- 350	OCT 18,
020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	6352684	NOV 28,	2009	PBD	2005
021055 001	BEXAROTENE; TARGRETIN	5962731	OCT 05,	2016	NP	APR 18,
021275 001	BIMATOPROST; LUMIGAN	6403649	SEP 21,	2012	NPP	SEP 15,
>ADD>	BIVALIRUDIN; ANGIOTRATE; ALPHAGAN	5196404	MAR 23,	2010	NPP	MAY 10,
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN	6465464	JUN 28,	2015	PED	2005
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6465464*PED	DEC 28,	2015	U-394	NPP
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6465464	JUN 28,	2015	U-394	PED
021324 001	BUDESONIDE; ENTOCORT EC	5643602	JUL 01,	2014	NP	JUN 20,
020441 002	BUDESONIDE; PULMICORT	5643602*PED	JAN 01,	2015	OCT 02,	2004
		4907583	APR 11,	2006	PED	APR 02,
		4907583	MAR 13,	2007		2005
		4668218*PED	OCT 11,	2006		
		4907583*PED	SEP 13,	2007		
		4668218	APR 11,	2006		
		4907583	MAR 13,	2007		
		4668218*PED	OCT 11,	2006		
		4907583*PED	SEP 13,	2007		
		4787536	FEB 27,	2006		
		4787536*PED	AUG 27,	2006		
		4787536	FEB 27,	2006		
		4787536*PED	AUG 27,	2006		
		4787536	FEB 27,	2006		
		4787536*PED	AUG 27,	2006		
		6291445	APR 29,	2017		
		6291445*PED	OCT 29,	2017		
		6291445	APR 29,	2017		
		6291445*PED	OCT 29,	2017		
		6291445	M-22	2004		
		NDP	OCT 01,	2002		
		NDP	OCT 01,	2002		
		PED	APR 26,	2005		
		PED	APR 01,	2003		
		NDP	OCT 08,	2005		
		ODDE	OCT 08,	2005		
		NDP	OCT 08,	2005		
		ODDE	OCT 08,	2005		
>ADD>	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE					
>ADD>	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE					
020733 001	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE					
020733 002	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE					

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCL CODE	EXCLUS EXPIRES
020732 002	BUPRENORPHINE HYDROCHLORIDE; SUBUTEX		OCT 08, 2005 NDF ODE	OCT 08, NDF	OCT 08, NDF	OCT 08, 2009
020732 003	BUPRENORPHINE HYDROCHLORIDE; SUBUTEX		OCT 08, 2005 NDF ODE	OCT 08, NDF	OCT 08, NDF	OCT 08, 2009
<u>>ADD></u>	<u>BUPROPION HYDROCHLORIDE; WELLBUTRIN SR</u>	<u>53158970</u>	<u>AUG 12, 2013</u>	<u>M-10</u>	<u>JUN 11,</u>	<u>2004</u>
020358 004	BUPROPION HYDROCHLORIDE; WELLBUTRIN SR	54227798 5731000 5763493 RE33994	AUG 12, 2013 AUG 12, 2013 AUG 12, 2013 AUG 18, 2004			
018731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR					
018731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR					
018731 003	BUSPIRONE HYDROCHLORIDE; BUSPAR					
018731 004	BUSPIRONE HYDROCHLORIDE; BUSPAR					
020954 001	BUSULFAN; BUSULFEX	5430057 5559148 5430057*PED MAR 30, 5559148*PED NOV 24,	SEP 30, 2013 MAY 24, 2015 PED MAR 30, 2014			
021408 001	BUTENAFINE HYDROCHLORIDE; MENTAX-TC BUTOCONAZOLE NITRATE; GYNIAZOLE 1	5266329 4551148 5196444 5196444 5196444 5196444 5196444 5196444 5196444 4839350 4918068 5956915 5466823 5563165 5760068 5760068	NOV 30, 2010 NOV 05, 2012 JUN 04, 2012 JUN 04, 2012 JUN 04, 2012 JUN 04, 2012 JUN 13, 2006 JUN 13, 2006 OCT 14, 2016 NOV 30, 2013 NOV 30, 2013 JUN 02, 2015 JUN 02, 2015 OCT 14,			
019881 001	CANDESARTAN CILEXETIL; ATACAND	4551148 5196444 5196444 5196444 5196444 5196444 5196444 5196444 4839350 4918068 5956915 5466823 5563165 5760068 5760068	JUN 04, 2012 JUN 04, 2012 JUN 04, 2012 JUN 04, 2012 JUN 04, 2012 JUN 13, 2006 JUN 13, 2006 OCT 14, 2016 NOV 30, 2013 NOV 30, 2013 JUN 02, 2015 JUN 02, 2015 OCT 14,			
020838 001	CANDESARTAN CILEXETIL; ATACAND					
020838 002	CANDESARTAN CILEXETIL; ATACAND					
020838 003	CANDESARTAN CILEXETIL; ATACAND					
020838 004	CANDESARTAN CILEXETIL; ATACAND HCT					
021093 001	CANDESARTAN CILEXETIL; ATACAND HCT					
021093 002	CANDESARTAN CILEXETIL; ATACAND HCT					
021222 001	CEFDITOREN PIVOXIL; SPECTRACEP					
020998 003	CELECOXIB; CELEBREX					

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME ; TRADE NAME	PATENT NUMBER	PATENT/PED EXPRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS CODE	EXPIRES
020740 001	CERIVASTATIN SODIUM;BAYCOL,	5006530	JUN 26,	2011				
020740 002	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26,	2011				
020740 003	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26,	2011				
020740 004	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26,	2011				
020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26,	2011				
020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26,	2011				
019835 001	CETIRIZINE HYDROCHLORIDE,ZYRTEC	4525358	JUN 25,	2007				
019835 002	CETIRIZINE HYDROCHLORIDE,ZYRTEC	4525358*PED	DEC 25,	2007				
020346 001	CETIRIZINE HYDROCHLORIDE,ZYRTEC	4525358	JUN 25,	2007				
021555 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP ONE-STEP	4525358*PED	DEC 25,	2007				
020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4525358*PED	DEC 25,	2007				
020822 001	CITALOPRAM HYDROBROMIDE;CELEXA	467044	DEC 09,	2003	U-2223	NCE	JUL 17,	2003
020822 002	CITALOPRAM HYDROBROMIDE;CELEXA					PED	JAN 17,	2004
020822 003	CITALOPRAM HYDROBROMIDE;CELEXA					NCE	JUL 17,	2003
021046 001	CITALOPRAM HYDROBROMIDE;CELEXA					PED	JAN 17,	2004
020839 001	CLOPIDOGREL BISULFATE;PLAVIX	6429210	JUN 10,	2019				
021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6433026	JUN 10,	2014				
021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6433026	JUN 10,	2014				
021165 001	DESLORAYADINE;CLARITIN	6100274	JUL 07,	2019				
021312 001	DESLORAYADINE;CLARITIN							
075863 001	DESOGESTREL;KARIVA							
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04,	2015				
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04,	2015				
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04,	2015				
021191 001	DIMTRISTOYL LECITHIN;IMAGENT	6280704	JUL 30,	2013				
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6280705	JUL 30,	2013				
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6287539	JUL 30,	2013				
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5605673	FEB 25,	2014				
021191 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	5626833	MAY 16,	2014				
021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	5639443	JUN 17,	2014				
021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	5695741	DEC 09,	2014				
020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	5720938	FEB 24,	2015				
		5798091	AUG 25,	2015				
		6419453	DEC 18,	2018				
		4913906	APR 03,	2007				
		4988731	JAN 29,	2008				
		6372160	MAR 31,	2019				
			NP	AUG 04,	2003			

PRESCRIPTION AND OTC DRUG PRODUCT

* PED and PED represent Pediatric Exclusivity
 * PED and PED represent Pediatric Exclusivity

APL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCL CODE	EXCLUS EXPIRES
020690 002 020862 001	DONEPEZIL HYDROCHLORIDE; ARICEPT DOXERCALCIFEROL; HECTOROL	6372760 5602116 5707980 5861386 5869473 5869473 5602116 5707980 5569652 5565467 5846976 5998427 6238695 6238695 6238695 5519021 5633169 5811423 5519021 5663169 5811423 5446194 5135950 4963590 5112861 5112861 6410054 6410054 4559332 6410054 6410054 4559332 6410054 6410054 4559332 5185351 5656650 5656650 5656650 5968902 5747447 5968902 5747447 RE34712 RE34712*PED	MAR 31, FEB 11, AUG 17, AUG 02, AUG 02, FEB 11, AUG 17, OCT 29, OCT 15, DEC 08, OCT 15, APR 06, APR 06, APR 06, MAY 21, SEP 02, AUG 07, MAY 21, SEP 02, AUG 07, AUG 07, AUG 29, OCT 31, NOV 27, MAY 12, MAY 12, DEC 08, NOV 05, APR 09, DEC 08, NOV 05, APR 09, DEC 08, NOV 05, APR 09, APR 09, APR 09, FEB 09, AUG 12, JUN 02, MAY 05, JUN 02, MAY 05, JUN 08, DEC 08,	2019 2014 2010 2008 2008 2014 2010 2013 2013 2015 2013 2013 2019 2019 2019 2019 2014 2012 2013 2014 2012 2012 2012 2010 2007 2009 2009 2019 2019 2019 2019 2019 2015 2009 2009 2009 2009 2009 2014 2015 2015 2015 2009 2009 NP FEB 14, AUG 29, MAR 01,	U-278 U-278 U-278 U-278 U-278 U-321 U-321 U-1 U-476 U-477 U-256 U-248 U-248 U-248 U-467 U-3 U-3 U-467 U-3 U-467 U-3 U-467 U-3 U-467 U-3 U-453 U-453 U-453 I-366 PED MAR 01,	EXCLUS EXPIRES 2005 2006 2005
021027 001	DOXERCALCIFEROL; HECTOROL					
021098 001 021319 001	DROSPIRENONE; YASMIN DUTASTERIDE; AVODART					
020972 001 020972 002 020972 003 021360 001	EFAVIRENZ; SUSTIVA EFAVIRENZ; SUSTIVA EFAVIRENZ; SUSTIVA EFAVIRENZ; SUSTIVA					
021360 002	EFAVIRENZ; SUSTIVA					
020796 001	ENTACAPONE; COMTAN					
021437 001 021437 002	EPLERENONE; INSPIRA EPLERENONE; INSPIRA					
021437 003	EPLERENONE; INSPIRA					
>ADD>	020738 006	EPROSARTAN MESYLATE; TEVETEN	APR 09, FEB 09,	2004 2010	U-3 U-3	DEC 22, 2002
	021268 001	EPROSARTAN MESYLATE; TEVETEN HCT	AUG 12, AUG 12, AUG 12,	2014 2014 2014	U-3 U-3 U-3	
021268 002 020718 001	EPTIFIBATIDE; INTEGRILLIN	5968902 5747447 5968902	JUN 02, MAY 05, JUN 02,	2015 2015 2015	U-453 U-453 U-453	
020718 002	EPTIFIBATIDE; INTEGRILLIN					
021323 001	ESCITALOPRAM OXALATE; LEXapro	RE34712 RE34712*PED	JUN 08, DEC 08,	2009 2009	NP FEB 14, AUG 29, MAR 01,	2005 2006 2005

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021323 002	ESCITALOPRAM OXALATE; LEXapro	RE34712 RE34712*PED	JUN 08, 2009 DEC 08, 2009	NP PED	AUG 14, 2005 FEB 14, 2006	
021323 003	ESCITALOPRAM OXALATE; LEXapro	RE34712 RE34712*PED	JUN 08, 2009 DEC 08, 2009	NP PED	MAR 01, 2006 AUG 14, 2005	
021153 001	ESOMEPRAZOLE MAGNEStum; NEXium	6369085	MAY 25, 2018	I-366	FEB 14, 2006	
021153 002	ESOMEPRAZOLE MAGNEStum; NEXium	6428810 6369085 6428810	NOV 03, 2019 MAY 25, 2018 NOV 03, 2019	U-469 U-469 U-469	AUG 29, 2005 FEB 14, 2006 MAR 01, 2006	
020655 001	ESTRADIOL; ALORA	5122383	MAY 17, 2011	I-351	APR 05, 2005	
020655 002	ESTRADIOL; ALORA	5227169	MAY 17, 2011	I-351	APR 05, 2005	
020655 003	ESTRADIOL; ALORA	5212199	MAY 17, 2011	I-351	APR 05, 2005	
020655 004	ESTRADIOL; ALORA	5164190	DEC 11, 2010	I-351	APR 05, 2005	
020538 005	ESTRADIOL; VIVELLE-DOT	5908638	JUL 26, 2015	I-254	AUG 16, 2003	
020538 006	ESTRADIOL; VIVELLE-DOT	5989581	APR 08, 2018	I-254	AUG 16, 2003	
020538 007	ESTRADIOL; VIVELLE-DOT	4616006	SEP 26, 2003	I-254	AUG 16, 2003	
020538 008	ESTRADIOL; VIVELLE-DOT	6214815	JUN 09, 2019	I-254	AUG 16, 2003	
020992 001	ESTROGENS, CONJUGATED; SYNTHETIC A; CENESTIN	4530839	SEP 26, 2003	I-254	AUG 16, 2003	
021187 001	ETHINYL ESTRADIOL; NUVARING	4544554	SEP 26, 2003	I-112	JUN 21, 2005	
021241 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN LO	4628051	SEP 26, 2003	I-112	AUG 22, 2005	
>ADD>	EZETIMIBE; ZETIA	RE37721 5846966	JUN 16, 2015 SEP 21, 2013	U-473 U-474	NCE	OCT 25, 2007
	FENOfibrate; FENOfibrate (MICRON I PEXOPENADINE HYDROCHLORIDE; ALLEGRA 020625 001	6399632	MAY 11, 2012	U-468	PC	SEP 15, 2002
075753 002	FENOfibrate; FENOfibrate (MICRON I PEXOPENADINE HYDROCHLORIDE; ALLEGRA 020872 001	6399632	MAY 11, 2012	U-468	PC	SEP 15, 2002
075753 003	PEXOPENADINE HYDROCHLORIDE; ALLEGRA 020872 001	6399632	MAY 11, 2012	U-468	PC	OCT 28, 2002
020872 002	PEXOPENADINE HYDROCHLORIDE; ALLEGRA 020872 004	6399632	MAY 11, 2012	U-468	PC	OCT 28, 2002
020872 004	PEXOPENADINE HYDROCHLORIDE; ALLEGRA 020786 001	6399632	MAY 11, 2012	U-468	PC	OCT 28, 2002
020786 001	PEXOPENADINE HYDROCHLORIDE; ALLEGRA-D 075442 001	6399632	MAY 11, 2012	U-468	PC	JUL 29, 2005
075442 002	FLECAinide ACETATE; FLECAinide ACETATE 075442 003	6399632	MAY 11, 2012	U-468	I-362	I-362
075442 003	FLECAinide ACETATE; FLECAinide ACETATE 018936 001	6399632	MAY 11, 2012	U-468	I-362	I-362
018936 003	FLUOXETINE HYDROCHLORIDE; PROZAC FLUOXETINE HYDROCHLORIDE; PROZAC	6399632	MAY 11, 2012	U-468	OCT 28, 2002	

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCL CODE	EXCLUSIVITY EXPIRES	
018936 004	FLUOXETINE HYDROCHLORIDE; PROZAC			I-362	JUL 29,	2005	
018936 006	FLUOXETINE HYDROCHLORIDE; PROZAC			I-362	JUL 29,	2005	
02101 001	FLUOXETINE HYDROCHLORIDE; PROZAC			I-362	JUL 29,	2005	
020974 001	FLUOXETINE HYDROCHLORIDE; PROZAC			I-362	JUL 29,	2005	
020974 002	FLUOXETINE HYDROCHLORIDE; PROZAC			I-362	JUL 29,	2005	
018936 007	FLUOXETINE HYDROCHLORIDE; SARAFEM			D-75	JUN 12,	2005	
018936 008	FLUOXETINE HYDROCHLORIDE; SARAFEM			D-76	MAY 23,	2005	
020121 001	FLUTICASONE PROPIONATE; FLONASE	6242003	APR 13, 2020				
021192 001	FLUVASTATIN SODIUM; LESCOL XL	4818816	AUG 19, 2003	NCE	APR 25,	2007	
021345 001	FONDAPARINUX SODIUM; ARIXTRA	4659516	OCT 01, 2004	U-258	I-354	MAY 24,	2005
021344 001	FULVESTRANT; FASLODEX	5084479	JAN 02, 2010	U-258	I-354	MAY 24,	2005
020235 001	GABAPENTIN; NEURONTIN	5084479*PED	JUL 02, 2010	U-258	I-354	MAY 24,	2005
020235 002	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24,	2005
020235 003	GABAPENTIN; NEURONTIN	5084479	JUL 02, 2010	U-258	I-354	MAY 24,	2005
020882 001	GABAPENTIN; NEURONTIN	5084479*PED	JUL 02, 2010	U-258	I-354	MAY 24,	2005
020882 002	GABAPENTIN; NEURONTIN	6054482	APR 25, 2017				
021129 001	GABAPENTIN; NEURONTIN	6054482*PED	OCT 25, 2017				
020131 001	GADOTERIDOL; PROHANCE	5474756	DEC 12, 2012	U-480			
>ADD:		5846519	DEC 08, 2015				
>ADD:		6143274	DEC 12, 2012				
021061 001	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015	NCE	DEC 17,	2004	
021061 002	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015	NCE	DEC 17,	2004	
021062 001	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015	NCE	DEC 17,	2004	
021062 002	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015	NCE	DEC 17,	2004	
020622 001	GLATIRAMER ACETATE; COPAXONE	6342476	MAY 24, 2014	U-441			
		6362161	MAY 24, 2014	U-441			
021460 001	GLIPIZIDE; METAGLIP			NC	OCT 21,	2005	
021460 002	GLIPIZIDE; METAGLIP			NC	OCT 21,	2005	
021460 003	GLIPIZIDE; METAGLIP			NC	OCT 21,	2005	
021178 001	GLYBURIDE; GLUCOVANCE			I-368	SEP 30,	2005	
021178 002	GLYBURIDE; GLUCOVANCE			I-368	SEP 30,	2005	
021178 003	GRANISETRON HYDROCHLORIDE; KYTRIL			I-369	AUG 16,	2005	
020239 001	GRANISETRON HYDROCHLORIDE; KYTRIL			I-369	AUG 16,	2005	
020239 002	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 20, 2007	U-105			
020305 002	HYDROCHLOROTHIAZIDE; ACCURETIC	4344949	OCT 03, 2002	U-3	DEC 28,	2002	
020125 001	HYDROCHLOROTHIAZIDE; ACCURETIC	4743450	FEB 24, 2007	PED	JUN 28,	2003	
020125 002	HYDROCHLOROTHIAZIDE; ACCURETIC	4344949	OCT 03, 2002	U-3			
		4743450*PED	APR 03, 2003	U-3			
		4743450*PED	AUG 24, 2007				

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS CODE
020125 003	HYDROCHLOROTHIAZIDE; ACCURETIC	4344949 4743450 434494*PED 4743450-PED	OCT 03, FEB 24, APR 03, AUG 24,	2002 2007 2003 2007	U-3	U-3
020758 001	HYDROCHLOROTHIAZIDE; AVAILIDE	5270317	SEP 30,	2011		
020758 002	HYDROCHLOROTHIAZIDE; AVAILIDE	5270317	SEP 30,	2011		
020758 003	HYDROCHLOROTHIAZIDE; AVAILIDE	5270317	SEP 30,	2011		
020818 001	HYDROCHLOROTHIAZIDE; DIOVAN HCT	6294197	JUN 18,	2017	U-3	
020818 002	HYDROCHLOROTHIAZIDE; DIOVAN HCT	6294197	JUN 18,	2017	U-3	
020387 001	HYDROCHLOROTHIAZIDE; HYZZAR	5153197	OCT 06,	2009	U-3	
020387 002	HYDROCHLOROTHIAZIDE; HYZZAR	5138069 5608075	FEB 11, MAR 04,	2010 2014	U-3	
		5138069*PED 515319*PED	FEB 11, APR 06,	2010 2014	U-3	
		5608075*PED	SEP 04,	2014		
		5138069	AUG 11,	2009	U-3	
		5153197	OCT 06,	2009	U-3	
020729 003	HYDROCHLOROTHIAZIDE; UNIRETIC	5138069*PED	FEB 11,	2010	U-3	
020716 001	HYDROCODONE BITARTRATE; VICOPROFEN	515319*PED	APR 06,	2010		
021374 001	IBUPROFEN; ADVIL COLD AND SINUS	5608075*PED	SEP 04,	2014		
		4743450	FEB 24,	2007		
		6348216	JUN 10,	2017		
		5071643	DEC 10,	2008		
		5071643*PED	JUN 10,	2009		
		5360615	DEC 10,	2008		
		5360615*PED	JUN 10,	2009		
021373 001	IBUPROFEN; CHILDREN' S ADVIL COL	NP	AUG 01,	2003		
075874 001	IFOSFAMIDE; IFOSFAMIDE/MESSNA KIT	5618913	APR 08,	2014		
075874 002	IFOSFAMIDE; IFOSFAMIDE/MESSNA KIT	5866538	JUN 20,	2017		
020986 001	INSULIN ASPART; NOVOLOG	5547930	SEP 28,	2013	U-471	
		5834422	SEP 28,	2013		
		59448751	JUN 19,	2017		
		5844060	SEP 28,	2013	U-471	
		5618913	APR 08,	2014		
		4396538	DEC 30,	2002	U-31	
		4396598	DEC 30,	2002	U-30	
		4396538	DEC 30,	2002	U-29	
019710 003	IOVERSOL; OPTIRAY 160	4396598	DEC 30,	2002	U-29	
019710 002	IOVERSOL; OPTIRAY 240	4396598	DEC 30,	2002	U-30	
019710 004	IOVERSOL; OPTIRAY 300	4396598	DEC 30,	2002	U-464	
		4396598	DEC 30,	2002		

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES CODE		EXCLUS CODE EXPIRES	
			PATENT EXPIRES	PED	EXCL	USE CODE
019710 001	IOVERSOL; OPTIRAY 320	4396598	DEC 30,	2002	U-28	
		4396598	DEC 30,	2002	U-29	
019710 005	IOVERSOL; OPTIRAY 350	4396598	DEC 30,	2002	U-463	
		4396598	DEC 30,	2002	U-62	
020757 001	IRBESARTAN; AVAPRO	4396598	DEC 30,	2002	U-464	
>ADD>	IRBESARTAN; AVAPRO	4396598	DEC 30,	2002	U-465	
>ADD>	IRBESARTAN; AVAPRO	52270317	SEP 30,	2011	I-373	SEP 17, 2005
>ADD>	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR	52270317	SEP 30,	2011	I-373	SEP 17, 2005
020571 001	ISOTRETINOIN; ACCUTANE	6403569	APR 28,	2020	I-373	SEP 17, 2005
018662 002	ISOTRETINOIN; ACCUTANE				M-12	MAY 02, 2005
018662 003	ISOTRETINOIN; ACCUTANE				M-12	MAY 02, 2005
018662 004	ISOTRETINOIN; ACCUTANE				M-12	MAY 02, 2005
020657 001	ITRACONAZOLE; SPORANOX	6407079	JUN 18,	2019	M-16	FEB 08, 2005
020966 001	ITRACONAZOLE; SPORANOX	6407079	JUN 18,	2019	M-16	FEB 08, 2005
019700 001	KETOROLAC TROMETHAMINE; ACULAR PRESERVATIVE	5047407*PED	NOV 17,	2009	D-2	JUN 24, 2005
020811 001	KETOROLAC TROMETHAMINE; ACULAR PRESERVATIVE	5047407*PED	MAY 17,	2010	NS	JUN 24, 2005
020564 001	LAMIVUDINE; EPIVIR	5905082	MAY 18,	2016	D-2	JUN 24, 2005
020564 003	LAMIVUDINE; EPIVIR	5905082*PED	NOV 18,	2016	U-248	
		5905082*PED	JAN 30,	2018	U-248	
		6180639*PED	JUL 30,	2018	U-248	
020596 001	LAMIVUDINE; EPIVIR	5013743	FEB 12,	2010	U-452	M-12 JUL 31, 2005
020406 001	LANSOPRAZOLE; PREVACID	5013743	FEB 12,	2010	U-452	M-12 JUL 31, 2005
020406 002	LANSOPRAZOLE; PREVACID	4628098	MAY 10,	2009		
021428 001	LANSOPRAZOLE; PREVACID	4689333	JUL 29,	2005	U-126	
		5013743	FEB 12,	2010	U-452	
		5028560	JUN 25,	2008		
		5045321	SEP 03,	2008		
		5093132	SEP 03,	2008		
		5433959	SEP 03,	2008		
		5464632	NOV 07,	2012		
		6123962	FEB 13,	2007		
		6328994	MAY 17,	2009		
		4628098	MAY 10,	2009	U-126	
021428 002	LANSOPRAZOLE; PREVACID	4689333	JUL 29,	2005	U-452	
		5013743	FEB 12,	2010		
		5026560	JUN 25,	2008		
		5045321	SEP 03,	2008		
		5093132	SEP 03,	2008		
		5433959	SEP 03,	2008		
		5464632	NOV 07,	2012		
		6123962	FEB 13,	2007		
		6328994	MAY 17,	2009		

PREScription AND OTC DRUG PRODUCT
 * PEd and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES	
020597 001 021343 001	LATANOPROST; XALATAN LEUPROLIDE ACETATE; ELIGARD	6429226 5599552 5733950 5739176 4938763 5278201 5324519 5599552 FEB 04, OCT 03, OCT 03, OCT 03, JAN 11, OCT 20, FEB 04, OCT 03,	SEP 06, FEB 04, OCT 03, OCT 03, JAN 11, OCT 20, FEB 04, OCT 03,	2009 2014 2008 2008 2011 2011 2014 2008	U-260		
021379 001	LEUPROLIDE ACETATE; ELIGARD	5731950 5739176 4938763 5278201 5324519 63175978 6395292 6451289 6451289 6451289 5362755 5547994 5760090 5844002 6083993 6335369 6429230	OCT 03, OCT 03, OCT 03, JAN 11, OCT 20, DEC 17, JAN 30, MAR 21, MAR 21, MAR 21, NOV 08, AUG 20, JAN 05, JAN 05, JAN 05, JAN 18, JAN 18,	2008 2008 2008 2011 2011 2018 2017 2021 2021 2021 2011 2013 2010 2010 2010 2021 2011	JUL 24, N.P.	2005	
>ADD> >ADD> >ADD>	020837 001 020837 002 020837 003	LEVALBUTEROL HYDROCHLORIDE; XOPENEX LEVALBUTEROL HYDROCHLORIDE; XOPENEX LEVALBUTEROL HYDROCHLORIDE; XOPENEX	6395292 6451289 6451289 6451289 5362755 5547994 5760090 5844002 6083993 6335369 6429230	JAN 30, MAR 21, MAR 21, MAR 21, NOV 08, AUG 20, JAN 05, JAN 05, JAN 05, JAN 18, JAN 18,	2017 2021 2021 2021 2011 2013 2010 2010 2010 2021 2011	I-347	JAN 30, 2005
>ADD> >ADD> >ADD>	020182 001 020634 001 020634 002 020634 003	LEVOCARNITINE; CARNITOR LEVOFLOXACIN; LEVAQUIN LEVOFLOXACIN; LEVAQUIN LEVOFLOXACIN; LEVAQUIN	5547994 5760090 5844002 6083993 6335369 6429230	AUG 20, JAN 05, JAN 05, JAN 05, JAN 18, JAN 18,	2013 2010 2010 2010 2021 2021	I-357 I-357 I-357 I-357 I-433 I-433	U-332
>ADD> >ADD> >ADD>	020635 001 020635 002 020635 003	LEVOFLOXACIN; LEVAQUIN LEVOFLOXACIN; LEVAQUIN LEVOFLOXACIN; LEVAQUIN	5547994 5760090 5844002 6083993 6335369 6429230	AUG 20, JAN 05, JAN 05, JAN 05, JAN 18, JAN 18,	2003 2003 2003 2003 2003 2003	I-357 I-357 I-357 I-357 I-433 I-433	U-332
>ADD>	021342 001	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30,	2020	I-357	APR 08, 2003
021342 002	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30,	2020	I-372	OCT 30, 2003	
021342 003	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30,	2020	I-357	APR 08, 2003	
021342 004	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30,	2020	I-372	OCT 30, 2003	
021342 005	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30,	2020	I-357	APR 08, 2003	
021342 006	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30,	2020	I-372	OCT 30, 2003	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME ; TRADE NAME	PATENT NUMBER	PATENT/PED	EXCL	USE	EXCLUSIVITY CODE	EXCLUSIVITY CODE
			EXPIRES	CODE	EXPIRES		
021342 007	LEVOTHYROXINE SODIUM ; LEVO-T	6399101	MAR 30,	2020			
021342 008	LEVOTHYROXINE SODIUM ; LEVO-T	6399101	MAR 30,	2020			
021342 009	LEVOTHYROXINE SODIUM ; LEVO-T	6399101	MAR 30,	2020			
021342 010	LEVOTHYROXINE SODIUM ; LEVO-T	6399101	MAR 30,	2020			
021342 011	LEVOTHYROXINE SODIUM ; LEVO-T	6399101	MAR 30,	2020			
021226 001	LOPINAVIR;KALETRA	6458818	NOV 07,	2017			
020470 001	LORATADINE;CLARITIN-D 24 HOUR	5314697	OCT 23,	2012			
>ADD>	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11,	2009			
020386 001	LOSARTAN POTASSIUM;COZAAR	5153197	OCT 06,	2009			
020386 002	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04,	2014			
020386 003	LOSARTAN POTASSIUM;COZAAR	5138069*	PED FEB 11,	2010			
021249 001	LOVASTATIN;ADVICOR	5153197*	PED APR 06,	2010			
021249 002	LOVASTATIN;ADVICOR	5608075*	PED SEP 04,	2014			
021249 003	LOVASTATIN;ADVICOR	5608075*	PED SEP 04,	2014			
021316 001	LOVASTATIN;ALTGOR	5138069	AUG 11,	2009			
021316 002	LOVASTATIN;ALTGOR	5153197	OCT 06,	2009			
021316 003	LOVASTATIN;ALTGOR	5608075	MAR 04,	2014			
021316 004	LOVASTATIN;ALTGOR	5138069*	PED FEB 11,	2010			
019643 002	LOVASTATIN;MEVACOR	6080778	MAR 23,	2018	U-456	JAN 30,	2005

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS CODE
019643 003	LOVASTATIN; MEVACOR				PED	AUG 14,	2005
019643 004	LOVASTATIN; MEVACOR				I-350	FEB 14,	2005
020652 001	MANGAFOLIPIR TRISODIUM; TESLASCAN	4933456	NOV 27, 2011		PED	AUG 14,	2005
076175 001	MEFLOQUINE HYDROCHLORIDE; MEFLOQUINE HCL				I-350	FEB 14,	2005
020938 002	MELOXICAM; MOBIC						
020922 001	MEQUILONOL; SOLAGE	6353029	AUG 24, 2020		PC	NOV 03,	2002
020855 001	MESNA; MESNEX				NCE	APR 13,	2005
013217 001	METAXALONE; SKELAXIN	6407128	DEC 03, 2021		NDF	MAR 21,	2005
013217 003	METAXALONE; SKELAXIN	6407128	DEC 03, 2021		U-189		
020357 001	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				PED	JUN 15,	2004
020357 002	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				I-320	DEC 15,	2003
020357 003	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				W	JUN 15,	2004
020357 004	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				PED	JUN 15,	2004
020357 005	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				I-320	DEC 15,	2003
021202 001	METHYLPHENIDATE HYDROCHLORIDE; CONCERTA	6475521	MAR 19, 2018		W	JUN 15,	2004
021121 004	METHYLPHENIDATE HYDROCHLORIDE; CONCERTA	4519001	JUL 12, 2002		NP	AUG 01,	2003
021259 001	METHYLPHENIDATE HYDROCHLORIDE; METADATE CD	4612008	SEP 16, 2003				
021284 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	4783337	SEP 16, 2003		U-372		
021284 002	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5082668	SEP 16, 2003				
021284 003	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5344215	OCT 27, 2020				
020415 001	MIRTAZAPINE; REMERON	5837284	MAY 15,			JUN 07,	2005
		6228398	MAY 01,		U-472	NP	
		5837284	MAY 15,		U-472	NP	
		6228398	MAY 01,		U-472	NP	
		5637284	MAY 15,		U-472	NP	
		6228398	MAY 01,		U-472	NP	
		6228398	NOV 01,		U-472	NP	
					M-18	APR 09,	2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS CODE EXPIRES
020415 002	MIRTAZAPINE; REMERON		M-18	APR 09, 2005	M-18	APR 09, 2005
020415 003	MIRTAZAPINE; REMERON		M-18	APR 09, 2005	M-18	APR 09, 2005
021208 001	MIRTAZAPINE; REMERON SOLTAB		M-18	APR 09, 2005	M-18	APR 09, 2005
>ADD>	MIRTAZAPINE; REMERON SOLTAB		M-18	APR 09, 2005	M-18	APR 09, 2005
>ADD>	MIRTAZAPINE; REMERON SOLTAB		OCT 13, 2007	ODE 1-360	JUL 17, 2005	JAN 17, 2006
>ADD>	MIRTAZAPINE; REMERON SOLTAB		I-360	JUL 17, 2005	PED	PED
021208 002	MIRTAZAPINE; REMERON SOLTAB		NDF	JUL 26, 2005	JUL 26, 2005	JAN 26, 2006
021208 003	MIRTAZAPINE; REMERON SOLTAB		NDF	JUL 26, 2005	PED	PED
019297 001	MITOXANTRONE HYDROCHLORIDE; NOVANTRONE		NCE	FEB 20, 2003	NCE	FEB 20, 2003
020762 001	MOMETASONE FURETATE MONOHYDRATE; NASONEX		PED	AUG 20, 2003	PED	PED
021409 001	MONTELUKAST SODIUM; SINGULAIR	5565473 * PED AUG 03, 2012	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017
		5565473 * PED AUG 03, 2012	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017
021260 001	MORPHINE SULFATE; AVINZA	6066339	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017
021260 002	MORPHINE SULFATE; AVINZA	6066339	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017
021260 003	MORPHINE SULFATE; AVINZA	6066339	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017
021260 004	MORPHINE SULFATE; AVINZA	6066339	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017	NOV 25, 2017
019583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2002	4420639 * PED JUN 13, 2003	DEC 13, 2002	4420639 * PED JUN 13, 2003
019583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2002	4420639 * PED JUN 13, 2003	DEC 13, 2002	4420639 * PED JUN 13, 2003
020763 001	NARATRIPTAN HYDROCHLORIDE; AMERGE	4997841	JUL 07, 2010	JUL 07, 2010	JUL 07, 2010	JUL 07, 2010
020763 002	NARATRIPTAN HYDROCHLORIDE; AMERGE	4997841	JUL 07, 2010	JUL 07, 2010	JUL 07, 2010	JUL 07, 2010
020152 001	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	4338317	MAR 16, 2003	4338317
020152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	5256664 * PED SEP 16, 2003	4338317 * PED SEP 16, 2003	5256664 * PED SEP 16, 2003	4338317 * PED SEP 16, 2003	4338317 * PED SEP 16, 2003
020152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	4338317	MAR 16, 2003	4338317
020152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	5256664 * PED OCT 28, 2012	4338317 * PED SEP 16, 2003	5256664 * PED OCT 28, 2012	4338317 * PED SEP 16, 2003	4338317 * PED SEP 16, 2003
020152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	4338317	MAR 16, 2003	4338317
020152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	5256664 * PED OCT 28, 2012	4338317 * PED OCT 28, 2012	5256664 * PED OCT 28, 2012	4338317 * PED OCT 28, 2012	4338317 * PED OCT 28, 2012

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES		PATENT/PED EXCL USE CODE	EXCLUS CODE	EXCLUS CODE EXPIRES
			EXPIRES	CODE			
020778 001	NELFINAVIR MESYLATE; VITACEPT	6162812	OCT 07,	2013			U-248
020779 001	NELFINAVIR MESYLATE; VITACEPT	6162812	OCT 07,	2013			U-248
020381 001	NIACIN; NIASPAN	6406715	OCT 31,	2017			U-450
020381 002	NIACIN; NIASPAN	6406715	OCT 31,	2017			U-450
020381 003	NIACIN; NIASPAN	6406715	OCT 31,	2017			U-450
020381 004	NIACIN; NIASPAN	6406715	OCT 31,	2017			U-450
020381 005	NIACIN; NIASPAN TITRATION ST	6406715	OCT 31,	2017			U-450
021330 001	NICOTINE POLACRILEX; COMMIT	6129930	SEP 20,	2013			U-354
021330 002	NICOTINE POLACRILEX; COMMIT						
020076 004	NICOTINE; HABITROL						
020076 005	NICOTINE; HABITROL						
020076 006	NICOTINE; HABITROL						
021498 001	NITAZOXANIDE; ALINIA						
>ADD>							
020555 001	NIZATIDINE; AXID AR	4375547	APR 12,	2002			
021008 001	OCTREOTIDE ACETATE; SANDOSTATIN LAR	6395292	JAN 30,	2017			
021286 001	OLMESARTAN MEDOXOMIL; BENICAR						
021286 003	OLMESARTAN MEDOXOMIL; BENICAR						
021286 004	OLMESARTAN MEDOXOMIL; BENICAR						
019810 001	OMEPRAZOLE; PRILOSEC	6166213*PED	APR 09,	2019			
019810 002	OMEPRAZOLE; PRILOSEC	6166213*PED	APR 09,	2019			
019810 003	OMEPRAZOLE; PRILOSEC	6166213*PED	APR 09,	2018			
020766 001	ORLISTAT; XENICAL	4598089	JUN 18,	2009			
021492 001	OXALIPLATIN; ELOXATIN	5420319	APR 07,	2013			
021492 002	OXALIPLATIN; ELOXATIN	5338874	APR 07,	2013			
		5290961	JAN 12,	2013			
		5420319	APR 07,	2013			
		5338874	APR 07,	2013			
		5290961	JAN 12,	2013			
021285 001	OXCARBAZEPINE; TRILEPTAL	4970075	AUG 29,	2006			
020553 001	OXYCODONE HYDROCHLORIDE; OXYCONTIN						
020553 002	OXYCODONE HYDROCHLORIDE; OXYCONTIN						
		5266331	OCT 26,	2007			
		5549912	OCT 26,	2007			
		5508042	APR 16,	2013			
		5656295	OCT 26,	2007			
		4970075	AUG 29,	2006			
		5266331	OCT 26,	2007			
		5549912	OCT 26,	2007			
		5508042	APR 16,	2013			
		5656295	OCT 26,	2007			

PREScription AND oTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT/PED EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020553 003	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		
		5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
020553 004	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5549912	OCT 26, 2007			
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		
		5997903	DEC 07, 2016		1-356	APR 19, 2005
		5997903	DEC 07, 2016		1-356	APR 19, 2005
		4758579	JUL 19, 2005		1-330	JUN 12, 2004
				NCE	FEB 02,	2005
				PED	JUN 17,	2002
020553 005	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	OCT 13,	2004
		6063927	APR 23, 2019	PED	JUN 14,	2005
		6080759	MAY 19, 2015	PED	JUN 17,	2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017		U-286	
		6133289	MAY 19, 2015		U-358	
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723	IPED JUN 29,	U-12		
		5789449	IPED JUL 06,	2009		
		5872132	IPED NOV 19,	2015	U-285	
		5900423	IPED NOV 19,	2015		
		6063927	IPED OCT 23,	2019		
		6080759	IPED NOV 19,	2015		
		6113944	*PED JUN 14,	2015		
		6121291	*PED SEP 17,	2017		
		6121291	*PED SEP 17,	2017	U-286	
		6121291	*PED SEP 17,	2017	U-431	
		6133289	*PED NOV 19,	2015	U-358	
		6172233	*PED JUL 15,	2018		
		4721723	DEC 29,	2006	U-12	I-261
		5872132	MAY 19,	2015	1-326	APR 13, 2004
		5900423	MAY 19,	2015	1-345	DEC 14, 2004
		5789449	JAN 06,	2009	PED	OCT 13,
		6063927	APR 23,	2019	PED	JUN 14,
		6080759	MAY 19,	2015	PED	NOV 17,
020031 002	PAROXETINE HYDROCHLORIDE; PAXIL	6113944	DEC 14,	2014		
		6121291	MAR 17,	2017		
		6133289	MAY 19,	2015		
		6172233	JAN 15,	2018		
		4721723	DEC 29,	2006		
		5872132	MAY 19,	2015		
		5900423	MAY 19,	2015		
		5789449	JAN 06,	2009		
		6063927	APR 23,	2019		
		6080759	MAY 19,	2015		
		6113944	DEC 14,	2014		
		6121291	MAR 17,	2017		
		6133289	MAY 19,	2015		
		6172233	JAN 15,	2018		
		6121291	MAR 17,	2017		
		4721723	*PED JUN 29,	2007		

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PRD EXPIRES	EXCL CODE	EXCLUS CODE	EXCLUS CODE		
020031 003	PAROXETINE HYDROCHLORIDE; PAXIL	5789449*PED JUL 06, 2009 5872132*PED NOV 19, 2015 5900423*PED NOV 19, 2015 6063927*PED OCT 23, 2019 6080759*PED NOV 19, 2015 6113944*PED JUN 14, 2015 6121291*PED SEP 17, 2017 6121291*PED SEP 17, 2017 6133289*PED NOV 19, 2015 6172233*PED JUL 15, 2018 4121723 DEC 29, 2006 5872132 MAY 19, 2015 5900423 MAY 19, 2015 5789449 JAN 06, 2009 6063927 APR 23, 2019 6080759 MAY 19, 2015 6113944 DEC 14, 2014 6121291 MAR 17, 2017 6133289 MAY 19, 2015 6172233 JAN 15, 2018 6121291 MAR 17, 2017 4721723*PED JUN 29, 2007 5789449*PED JUL 06, 2009 5872132*PED NOV 19, 2015 5900423*PED NOV 19, 2015 6063927*PED OCT 23, 2019 6080759*PED NOV 19, 2015 6113944*PED JUN 14, 2015 6121291*PED SEP 17, 2017 6133289*PED NOV 19, 2015 6172233*PED JUL 15, 2018 4121723 DEC 29, 2006 5872132 MAY 19, 2015 5900423 MAY 19, 2015 5789449 JAN 06, 2009 6063927 APR 23, 2019 6080759 MAY 19, 2015 6113944 DEC 14, 2014 6133289 MAY 19, 2015 6121291 MAR 17, 2017 6133289 MAY 19, 2015 6172233*PED JUL 15, 2018 4121723 DEC 29, 2006 5872132 MAY 19, 2015 5900423 MAY 19, 2015 5789449 JAN 06, 2009 6063927 APR 23, 2019 6080759 MAY 19, 2015 6113944 DEC 14, 2014 6133289 MAY 19, 2015 6121291 MAR 17, 2017 6133289 MAY 19, 2015 6172233*PED JUL 15, 2018 4121723 DEC 29, 2006 5872132 MAY 19, 2015 5900423 MAY 19, 2015 5789449*PED JUL 06, 2009 6063927*PED NOV 19, 2015 6080759*PED OCT 23, 2019 6113944*PED JUN 14, 2015 6121291*PED SEP 17, 2017 6121291*PED SEP 17, 2017 6133289*PED NOV 19, 2015	U-285 U-285	I-261 I-326 I-345 DEC 14, 2004 OCT 13, 2004 JUN 14, 2005 NOV 17, 2002	MAY 17, 2002 APR 13, 2004 DEC 14, 2004 OCT 13, 2004 JUN 14, 2005 NOV 17, 2002	I-261 I-326 I-345 DEC 14, 2004 OCT 13, 2004 JUN 14, 2005 NOV 17, 2002	MAY 17, 2002 APR 13, 2004 DEC 14, 2004 OCT 13, 2004 JUN 14, 2005 NOV 17, 2002	I-261 I-326 I-345 DEC 14, 2004 OCT 13, 2004 JUN 14, 2005 NOV 17, 2002
020031 004	PAROXETINE HYDROCHLORIDE; PAXIL	5789449*PED NOV 19, 2015 6172233*PED JUL 15, 2018 4121723 DEC 29, 2006 5872132 MAY 19, 2015 5900423 MAY 19, 2015 5789449 JAN 06, 2009 6063927 APR 23, 2019 6080759 MAY 19, 2015 6113944 DEC 14, 2014 6133289 MAY 19, 2015 6121291 MAR 17, 2017 6133289 MAY 19, 2015 6172233*PED JUL 15, 2018 4121723 DEC 29, 2006 5872132 MAY 19, 2015 5900423 MAY 19, 2015 5789449*PED JUL 06, 2009 6063927*PED NOV 19, 2015 6080759*PED OCT 23, 2019 6113944*PED JUN 14, 2015 6121291*PED SEP 17, 2017 6121291*PED SEP 17, 2017 6133289*PED NOV 19, 2015	U-431 U-12 U-358 U-431 U-12 U-285 U-431 U-358 U-431 U-12 U-358 U-431 U-358 U-431 U-358 U-431 U-358 U-431 U-358 U-431 U-358 U-431 U-358 U-431 U-358 U-431 U-358 U-431 U-358	U-431 U-12 U-285 U-431 U-12 U-285 U-431 U-358 U-431 U-12 U-358 U-431 U-358 U-431 U-358 U-431 U-358 U-431 U-358 U-431 U-358 U-431 U-358 U-431 U-358 U-431 U-358	MAY 17, 2002 APR 13, 2004 DEC 14, 2004 OCT 13, 2004 JUN 14, 2005 NOV 17, 2002	I-261 I-326 I-345 DEC 14, 2004 OCT 13, 2004 JUN 14, 2005 NOV 17, 2002	MAY 17, 2002 APR 13, 2004 DEC 14, 2004 OCT 13, 2004 JUN 14, 2005 NOV 17, 2002	

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL	USE CODE	EXCLUS CODE	EXCLUS CODE EXPIRES
020031 005	PAROXETINE HYDROCHLORIDE; PAXIL	6172233*PED JUL 15, 2018	U-12	I-261	MAY 17, 2002		
		4721723 DEC 29, 2006		I-326	APR 13, 2004		
		5872132 MAY 19, 2015		I-345	DEC 14, 2004		
		5900423 MAY 19, 2015		OCT 13,	2004		
		5789449 JAN 06, 2009	U-285	PED	JUN 14, 2005		
		6063927 APR 23, 2019		PED	NOV 17, 2002		
		6080759 MAY 19, 2015					
		6113944 DEC 14, 2014					
		6121291 MAR 17, 2017	U-286				
		6133289 MAY 15, 2015	U-358				
		6172233 JAN 15, 2018					
		6121291 MAR 17, 2017	U-431				
		4721723*PED JUN 29, 2007	U-12				
		5789449*PED JUL 06, 2009	U-285				
		5872132*PED NOV 19, 2015					
		5900423*PED NOV 19, 2015					
		6063927*PED OCT 23, 2019					
		6080759*PED NOV 19, 2015					
		6113944*PED JUN 14, 2015	U-286				
		6121291*PED SEP 17, 2017	U-431				
		6121291*PED SEP 17, 2017	U-431				
		6133289*PED NOV 19, 2015	U-358				
		6172233*PED JUL 15, 2018					
		4721723 DEC 29, 2006	I-261	MAY 17, 2002			
		5811436 SEP 22, 2015		PED	NOV 17, 2002		
		5872132 MAY 19, 2015	I-345	DEC 14, 2004			
		5900423 MAY 19, 2015	OCT 13,	2004			
		5789449 JAN 06, 2009	U-285	PED	JUN 14, 2005		
		6063927 APR 23, 2019		PED	NOV 17, 2002		
		6080759 MAY 19, 2015					
		6121291 MAR 17, 2017	U-286				
		6133289 MAY 19, 2015	U-358				
		6172233 JAN 15, 2018					
		6121291 MAR 17, 2017	U-431				
		4721723*PED JUN 29, 2007					
		5789449*PED JUL 06, 2009	U-285				
		5811436*PED MAR 22, 2016					
		5872132*PED NOV 19, 2015					
		5900423*PED NOV 19, 2015					
		6063927*PED OCT 23, 2019					
		6080759*PED NOV 19, 2015					
		6121291*PED SEP 17, 2017	U-286				
		6121291*PED SEP 17, 2017	U-431				
		6133289*PED NOV 19, 2015	U-358				
		6172233*PED JUL 15, 2018					

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES		EXCL USE CODE		EXCLUS EXPIRES		
			PATENT	PED	EXCL	USE CODE	EXCLUS	EXPIRES	
020885 004	PAROXETINE HYDROCHLORIDE; PAXIL	5900423*PED NOV 19, 2015 6063927*PED OCT 23, 2019 6080759*PED NOV 19, 2015 6121291*PED SEP 17, 2017 6121291*PED SEP 17, 2017 6133289*PED NOV 19, 2015 6172233*PED JUL 15, 2018 5872132 MAY 19, 2015 5900423 MAY 19, 2015 5789449 JAN 06, 2009 5789449 DEC 29, 2006 4721723 APR 23, 2019 6062927 MAY 19, 2015 6080759 MAR 17, 2017 6121291 MAY 19, 2015 6133289 JAN 15, 2018 6172233 MAR 17, 2017 6121291 4721723*PED JUN 29, 2007 5789449*PED JUL 06, 2009 5872132*PED NOV 19, 2015 5900423*PED NOV 19, 2015 6063927*PED OCT 23, 2019 6080759*PED NOV 19, 2015 6121291*PED SEP 17, 2017 6121291*PED SEP 17, 2017 6133289*PED NOV 19, 2015 6172233*PED JUL 15, 2018 5872132 MAY 19, 2015 5839177 JUN 13, 2006 5422123 JUN 06, 2012 4721723 DEC 29, 2006 5900423 MAY 19, 2015 5789449 JAN 06, 2009 6063927 APR 23, 2019 6080759 MAY 19, 2015 6121291 MAR 17, 2017 6133289 MAY 19, 2015 6172233 JAN 15, 2018 4721723*PED JUN 29, 2007 4839177*PED DEC 13, 2006 5422123*PED DEC 06, 2012 5789449*PED JUL 06, 2009 5872132*PED NOV 19, 2015 5900423*PED NOV 19, 2015 6063927*PED OCT 23, 2019 6080759*PED NOV 19, 2015 6121291*PED SEP 17, 2017 6133289*PED NOV 19, 2015 6172233*PED JUL 15,	U-358		I-261	MAY 17, 2002 PED NOV 17, 2002 I-345	DEC 14, 2004	APR 13, 2004	
020936 001	PAROXETINE HYDROCHLORIDE; PAXIL CR				U-12	I-326	JUN 14, 2005 PED OCT 13, 2004		

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019898 008	PRAVASTATIN SODIUM; PRAVACHOL	4346227 5030447 5180589 5622985	OCT 20, 2005 JUL 09, 2008 JUL 09, 2008 APR 22, 2014	NS D-70 PED U-335	DEC 18, 2004 DEC 18, 2004 JUN 18, 2005 PED	DEC 18, DEC 18, JUN 18, U-335	2004 2004 2005 2005
		4346227*PED APR 20, 5180589*PED JAN 09, 5622985*PED OCT 22, 5030447*PED JAN 09,	2006 2009 2014 2009	I-281 PED D-51 PED	JUN 09, 2003 DEC 09, 2003 JAN 18, 2003 JUL 18, 2003	I-287 PED I-304 PED	FEB 10, 2003 AUG 10, 2003 JAN 18, 2003 OCT 29, 2005
>ADD> >ADD<	019885 001 QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949 4743450 5684016 5747504	OCT 03, 2002 FEB 24, 2007 NOV 04, 2014 APR 10, 2005	U-3	U-3		
		4344949*PED APR 03, 4743450*PED AUG 24, 5684016*PED MAY 04, 5747504*PED OCT 10,	2003 2007 2015 2005	U-210 U-3 U-210 U-210			
019885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949 4743450 5684016 5747504	OCT 03, 2002 FEB 24, 2007 NOV 04, 2014 APR 10, 2005	U-3	U-210 U-3 U-210 U-210		
		4344949*PED MAY 04, 4743450*PED AUG 24, 5684016*PED OCT 10, 5747504*PED OCT 10,	2005 2007 2015 2005	U-210 U-3 U-210 U-210			
019885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949 4743450 5684016 5747504	OCT 03, 2002 FEB 24, 2007 NOV 04, 2014 APR 10, 2005	U-3	U-210 U-3 U-210 U-210		
		4344949*PED MAY 04, 4743450*PED AUG 24, 5684016*PED MAY 04, 5747504*PED OCT 10,	2005 2007 2015 2005	U-210 U-3 U-210 U-210			
019885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949 4743450 5684016 5747504	OCT 03, 2002 FEB 24, 2007 NOV 04, 2014 APR 10, 2005	U-3	U-210 U-3 U-210 U-210		
		4344949*PED MAY 04, 4743450*PED AUG 24, 5684016*PED MAY 04, 5747504*PED OCT 10,	2007 2005 2003 2005	U-210 U-3 U-210 U-210			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCL CODE	EXCLUS EXPIRES
020973 001	RABEPRAZOLE SODIUM; ACIPHEX	5035899 5045552	APR 04, SEP 03,	2009 U-385 I-346	AUG 19, FEB 12,	2004 2005
>ADD> 020973 002	RABEPRAZOLE SODIUM; ACIPHEX				I-371	NOV 08,
>ADD> 020815 001	RALOXIFENE HYDROCHLORIDE; EVISTA	4418068	APR 03,	2003		
>ADD> 020741 001	REPAGLINIDE; PRANDIN	6458811 5312924	MAR 10, SEP 05,	2017 2006	I-367	OCT 21,
>ADD>		6143769	SEP 05,	2006		
>ADD>		RE37035	MAR 14,	2009		
>ADD> 020741 002	REPAGLINIDE; PRANDIN	5312924	SEP 05,	2006	U-214	I-367
>ADD>		6143769	SEP 05,	2006		
>ADD>		RE37035	MAR 14,	2009		
>ADD>		6472373	SEP 21,	2017		
>ADD>		6472373*PED	MAR 21,	2018	U-479	
>ADD>		6177074	NOV 01,	2016	U-454	
>ADD>		6177074*PED	MAY 01,	2017	U-454	
>ADD>		6461605	NOV 01,	2016	U-478	
>ADD> 020903 001	RIBAVIRIN; REBETOL	6461605*PED	MAY 01,	2017	U-478	
>ADD>		5527814	JUN 18,	2013	U-353	NCE
>ADD>		59494329	JUL 17,	2018	I-292	APR 14,
>ADD>		6015801	JUL 17,	2018	I-291	APR 14,
					D-73	MAY 17,
						2005
020599 001	RILUZOLE; RILUTEK	5298520	JUN 29,	2012	D-74	MAY 17,
020835 003	RISEDRONATE SODIUM; ACTONEL	5298520	JUN 29,	2012	M-15	MAR 03,
		5298520	JUN 29,	2012	M-15	MAR 03,
		5298520	JUN 29,	2012	M-15	MAR 03,
		5691374	MAY 18,	2015	M-15	MAR 03,
		6063811	MAY 06,	2017	M-15	MAR 03,
		5691374	MAY 18,	2015	M-15	MAR 03,
		5691374	MAY 06,	2017	M-15	MAR 03,
020272 001	RISPERIDONE; RISPERDAL	5298520	JUN 29,	2012	U-240	
020272 002	RISPERIDONE; RISPERDAL	5298520	JUN 29,	2012	U-240	
020272 003	RISPERIDONE; RISPERDAL	5298520	JUN 29,	2012	U-240	
020272 004	RISPERIDONE; RISPERDAL	5298520	JUN 29,	2012	U-240	
020272 005	RISPERIDONE; RISPERDAL	5298520	JUN 29,	2012	U-240	
020272 007	RISPERIDONE; RISPERDAL	5691374	MAY 18,	2015	I-353	APR 11,
020272 008	RISPERIDONE; RISPERDAL	6063811	MAY 06,	2017	U-266	2005
020588 001	RIZATRIPTAN BENZOATE; MAXALT	5691374	MAY 18,	2015	I-353	APR 11,
020864 001	RIZATRIPTAN BENZOATE; MAXALT	5298520	JUN 29,	2012	U-240	
020864 002	RIZATRIPTAN BENZOATE; MAXALT-MLT	5298520	JUN 29,	2012	U-240	
020865 001	RIZATRIPTAN BENZOATE; MAXALT-MLT	5691374	MAY 18,	2015	I-353	APR 11,
020865 002	ROFECOXIB; VIOXX	6063811	MAY 06,	2017	U-266	2005
021042 001	ROFECOXIB; VIOXX	5691374	MAY 18,	2015	I-353	APR 11,
021042 002	ROFECOXIB; VIOXX	6063811	MAY 06,	2017	I-353	APR 11, 2005
021042 003	ROFECOXIB; VIOXX	6063811	MAY 06,	2017		

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCL CODE	EXCLUS EXPIRES
021052 001	ROFECOXIB; VIOXX	5691374 6063811	MAY 18, 2015 MAY 06, 2017	U-266 U-266	I-353 I-353	APR 11, 2005 APR 11, 2005
021052 002	ROFECOXIB; VIOXX	5691374 6063811	MAY 18, MAY 18,	2017 2017	U-266 U-266	APR 11, 2005 APR 11, 2005
020658 001	ROPINIROLE HYDROCHLORIDE; REQUIP	4452808	DEC 07,	2007		
020658 002	ROPINIROLE HYDROCHLORIDE; REQUIP	4452808	DEC 07,	2007		
020658 003	ROPINIROLE HYDROCHLORIDE; REQUIP	4452808	DEC 07,	2007		
020658 004	ROPINIROLE HYDROCHLORIDE; REQUIP	4452808	DEC 07,	2007		
020658 005	ROPINIROLE HYDROCHLORIDE; REQUIP	4452808	DEC 07,	2007		
020658 006	ROPINIROLE HYDROCHLORIDE; REQUIP	4452808	DEC 07,	2007		
020658 007	ROPINIROLE HYDROCHLORIDE; REQUIP	4452808	DEC 07,	2007		
020692 001	SALMETEROL XINAFOATE; SEREVENT	6352717 6008228	NOV 16, JUN 06,	2019 2015		
020828 001	SAQUINAVIR; FORTOVASE SECRETIN; SECRETFLO			NPF U-12 OBE U-12	APR 04, APR 04, MAY 16,	2005 2009 2005
021209 001		4536518 4536518*PED	DEC 30, JUN 30,	2005 2006		
019839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699 5248699*PED	AUG 13, FEB 13,	2012 2013		
019839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	5744501 5789449	JAN 06, JAN 06,	2009 2009	U-461 U-460	
019839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518 4536518*PED	DEC 30, JUN 30,	2005 2006	U-12 U-12	MAY 16, MAY 16,
019839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699 5248699*PED	AUG 13, FEB 13,	2012 2013		
019839 005	SERTRALINE HYDROCHLORIDE; ZOLOFT	5744501 5789449	JAN 06, JAN 06,	2009 2009	U-461 U-460	
		4536518 4536518*PED	DEC 30, JUN 30,	2005 2006	U-12 U-12	MAY 16, MAY 16,
		5248699 5248699*PED	AUG 13, FEB 13,	2012 2013		
		5744501 5789449	JAN 06, JAN 06,	2009 2009	U-461 U-460	
		4536518 4536518*PED	DEC 30, JUN 30,	2005 2006	U-12 U-12	MAY 16, MAY 16,
		5248699 5248699*PED	AUG 13, FEB 13,	2012 2013		
		5744501 5789449	JAN 06, JAN 06,	2009 2009	U-461 U-460	
		4536518 4536518*PED	DEC 30, JUN 30,	2005 2006	U-12 U-12	MAY 16, MAY 16,
		5248699 5248699*PED	AUG 13, FEB 13,	2012 2013		
		5744501 5789449	JAN 06, JAN 06,	2009 2009	U-461 U-460	
		4536518 4536518*PED	DEC 30, JUN 30,	2005 2006	U-12 U-12	MAY 16, MAY 16,
		5248699 5248699*PED	AUG 13, FEB 13,	2012 2013		
		5744501 5789449	JAN 06, JAN 06,	2009 2009	U-461 U-460	
		4536518 4536518*PED	DEC 30, JUN 30,	2005 2006	U-12 U-12	MAY 16, MAY 16,

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPRIES
020990 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	I-355	MAY 16, 2005		
		5248699*PED	FEB 13, 2013	U-461			
		5744501	JAN 06, 2009	U-460			
020478 001	SEVOFLURANE;ULTANE	5789449	JAN 06, 2009	M-17	MAR 30, 2004		
020632 001	SIBUTRAMINE, HYDROCHLORIDE;MERIDIA	6444859	JAN 27, 2017	PED	SEP 30, 2004		
020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	6444859*PED	JUL 27, 2017				
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007	U-439			
020895 001	SILDENAFIL CITRATE;VIAGRA	5436272	JUL 25, 2012	U-439			
020895 002	SILDENAFIL CITRATE;VIAGRA	4746680	JUN 11, 2007	U-439			
020895 003	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012	U-155			
019766 001	SIMVASTATIN;ZOCOR	5250534	OCT 22, 2019	U-155			
019766 002	SIMVASTATIN;ZOCOR	6469012	MAR 27, 2012	U-155			
019766 003	SIMVASTATIN;ZOCOR	5250534	OCT 22, 2019	U-155			
019766 004	SIMVASTATIN;ZOCOR	6469012	MAR 27, 2012	U-155			
019766 005	SIMVASTATIN;ZOCOR	5100899	JUN 06, 2009	I-350	OCT 18, 2005		
>ADD>	SIROLIMUS;RAPAMUNE	5212155	MAY 18, 2010	PED	APR 18, 2005		
>ADD>		5308847	MAY 03, 2011	I-350	OCT 18, 2005		
>ADD>		5403833	APR 04, 2012	PED	APR 18, 2006		
>ADD>		5989591	MAR 11, 2018	I-350	OCT 18, 2005		
021110 001	SODIUM OXYBATE;XYREM			PED	APR 18, 2006		
020572 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2004	U-290			
020573 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2004	U-291			
021075 001	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12, 2012	U-292			
021075 002	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12, 2012	U-293			
021075 003	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12, 2012	ODE	JUL 17, 2009		
020604 004	SOMATROPIN RECOMBINANT; SEROSTIM	4795751	FEB 04, 2010	U-160			
020677 001	SPARFLOXACIN; ZAGAM	63368627	MAR 02, 2012	U-444			
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	63368627	MAR 02, 2012	U-444			
020132 002	SUMATRIPTAN SUCCINATE; IMITREX						

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUSIVITY CODE	EXCLUSIVITY EXPIRES
020132 003 017970 001	SUMATRIPTAN SUCCINATE;IMITREX TAMOXIFEN CITRATE;NOLVADEX	6368627 4536516 4536516*PED 4536516	MAR 02, 2012 AUG 20, 2002 FEB 20, 2003 AUG 20, 2002	U-444 M-20 PED	AUG 30, 2005 MAR 01, 2006		
017970 002	TAMOXIFEN CITRATE;NOLVADEX	4536516*PED	FEB 20, 2003				
>ADD> >ADD> >ADD> >ADD> >ADD>	021184 003 020600 001	4536516*PED 5089509 5089509 5089509 5089509	JUN 13, 2011 JUN 13, 2011 JUN 13, 2011 JUN 13, 2011	U-481 NP U-193 U-481	SEP 30, 2005		
>ADD> >ADD> >ADD> >ADD>	021184 003 021184 002	4536516*PED 5089509 5089509 5089509 5089509	JUN 13, 2011 JUN 13, 2011 JUN 13, 2011 JUN 13, 2011	U-481 NP U-481 U-481	SEP 30, 2005		
019785 001	TAZAROTENE;AVAGE	5089509	JUN 13, 2011	U-481			
019785 003	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U-481			
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4452774	DEC 21, 2004				
021200 001	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	DEC 21, 2004				
021200 002	TEGASEROD MALEATE;ZELNORM	5510353	APR 26, 2013	U-466	NCR	JUL 24, 2007	
021200 002	TEGASEROD MALEATE;ZELNORM	5510353	APR 26, 2013	U-466	NCR	JUL 24, 2007	
021029 001	TEMODOAR	5260291	NOV 09, 2010	NCE	AUG 11,	2004	
021029 002	TEMODOAR	5260291*PED	MAY 09, 2011	ODE	AUG 11,	2006	
021029 003	TEMODOAR	5260291	NOV 09, 2010	FED	FEB 11,	2005	
021029 004	TEMODOAR	5260291*PED	MAY 09, 2011	FED	FEB 11,	2005	
020846 001	TERBINAFINE;LAMISIL	4755534 4680291	DEC 30, 2006 JUL 14, 2004	U-445 U-445	NP	NOV 26, 2005	
>ADD> >ADD> >ADD> >ADD>	0211318 001 020791 001	TERIPARATIDE ACETATE;PORTERO TESTOSTERONE;TESTODERM TTS	NOV 10, 2019 OCT 23, 2020	U-440 U-440			
020785 001	THALIDOMIDE;THALOMID	6346210					
>ADD> >ADD>	020646 001	TIAGABINE HYDROCHLORIDE;GABITRIL	6315720 5010090	SEP 30, <td>JUN 10,</td> <td>2011</td> <td></td>	JUN 10,	2011	
>ADD>	020646 002	TIAGABINE HYDROCHLORIDE;GABITRIL	5956951	JUN 10, 2017			
>ADD>	020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5866590	APR 29, 2016			
>ADD>	020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
>ADD>	020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5956951	JUN 10, 2017			
>ADD>	020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5866590	APR 29,	2016		

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME ; TRADE NAME	PATENT NUMBER	PATENT/EXPIRES	EXCL CODE	USE CODE	EXCLUSIVITY CODE	EXPIRES
>ADD> 020646 004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011				
>ADD>		5958951	JUN 10, 2017				
>ADD>		5866590	APR 29, 2016				
>ADD>		5010090	SEP 30, 2011				
>ADD>		5958951	JUN 10, 2017				
>ADD>		5866590	APR 29, 2016				
>ADD>		6455557	NOV 28, 2021				
>ADD>		6455557	NOV 28, 2021				
>ADD>		5236952	JAN 29, 2012				
>ADD>		5236952	JAN 29, 2012				
021447 001	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	5153222	OCT 06, 2009	U-455	NCE	PC	FEB 17, 2003
021447 002	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	5153222	OCT 06, 2009	U-455	NCE	PC	DEC 10, 2002
021447 003	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	5153222	OCT 06, 2009	U-455	NCE	PC	DEC 07, 2002
021447 004	TOLCAPHONE;TASMAR	5153222	OCT 06, 2009	U-455	NCE	PC	DEC 10, 2002
020697 001	TOLCAPHONE;TASMAR	5153222	OCT 06, 2009	U-455	NCE	PC	DEC 10, 2002
020697 002	TOLTERODINE TARTRATE;DETROL LA	5559269	NOV 05, 2013	U-318			
021228 001	TOLTERODINE TARTRATE;DETROL LA	5559269	NOV 05, 2013	U-318			
021228 002	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758	MAY 28, 2010				
020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758*PED	NOV 28, 2010				
076110 001	TORSEMIDE;TORSEMIDE	5153222	OCT 06, 2009	U-455	NCE	PC	FEB 17, 2003
076110 002	TORSEMIDE;TORSEMIDE	5153222	OCT 06, 2009	U-455	NCE	PC	DEC 10, 2002
076110 003	TORSEMIDE;TORSEMIDE	5153222	OCT 06, 2009	U-455	NCE	PC	DEC 07, 2002
076110 004	TORSEMIDE;TORSEMIDE	5153222	OCT 06, 2009	U-455	NCE	PC	DEC 10, 2002
021272 001	TREPFRONTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	PC	DEC 10, 2002
021272 002	TREPFRONTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	PC	DEC 10, 2002
021272 003	TREPFRONTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	PC	DEC 10, 2002
021272 004	TREPFRONTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	PC	DEC 10, 2002
020475 002	TRETINOIN;RETIN A MICRO	4690825	OCT 04, 2005	U-134	NS	PC	FEB 17, 2003
021289 001	UROFOLLITROPIN;BRAVELLE	5955109	SEP 21, 2016	U-134	NS	PC	DEC 10, 2002
020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009				
020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	5879706	JAN 19, 2016				
021341 002	VALDECOXIB;BEVTRA	5879706	JAN 19, 2016				
021341 003	VALDECOXIB;BEVTRA	6107302	JAN 19, 2016				
020593 001	VALPROATE SODIUM;DEPACON	4957924	JUN 23, 2009				
020665 001	VALSARTAN;DIOVAN	5879706	JAN 19, 2016				
020665 002	VALSARTAN;DIOVAN	6107302	JAN 19, 2016				
021283 001	VALSARTAN;DIOVAN	5633272	FEB 13, 2015	U-462		D-72	JAN 24, 2005
021283 002	VALSARTAN;DIOVAN	5633272	FEB 13, 2015	U-462		I-365	AUG 14, 2005
021283 003	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3		I-365	AUG 14, 2005
021283 003	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3		I-365	AUG 14, 2005
021283 003	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3		I-365	AUG 14, 2005

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL./PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES	
0 21283 004	VALSARTAN; DIOVAN	5339578	MAR 21, 2012	I-365	AUG 14,	2005	
>ADD> 0 20151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	6294197	JUN 18, 2017	U-3	I-325	MAY 02,	2004
>ADD> 0 20151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4551186	DEC 13, 2007	PED	SEP 02,	2004	
>ADD> 0 20151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4551186*PED	JUN 13, 2008		I-325	MAY 02,	2004
>ADD> 0 20151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4551186	DEC 13, 2007	PED	SEP 02,	2004	
>ADD> 0 20151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4551186*PED	JUN 13, 2008		I-325	MAY 02,	2004
>ADD> 0 20151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4551186	DEC 13, 2007	PED	SEP 02,	2004	
>ADD> 0 20699 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	4551186*PED	JUN 13, 2007	PED	SEP 02,	2004	
>ADD>		4551186	DEC 13, 2007	PED	SEP 02,	2004	
>ADD>		4531186*PED	JUN 13, 2008		I-325	MAY 02,	2004
>ADD>		4551186	DEC 13, 2007	PED	SEP 02,	2004	
>ADD>		4551186*PED	JUN 13, 2008		I-325	MAY 02,	2004
>ADD>		4551186	DEC 13, 2007	PED	SEP 02,	2004	
>ADD>		624171	MAR 20,	2017	U-398		
>ADD>		5916923	JUN 28,	2013	U-451		
>ADD>		6403120	MAR 20,	2017	U-459		
>ADD>		6419958	MAR 20,	2017	U-459		
>ADD>		6444708	JUN 28,	2013			
>ADD>		4551186*PED	JUN 13,	2008			
>ADD>		5916923*PED	DEC 28,	2013	U-398		
>ADD>		6274171*PED	SEP 20,	2017	U-451		
>ADD>		6403120*PED	SEP 20,	2017	U-459		
>ADD>		6419958*PED	SEP 20,	2013			
>ADD>		6444708*PED	DEC 28,	2013	I-325	MAY 02,	2004
>ADD>		4551186	DEC 13,	2007	PED	SEP 02,	2004
>ADD>		624171	MAR 20,	2017	U-398		
>ADD>		5916923	JUN 28,	2013	U-451		
>ADD>		6403120	MAR 20,	2017	U-459		
>ADD>		6419958	MAR 20,	2017	U-459		
>ADD>		6444708	JUN 28,	2013			
>ADD>		4551186*PED	JUN 13,	2008			
>ADD>		5916923*PED	DEC 28,	2013	U-398		
>ADD>		6274171*PED	SEP 20,	2017	U-451		
>ADD>		6403120*PED	SEP 20,	2017	U-459		
>ADD>		6444708*PED	SEP 20,	2013			
>ADD>		4551186	DEC 13,	2007	I-325	MAY 02,	2004
>ADD>		6274171	MAR 20,	2017	U-451		
>ADD>		5916923	JUN 28,	2013	U-459		
>ADD>		6403120	MAR 20,	2017	U-459		
>ADD>		6419958	JUN 28,	2013	U-398		
>ADD>		6444708	JUN 28,	2013	U-451		
>ADD>		4551186*PED	JUN 13,	2008			
>ADD>		5916923*PED	DEC 28,	2013	U-398		
>ADD>		6274171*PED	SEP 20,	2017	U-451		
>ADD>		6403120*PED	SEP 20,	2013	U-459		
>ADD>		6419958*PED	DEC 28,	2013			

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE CODE		EXCLUS CODE EXPIRES	
			EXPIRES	PED	CODE	EXPIRES
>ADD> 020699 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	4535186 62274171 5916923 6403120 6419958 6444708 4535186*PED 5916923*PED 6274171*PED 6403120*PED	DEC 13, MAR 20, JUN 28, MAR 20, MAR 20, JUN 28, JUN 13, DEC 28, SEP 20, SEP 20,	2007 2017 2013 2017 2017 2013 2008 2013 2017 2017	I-325 PED	MAY 02, 2004 SEP 02, 2004
>ADD> 020388 001	VERTEPORFIN; VISUDYNE VINORELBINE TARTRATE; NAVELBINE	4883790 4307100 4307100*PED	JAN 20, JUL 08, JAN 08,	2007 2002 2003	U-459	U-459
021266 001 021266 002 021267 001 021036 001 020825 001 020825 002 020825 003 020825 004 020919 001	VORICONAZOLE; VFEND VORICONAZOLE; VFEND VORICONAZOLE; VFEND ZANAMIVIR; RELENZA ZIPRASIDONE HYDROCHLORIDE; GEODON ZIPRASIDONE HYDROCHLORIDE; GEODON ZIPRASIDONE HYDROCHLORIDE; GEODON ZIPRASIDONE HYDROCHLORIDE; GEODON ZIPRASIDONE MESYLATE; GEODON	6294572 6150366 6150366 6150366 6150366 6150366 6399777 4831031 6110918 6232304	DEC 15, MAY 27, MAY 27, MAY 27, MAY 27, MAY 27, APR 01, MAR 02, MAR 26, APR 01,	2014 2019 2019 2019 2019 2019 2017 2007 2017 2017	NCE NCE NCE NCE NCE NCE NDF NDF	MAY 24, 2007 MAY 24, 2007 MAY 24, 2007 MAY 24, 2007 MAY 24, 2007 MAY 24, 2007 JUN 21, 2005
021223 001 021231 001 020789 001	ZOLEDRONIC ACID; ZOMETTA ZOLMITRIPTAN; ZOMIG-ZMT ZONISAMIDE; ZONEGRAN	5466699 6342515	NOV 14, DEC 21,	2012 2018	I-361 U-438	FEB 22, 2005 NOV 25, 2002

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 22ND EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

- W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.3 OF SUPPLEMENT WAIVED EXCLUSIVITY

REFERENCES NEW DOSING SCHEDULE

- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)

NEW INDICATION

- I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
- I-349 ACUTE CORONARY SYNDROME
- I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
- I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
- I-352 ANTI COAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
- I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
- I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
- I-355 PREMENSTRUAL DYSPHORIC DISORDER
- I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-358 TREATMENT OF PANIC DISORDER
- I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
- I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE

- I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
- I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
- I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
- I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
- I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
- I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
- I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
- I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- I-372 NOSOCOMIAL PNEUMONIA
- I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY

MISCELLANEOUS EXCLUSIVITY CODES

- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
- M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
- M-22 CHANGE IN TIME TO ONSET OF ACTION

PATENT USE CODES

- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 METHOD OF TREATING
- U-445 USE AS AN ANTIMYCOTIC AGENT
- U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE

- METER
U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
- TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-451
U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
- TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-453
U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
- TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
U-455
U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
- METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
U-457
U-458 METHOD OF USE OF IMAGENT
- TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-459
U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
- METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
U-461 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
U-462
- VENOGRAPHY
U-463
U-464 PERIPHERAL ARTERIOGRAPHY
- CT IMAGING OF THE HEAD
U-465
- TREATMENT OF IRRITABLE BOWEL SYNDROME
U-466
U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
- METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
U-468
U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENT
- THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
U-470
U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
- TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
U-473
U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
- TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-475
U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
U-477
U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
- METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
U-479
U-480 CONTRAST AGENT FOR MRI
U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY

New 22nd Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code

* 8392

*Charge your order.
It's easy!*



Yes, enter my subscription as follows:

subscriptions of APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, ADP, and the monthly Cumulative Supplements, for \$105.00 per year.

The total cost of my order is \$ _____. Price includes regular shipping and handling and is subject to change.
International customers please add 40%.

For privacy protection, check the box below:

Do not make my name available to other mailers.

Please choose method of payment:

Check payable to Superintendent of Documents

GPO Deposit Account **11111111-1**

VISA or MasterCard

1111111111111111

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

(_____) Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

Thank you for your order!

(Authorizing Signature)

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To FAX your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90039 3121

RM301.45 .A66 2002 Nov. suppl.

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only

LIBRARY

ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL
ST. LOUIS, MO. 63110